original_sentence	e1	e2	relation_type	metadata	preprocessed_sentence
Tamoxifen, an estrogen antagonist, is the standard hormone treatment for breast cancer. 	Tamoxifen	estrogen antagonist	none	{'e1': {'word': 'Tamoxifen', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d209.s1.e0'}, 'e2': {'word': 'estrogen antagonist', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d209.s1.e1'}, 'sentence_id': 'DDI-MedLine.d209.s1'}	O hormone treatment O breast cancer O O O O O O O O O O O E-CANCER O
Paroxetine and fluoxetine reduce the plasma concentration of endoxifen by about 50%. 	Paroxetine	fluoxetine	none	{'e1': {'word': 'Paroxetine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d209.s5.e0'}, 'e2': {'word': 'fluoxetine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d209.s5.e1'}, 'sentence_id': 'DDI-MedLine.d209.s5'}	O about 50 O S-SIMPLE_CHEMICAL O O S-ORGANISM_SUBSTANCE O O O O O O O O
Paroxetine and fluoxetine reduce the plasma concentration of endoxifen by about 50%. 	Paroxetine	endoxifen	mechanism	{'e1': {'word': 'Paroxetine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d209.s5.e0'}, 'e2': {'word': 'endoxifen', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d209.s5.e2'}, 'sentence_id': 'DDI-MedLine.d209.s5'}	O about 50 O S-SIMPLE_CHEMICAL O O S-ORGANISM_SUBSTANCE O O O O O O O O
Paroxetine and fluoxetine reduce the plasma concentration of endoxifen by about 50%. 	fluoxetine	endoxifen	mechanism	{'e1': {'word': 'fluoxetine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d209.s5.e1'}, 'e2': {'word': 'endoxifen', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d209.s5.e2'}, 'sentence_id': 'DDI-MedLine.d209.s5'}	O about 50 O S-SIMPLE_CHEMICAL O O S-ORGANISM_SUBSTANCE O O O O O O O O
It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer, especially SSRI antidepressants such as paroxetine and fluoxetine. 	tamoxifen	SSRI antidepressants	advise	{'e1': {'word': 'tamoxifen', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d209.s9.e0'}, 'e2': {'word': 'SSRI antidepressants', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d209.s9.e1'}, 'sentence_id': 'DDI-MedLine.d209.s9'}	O better to O isoenzyme CYP O tamoxifen for O , especially O and fluoxetine O O O S-GENE_OR_GENE_PRODUCT O O S-ORGANISM O O S-SIMPLE_CHEMICAL O O E-CANCER O O O O O O O O S-SIMPLE_CHEMICAL O
It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer, especially SSRI antidepressants such as paroxetine and fluoxetine. 	tamoxifen	paroxetine	advise	{'e1': {'word': 'tamoxifen', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d209.s9.e0'}, 'e2': {'word': 'paroxetine', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d209.s9.e2'}, 'sentence_id': 'DDI-MedLine.d209.s9'}	O better to O isoenzyme CYP O tamoxifen for O , especially O and fluoxetine O O O S-GENE_OR_GENE_PRODUCT O O S-ORGANISM O O S-SIMPLE_CHEMICAL O O E-CANCER O O O O O O O O S-SIMPLE_CHEMICAL O
It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer, especially SSRI antidepressants such as paroxetine and fluoxetine. 	tamoxifen	fluoxetine	advise	{'e1': {'word': 'tamoxifen', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d209.s9.e0'}, 'e2': {'word': 'fluoxetine', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d209.s9.e3'}, 'sentence_id': 'DDI-MedLine.d209.s9'}	O better to O isoenzyme CYP O tamoxifen for O , especially O and fluoxetine O O O S-GENE_OR_GENE_PRODUCT O O S-ORGANISM O O S-SIMPLE_CHEMICAL O O E-CANCER O O O O O O O O S-SIMPLE_CHEMICAL O
It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer, especially SSRI antidepressants such as paroxetine and fluoxetine. 	SSRI antidepressants	paroxetine	none	{'e1': {'word': 'SSRI antidepressants', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d209.s9.e1'}, 'e2': {'word': 'paroxetine', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d209.s9.e2'}, 'sentence_id': 'DDI-MedLine.d209.s9'}	O better to O isoenzyme CYP O tamoxifen for O , especially O and fluoxetine O O O S-GENE_OR_GENE_PRODUCT O O S-ORGANISM O O S-SIMPLE_CHEMICAL O O E-CANCER O O O O O O O O S-SIMPLE_CHEMICAL O
It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer, especially SSRI antidepressants such as paroxetine and fluoxetine. 	SSRI antidepressants	fluoxetine	none	{'e1': {'word': 'SSRI antidepressants', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d209.s9.e1'}, 'e2': {'word': 'fluoxetine', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d209.s9.e3'}, 'sentence_id': 'DDI-MedLine.d209.s9'}	O better to O isoenzyme CYP O tamoxifen for O , especially O and fluoxetine O O O S-GENE_OR_GENE_PRODUCT O O S-ORGANISM O O S-SIMPLE_CHEMICAL O O E-CANCER O O O O O O O O S-SIMPLE_CHEMICAL O
It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer, especially SSRI antidepressants such as paroxetine and fluoxetine. 	paroxetine	fluoxetine	none	{'e1': {'word': 'paroxetine', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d209.s9.e2'}, 'e2': {'word': 'fluoxetine', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d209.s9.e3'}, 'sentence_id': 'DDI-MedLine.d209.s9'}	O better to O isoenzyme CYP O tamoxifen for O , especially O and fluoxetine O O O S-GENE_OR_GENE_PRODUCT O O S-ORGANISM O O S-SIMPLE_CHEMICAL O O E-CANCER O O O O O O O O S-SIMPLE_CHEMICAL O
Depression does not always require antidepressant drug therapy, and antidepressants have no proven preventive impact on hot flushes linked to the menopause. 	antidepressant drug	antidepressants	none	{'e1': {'word': 'antidepressant drug', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d209.s10.e0'}, 'e2': {'word': 'antidepressants', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d209.s10.e1'}, 'sentence_id': 'DDI-MedLine.d209.s10'}	O antidepressants have O on hot O the menopause O O O O O O O O O O O O O O O O O O O O O
If in certain cases, an antidepressant is considered necessary, it may be advisable to replace tamoxifen with anastrozole.	antidepressant	tamoxifen	advise	{'e1': {'word': 'antidepressant', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d209.s11.e0'}, 'e2': {'word': 'tamoxifen', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d209.s11.e1'}, 'sentence_id': 'DDI-MedLine.d209.s11'}	O certain cases O antidepressant is O to replace O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O
If in certain cases, an antidepressant is considered necessary, it may be advisable to replace tamoxifen with anastrozole.	antidepressant	anastrozole	none	{'e1': {'word': 'antidepressant', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d209.s11.e0'}, 'e2': {'word': 'anastrozole', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d209.s11.e2'}, 'sentence_id': 'DDI-MedLine.d209.s11'}	O certain cases O antidepressant is O to replace O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O
If in certain cases, an antidepressant is considered necessary, it may be advisable to replace tamoxifen with anastrozole.	tamoxifen	anastrozole	none	{'e1': {'word': 'tamoxifen', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d209.s11.e1'}, 'e2': {'word': 'anastrozole', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d209.s11.e2'}, 'sentence_id': 'DDI-MedLine.d209.s11'}	O certain cases O antidepressant is O to replace O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O
Ticagrelor (Brilinta)--better than clopidogrel (Plavix)	Ticagrelor	Brilinta	none	{'e1': {'word': 'Ticagrelor', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d193.s0.e0'}, 'e2': {'word': 'Brilinta', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d193.s0.e1'}, 'sentence_id': 'DDI-MedLine.d193.s0'}	O ) O O O O O O O O O O
Ticagrelor (Brilinta)--better than clopidogrel (Plavix)	Ticagrelor	clopidogrel	none	{'e1': {'word': 'Ticagrelor', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d193.s0.e0'}, 'e2': {'word': 'clopidogrel', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d193.s0.e2'}, 'sentence_id': 'DDI-MedLine.d193.s0'}	O ) O O O O O O O O O O
Ticagrelor (Brilinta)--better than clopidogrel (Plavix)	Ticagrelor	Plavix	none	{'e1': {'word': 'Ticagrelor', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d193.s0.e0'}, 'e2': {'word': 'Plavix', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d193.s0.e3'}, 'sentence_id': 'DDI-MedLine.d193.s0'}	O ) O O O O O O O O O O
Ticagrelor (Brilinta)--better than clopidogrel (Plavix)	Brilinta	clopidogrel	none	{'e1': {'word': 'Brilinta', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d193.s0.e1'}, 'e2': {'word': 'clopidogrel', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d193.s0.e2'}, 'sentence_id': 'DDI-MedLine.d193.s0'}	O ) O O O O O O O O O O
Ticagrelor (Brilinta)--better than clopidogrel (Plavix)	Brilinta	Plavix	none	{'e1': {'word': 'Brilinta', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d193.s0.e1'}, 'e2': {'word': 'Plavix', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d193.s0.e3'}, 'sentence_id': 'DDI-MedLine.d193.s0'}	O O O O O O O O O O O
Ticagrelor (Brilinta)--better than clopidogrel (Plavix)	clopidogrel	Plavix	none	{'e1': {'word': 'clopidogrel', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d193.s0.e2'}, 'e2': {'word': 'Plavix', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d193.s0.e3'}, 'sentence_id': 'DDI-MedLine.d193.s0'}	O ) O O O O O O O O O O
The FDA has approved ticagrelor (Brilinta-AstraZeneca), an oral antiplatelet drug, for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). 	ticagrelor	Brilinta	none	{'e1': {'word': 'ticagrelor', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d193.s1.e0'}, 'e2': {'word': 'Brilinta', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d193.s1.e1'}, 'sentence_id': 'DDI-MedLine.d193.s1'}	O approved ticagrelor O AstraZeneca ) O antiplatelet drug O to reduce O coronary syndrome O ACS ) O O O O O O S-ORGANISM_SUBDIVISION O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O S-ORGANISM O O S-MULTI-TISSUE_STRUCTURE O O O O O
The FDA has approved ticagrelor (Brilinta-AstraZeneca), an oral antiplatelet drug, for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). 	ticagrelor	antiplatelet drug	none	{'e1': {'word': 'ticagrelor', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d193.s1.e0'}, 'e2': {'word': 'antiplatelet drug', 'word_index': [(7, 8)], 'id': 'DDI-MedLine.d193.s1.e2'}, 'sentence_id': 'DDI-MedLine.d193.s1'}	O approved ticagrelor O AstraZeneca ) O antiplatelet drug O to reduce O coronary syndrome O ACS ) O O O O O O S-ORGANISM_SUBDIVISION O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O S-ORGANISM O O S-MULTI-TISSUE_STRUCTURE O O O O O
The FDA has approved ticagrelor (Brilinta-AstraZeneca), an oral antiplatelet drug, for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). 	ticagrelor	aspirin	effect	{'e1': {'word': 'ticagrelor', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d193.s1.e0'}, 'e2': {'word': 'aspirin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d193.s1.e3'}, 'sentence_id': 'DDI-MedLine.d193.s1'}	O approved ticagrelor O AstraZeneca ) O antiplatelet drug O to reduce O coronary syndrome O ACS ) O O O O O O S-ORGANISM_SUBDIVISION O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O S-ORGANISM O O S-MULTI-TISSUE_STRUCTURE O O O O O
The FDA has approved ticagrelor (Brilinta-AstraZeneca), an oral antiplatelet drug, for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). 	Brilinta	antiplatelet drug	none	{'e1': {'word': 'Brilinta', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d193.s1.e1'}, 'e2': {'word': 'antiplatelet drug', 'word_index': [(7, 8)], 'id': 'DDI-MedLine.d193.s1.e2'}, 'sentence_id': 'DDI-MedLine.d193.s1'}	O approved ticagrelor O AstraZeneca ) O antiplatelet drug O to reduce O coronary syndrome O ACS ) O O O O O O S-ORGANISM_SUBDIVISION O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O S-ORGANISM O O S-MULTI-TISSUE_STRUCTURE O O O O O
The FDA has approved ticagrelor (Brilinta-AstraZeneca), an oral antiplatelet drug, for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). 	Brilinta	aspirin	effect	{'e1': {'word': 'Brilinta', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d193.s1.e1'}, 'e2': {'word': 'aspirin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d193.s1.e3'}, 'sentence_id': 'DDI-MedLine.d193.s1'}	O approved ticagrelor O AstraZeneca ) O antiplatelet drug O to reduce O coronary syndrome O ACS ) O O O O O O S-ORGANISM_SUBDIVISION O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O S-ORGANISM O O S-MULTI-TISSUE_STRUCTURE O O O O O
The FDA has approved ticagrelor (Brilinta-AstraZeneca), an oral antiplatelet drug, for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). 	antiplatelet drug	aspirin	none	{'e1': {'word': 'antiplatelet drug', 'word_index': [(7, 8)], 'id': 'DDI-MedLine.d193.s1.e2'}, 'e2': {'word': 'aspirin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d193.s1.e3'}, 'sentence_id': 'DDI-MedLine.d193.s1'}	O approved ticagrelor O AstraZeneca ) O antiplatelet drug O to reduce O coronary syndrome O ACS ) O O O O O O S-ORGANISM_SUBDIVISION O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O S-ORGANISM O O S-MULTI-TISSUE_STRUCTURE O O O O O
It will compete with clopidogrel (Plavix) and prasugrel (Effient) for such use. 	clopidogrel	Plavix	none	{'e1': {'word': 'clopidogrel', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d193.s2.e0'}, 'e2': {'word': 'Plavix', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d193.s2.e1'}, 'sentence_id': 'DDI-MedLine.d193.s2'}	O compete with O and prasugrel O O O O O O O O O O O O O O O
It will compete with clopidogrel (Plavix) and prasugrel (Effient) for such use. 	clopidogrel	prasugrel	none	{'e1': {'word': 'clopidogrel', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d193.s2.e0'}, 'e2': {'word': 'prasugrel', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d193.s2.e2'}, 'sentence_id': 'DDI-MedLine.d193.s2'}	O compete with O and prasugrel O O O O O O O O O O O O O O O
It will compete with clopidogrel (Plavix) and prasugrel (Effient) for such use. 	clopidogrel	Effient	none	{'e1': {'word': 'clopidogrel', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d193.s2.e0'}, 'e2': {'word': 'Effient', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d193.s2.e3'}, 'sentence_id': 'DDI-MedLine.d193.s2'}	O compete with O and prasugrel O O O O O O O O O O O O O O O
It will compete with clopidogrel (Plavix) and prasugrel (Effient) for such use. 	Plavix	prasugrel	none	{'e1': {'word': 'Plavix', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d193.s2.e1'}, 'e2': {'word': 'prasugrel', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d193.s2.e2'}, 'sentence_id': 'DDI-MedLine.d193.s2'}	O compete with O and prasugrel O O O O O O O O O O O O O O O
It will compete with clopidogrel (Plavix) and prasugrel (Effient) for such use. 	Plavix	Effient	none	{'e1': {'word': 'Plavix', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d193.s2.e1'}, 'e2': {'word': 'Effient', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d193.s2.e3'}, 'sentence_id': 'DDI-MedLine.d193.s2'}	O compete with O and prasugrel O O O O O O O O O O O O O O O
It will compete with clopidogrel (Plavix) and prasugrel (Effient) for such use. 	prasugrel	Effient	none	{'e1': {'word': 'prasugrel', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d193.s2.e2'}, 'e2': {'word': 'Effient', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d193.s2.e3'}, 'sentence_id': 'DDI-MedLine.d193.s2'}	O compete with O and prasugrel O O O O O O O O O O O O O O O
"Influence of piperine on ibuprofen induced antinociception and its pharmacokinetics.
"	piperine	ibuprofen	none	{'e1': {'word': 'piperine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d195.s0.e0'}, 'e2': {'word': 'ibuprofen', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d195.s0.e1'}, 'sentence_id': 'DDI-MedLine.d195.s0'}	O pharmacokinetics . O S-SIMPLE_CHEMICAL O O O O O O O O
In the present study piperine (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of ibuprofen evaluated by both acetic acid writhing and formalin test, when it was administered with ibuprofen. 	piperine	ibuprofen	effect	{'e1': {'word': 'piperine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d195.s4.e0'}, 'e2': {'word': 'ibuprofen', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d195.s4.e1'}, 'sentence_id': 'DDI-MedLine.d195.s4'}	O present study O mg / O dependent antinociceptive O both acetic S-SIMPLE_CHEMICAL was administered O ibuprofen . O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
In the present study piperine (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of ibuprofen evaluated by both acetic acid writhing and formalin test, when it was administered with ibuprofen. 	piperine	acetic acid	none	{'e1': {'word': 'piperine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d195.s4.e0'}, 'e2': {'word': 'acetic acid', 'word_index': [(11, 12)], 'id': 'DDI-MedLine.d195.s4.e2'}, 'sentence_id': 'DDI-MedLine.d195.s4'}	O present study O mg / O dependent antinociceptive O both acetic S-SIMPLE_CHEMICAL was administered O ibuprofen . O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
In the present study piperine (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of ibuprofen evaluated by both acetic acid writhing and formalin test, when it was administered with ibuprofen. 	piperine	ibuprofen	none	{'e1': {'word': 'piperine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d195.s4.e0'}, 'e2': {'word': 'ibuprofen', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d195.s4.e3'}, 'sentence_id': 'DDI-MedLine.d195.s4'}	O present study O mg / O dependent antinociceptive O both acetic S-SIMPLE_CHEMICAL was administered O ibuprofen . O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
In the present study piperine (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of ibuprofen evaluated by both acetic acid writhing and formalin test, when it was administered with ibuprofen. 	ibuprofen	acetic acid	none	{'e1': {'word': 'ibuprofen', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d195.s4.e1'}, 'e2': {'word': 'acetic acid', 'word_index': [(11, 12)], 'id': 'DDI-MedLine.d195.s4.e2'}, 'sentence_id': 'DDI-MedLine.d195.s4'}	O present study O mg / O dependent antinociceptive O both acetic S-SIMPLE_CHEMICAL was administered O ibuprofen . O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
In the present study piperine (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of ibuprofen evaluated by both acetic acid writhing and formalin test, when it was administered with ibuprofen. 	ibuprofen	ibuprofen	none	{'e1': {'word': 'ibuprofen', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d195.s4.e1'}, 'e2': {'word': 'ibuprofen', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d195.s4.e3'}, 'sentence_id': 'DDI-MedLine.d195.s4'}	O present study O mg / O dependent antinociceptive O both acetic S-SIMPLE_CHEMICAL was administered O ibuprofen . O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
In the present study piperine (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of ibuprofen evaluated by both acetic acid writhing and formalin test, when it was administered with ibuprofen. 	acetic acid	ibuprofen	none	{'e1': {'word': 'acetic acid', 'word_index': [(11, 12)], 'id': 'DDI-MedLine.d195.s4.e2'}, 'e2': {'word': 'ibuprofen', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d195.s4.e3'}, 'sentence_id': 'DDI-MedLine.d195.s4'}	O present study O mg / O dependent antinociceptive O both acetic S-SIMPLE_CHEMICAL was administered O ibuprofen . O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
Ibuprofen plasma concentration was also increased when it was administered with piperine. 	Ibuprofen	piperine	mechanism	{'e1': {'word': 'Ibuprofen', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d195.s5.e0'}, 'e2': {'word': 'piperine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d195.s5.e1'}, 'sentence_id': 'DDI-MedLine.d195.s5'}	O administered with S-ORGANISM_SUBSTANCE O O O O O O O O O S-SIMPLE_CHEMICAL O
The synergistic antinociception activity of ibuprofen when administered with piperine can be attributed to increased plasma concentration of ibuprofen. 	ibuprofen	piperine	mechanism	{'e1': {'word': 'ibuprofen', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d195.s6.e0'}, 'e2': {'word': 'piperine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d195.s6.e1'}, 'sentence_id': 'DDI-MedLine.d195.s6'}	O activity of O concentration of O O O O O O O S-SIMPLE_CHEMICAL O O O O O S-ORGANISM_SUBSTANCE O O O O
The synergistic antinociception activity of ibuprofen when administered with piperine can be attributed to increased plasma concentration of ibuprofen. 	ibuprofen	ibuprofen	none	{'e1': {'word': 'ibuprofen', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d195.s6.e0'}, 'e2': {'word': 'ibuprofen', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d195.s6.e2'}, 'sentence_id': 'DDI-MedLine.d195.s6'}	O activity of O concentration of O O O O O O O S-SIMPLE_CHEMICAL O O O O O S-ORGANISM_SUBSTANCE O O O O
The synergistic antinociception activity of ibuprofen when administered with piperine can be attributed to increased plasma concentration of ibuprofen. 	piperine	ibuprofen	none	{'e1': {'word': 'piperine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d195.s6.e1'}, 'e2': {'word': 'ibuprofen', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d195.s6.e2'}, 'sentence_id': 'DDI-MedLine.d195.s6'}	O activity of O concentration of O O O O O O O S-SIMPLE_CHEMICAL O O O O O S-ORGANISM_SUBSTANCE O O O O
From this study it can be concluded that piperine can be used as a bioenhancer along with ibuprofen.	piperine	ibuprofen	effect	{'e1': {'word': 'piperine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d195.s7.e0'}, 'e2': {'word': 'ibuprofen', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d195.s7.e1'}, 'sentence_id': 'DDI-MedLine.d195.s7'}	O can be O be used O ibuprofen . O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O
"Antidepressant-warfarin interaction and associated gastrointestinal bleeding risk in a case-control study.
"	Antidepressant	warfarin	none	{'e1': {'word': 'Antidepressant', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d218.s0.e0'}, 'e2': {'word': 'warfarin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d218.s0.e1'}, 'sentence_id': 'DDI-MedLine.d218.s0'}	O study . O O O O O S-ORGANISM_SUBDIVISION O O O O O O O O O
We sought to evaluate whether initiation of an antidepressant increases the risk of hospitalization for gastrointestinal bleeding in warfarin users.	antidepressant	warfarin	none	{'e1': {'word': 'antidepressant', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d218.s3.e0'}, 'e2': {'word': 'warfarin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d218.s3.e1'}, 'sentence_id': 'DDI-MedLine.d218.s3'}	O to evaluate O the risk O for gastrointestinal O O O O O O O O O O O O S-ORGANISM_SUBDIVISION O O O O O
In total, 430,455 warfarin users contributed 407,370 person-years of warfarin use. 	warfarin	warfarin	none	{'e1': {'word': 'warfarin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d218.s5.e0'}, 'e2': {'word': 'warfarin', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d218.s5.e1'}, 'sentence_id': 'DDI-MedLine.d218.s5'}	O , 430,455 O - years O warfarin use O O O O O O O O O O O O
Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). 	Warfarin	citalopram	effect	{'e1': {'word': 'Warfarin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d218.s8.e0'}, 'e2': {'word': 'citalopram', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d218.s8.e1'}, 'sentence_id': 'DDI-MedLine.d218.s8'}	O gastrointestinal bleeding O OR = O % CI O - 2.38 O 95 % O 2.38 ] O = 1.64 O % CI S-ORGANISM_SUBDIVISION , 1.02 O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). 	Warfarin	fluoxetine	effect	{'e1': {'word': 'Warfarin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d218.s8.e0'}, 'e2': {'word': 'fluoxetine', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d218.s8.e2'}, 'sentence_id': 'DDI-MedLine.d218.s8'}	O gastrointestinal bleeding O OR = O % CI O - 2.38 O 95 % O 2.38 ] O = 1.64 O % CI S-ORGANISM_SUBDIVISION , 1.02 O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). 	Warfarin	paroxetine	effect	{'e1': {'word': 'Warfarin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d218.s8.e0'}, 'e2': {'word': 'paroxetine', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d218.s8.e3'}, 'sentence_id': 'DDI-MedLine.d218.s8'}	O gastrointestinal bleeding O OR = O % CI O - 2.38 O 95 % O 2.38 ] O = 1.64 O % CI S-ORGANISM_SUBDIVISION , 1.02 O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). 	Warfarin	amitriptyline	effect	{'e1': {'word': 'Warfarin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d218.s8.e0'}, 'e2': {'word': 'amitriptyline', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d218.s8.e4'}, 'sentence_id': 'DDI-MedLine.d218.s8'}	O gastrointestinal bleeding O OR = O % CI O - 2.38 O 95 % O 2.38 ] O = 1.64 O % CI S-ORGANISM_SUBDIVISION , 1.02 O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). 	citalopram	fluoxetine	none	{'e1': {'word': 'citalopram', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d218.s8.e1'}, 'e2': {'word': 'fluoxetine', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d218.s8.e2'}, 'sentence_id': 'DDI-MedLine.d218.s8'}	O gastrointestinal bleeding O OR = O % CI O - 2.38 O 95 % O 2.38 ] O = 1.64 O % CI S-ORGANISM_SUBDIVISION , 1.02 O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). 	citalopram	paroxetine	none	{'e1': {'word': 'citalopram', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d218.s8.e1'}, 'e2': {'word': 'paroxetine', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d218.s8.e3'}, 'sentence_id': 'DDI-MedLine.d218.s8'}	O gastrointestinal bleeding O OR = O % CI O - 2.38 O 95 % O 2.38 ] O = 1.64 O % CI S-ORGANISM_SUBDIVISION , 1.02 O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). 	citalopram	amitriptyline	none	{'e1': {'word': 'citalopram', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d218.s8.e1'}, 'e2': {'word': 'amitriptyline', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d218.s8.e4'}, 'sentence_id': 'DDI-MedLine.d218.s8'}	O gastrointestinal bleeding O OR = O % CI O - 2.38 O 95 % O 2.38 ] O = 1.64 O % CI S-ORGANISM_SUBDIVISION , 1.02 O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). 	fluoxetine	paroxetine	none	{'e1': {'word': 'fluoxetine', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d218.s8.e2'}, 'e2': {'word': 'paroxetine', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d218.s8.e3'}, 'sentence_id': 'DDI-MedLine.d218.s8'}	O gastrointestinal bleeding O OR = O % CI O - 2.38 O 95 % O 2.38 ] O = 1.64 O % CI S-ORGANISM_SUBDIVISION , 1.02 O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). 	fluoxetine	amitriptyline	none	{'e1': {'word': 'fluoxetine', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d218.s8.e2'}, 'e2': {'word': 'amitriptyline', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d218.s8.e4'}, 'sentence_id': 'DDI-MedLine.d218.s8'}	O gastrointestinal bleeding O OR = O % CI O - 2.38 O 95 % O 2.38 ] O = 1.64 O % CI S-ORGANISM_SUBDIVISION , 1.02 O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). 	paroxetine	amitriptyline	none	{'e1': {'word': 'paroxetine', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d218.s8.e3'}, 'e2': {'word': 'amitriptyline', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d218.s8.e4'}, 'sentence_id': 'DDI-MedLine.d218.s8'}	O gastrointestinal bleeding O OR = O % CI O - 2.38 O 95 % O 2.38 ] O = 1.64 O % CI S-ORGANISM_SUBDIVISION , 1.02 O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
Also mirtazapine, which is not believed to interact with warfarin, increased the risk of GI bleeding (OR   =   1.75 [95% CI, 1.30-2.35]). 	mirtazapine	warfarin	effect	{'e1': {'word': 'mirtazapine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d218.s9.e0'}, 'e2': {'word': 'warfarin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d218.s9.e1'}, 'sentence_id': 'DDI-MedLine.d218.s9'}	O is not S-SIMPLE_CHEMICAL bleeding ( O = 1.75 O 1.30 - O ) . O O O O O O O O O O O O O O O O O O O O O O O O O O O O
Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. 	Warfarin	citalopram	effect	{'e1': {'word': 'Warfarin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d218.s10.e0'}, 'e2': {'word': 'citalopram', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d218.s10.e1'}, 'sentence_id': 'DDI-MedLine.d218.s10'}	O paroxetine , O an increased O for gastrointestinal O O O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O O O O S-ORGANISM_SUBDIVISION O O
Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. 	Warfarin	fluoxetine	effect	{'e1': {'word': 'Warfarin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d218.s10.e0'}, 'e2': {'word': 'fluoxetine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d218.s10.e2'}, 'sentence_id': 'DDI-MedLine.d218.s10'}	O paroxetine , O an increased O for gastrointestinal O O O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O O O O S-ORGANISM_SUBDIVISION O O
Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. 	Warfarin	paroxetine	effect	{'e1': {'word': 'Warfarin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d218.s10.e0'}, 'e2': {'word': 'paroxetine', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d218.s10.e3'}, 'sentence_id': 'DDI-MedLine.d218.s10'}	O paroxetine , O an increased O for gastrointestinal O O O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O O O O S-ORGANISM_SUBDIVISION O O
Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. 	Warfarin	amitriptyline	effect	{'e1': {'word': 'Warfarin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d218.s10.e0'}, 'e2': {'word': 'amitriptyline', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d218.s10.e4'}, 'sentence_id': 'DDI-MedLine.d218.s10'}	O paroxetine , O an increased O for gastrointestinal O O O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O O O O S-ORGANISM_SUBDIVISION O O
Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. 	Warfarin	mirtazapine	effect	{'e1': {'word': 'Warfarin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d218.s10.e0'}, 'e2': {'word': 'mirtazapine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d218.s10.e5'}, 'sentence_id': 'DDI-MedLine.d218.s10'}	O paroxetine , O an increased O for gastrointestinal O O O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O O O O S-ORGANISM_SUBDIVISION O O
Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. 	citalopram	fluoxetine	none	{'e1': {'word': 'citalopram', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d218.s10.e1'}, 'e2': {'word': 'fluoxetine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d218.s10.e2'}, 'sentence_id': 'DDI-MedLine.d218.s10'}	O paroxetine , O an increased O for gastrointestinal O O O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O O O O S-ORGANISM_SUBDIVISION O O
Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. 	citalopram	paroxetine	none	{'e1': {'word': 'citalopram', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d218.s10.e1'}, 'e2': {'word': 'paroxetine', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d218.s10.e3'}, 'sentence_id': 'DDI-MedLine.d218.s10'}	O paroxetine , O an increased O for gastrointestinal O O O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O O O O S-ORGANISM_SUBDIVISION O O
Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. 	citalopram	amitriptyline	none	{'e1': {'word': 'citalopram', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d218.s10.e1'}, 'e2': {'word': 'amitriptyline', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d218.s10.e4'}, 'sentence_id': 'DDI-MedLine.d218.s10'}	O paroxetine , O an increased O for gastrointestinal O O O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O O O O S-ORGANISM_SUBDIVISION O O
Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. 	citalopram	mirtazapine	none	{'e1': {'word': 'citalopram', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d218.s10.e1'}, 'e2': {'word': 'mirtazapine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d218.s10.e5'}, 'sentence_id': 'DDI-MedLine.d218.s10'}	O paroxetine , O an increased O for gastrointestinal O O O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O O O O S-ORGANISM_SUBDIVISION O O
Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. 	fluoxetine	paroxetine	none	{'e1': {'word': 'fluoxetine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d218.s10.e2'}, 'e2': {'word': 'paroxetine', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d218.s10.e3'}, 'sentence_id': 'DDI-MedLine.d218.s10'}	O paroxetine , O an increased O for gastrointestinal O O O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O O O O S-ORGANISM_SUBDIVISION O O
Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. 	fluoxetine	amitriptyline	none	{'e1': {'word': 'fluoxetine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d218.s10.e2'}, 'e2': {'word': 'amitriptyline', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d218.s10.e4'}, 'sentence_id': 'DDI-MedLine.d218.s10'}	O paroxetine , O an increased O for gastrointestinal O O O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O O O O S-ORGANISM_SUBDIVISION O O
Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. 	fluoxetine	mirtazapine	none	{'e1': {'word': 'fluoxetine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d218.s10.e2'}, 'e2': {'word': 'mirtazapine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d218.s10.e5'}, 'sentence_id': 'DDI-MedLine.d218.s10'}	O paroxetine , O an increased O for gastrointestinal O O O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O O O O S-ORGANISM_SUBDIVISION O O
Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. 	paroxetine	amitriptyline	none	{'e1': {'word': 'paroxetine', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d218.s10.e3'}, 'e2': {'word': 'amitriptyline', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d218.s10.e4'}, 'sentence_id': 'DDI-MedLine.d218.s10'}	O paroxetine , O an increased O for gastrointestinal O O O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O O O O S-ORGANISM_SUBDIVISION O O
Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. 	paroxetine	mirtazapine	none	{'e1': {'word': 'paroxetine', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d218.s10.e3'}, 'e2': {'word': 'mirtazapine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d218.s10.e5'}, 'sentence_id': 'DDI-MedLine.d218.s10'}	O paroxetine , O an increased O for gastrointestinal O O O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O O O O S-ORGANISM_SUBDIVISION O O
Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. 	amitriptyline	mirtazapine	none	{'e1': {'word': 'amitriptyline', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d218.s10.e4'}, 'e2': {'word': 'mirtazapine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d218.s10.e5'}, 'sentence_id': 'DDI-MedLine.d218.s10'}	O paroxetine , O an increased O for gastrointestinal O O O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O O O O O O S-ORGANISM_SUBDIVISION O O
"Improved parathyroid hormone control by cinacalcet is associated with reduction in darbepoetin requirement in patients with end-stage renal disease.
"	cinacalcet	darbepoetin	none	{'e1': {'word': 'cinacalcet', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d166.s0.e0'}, 'e2': {'word': 'darbepoetin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d166.s0.e1'}, 'sentence_id': 'DDI-MedLine.d166.s0'}	O with reduction S-ORGAN O O O S-SIMPLE_CHEMICAL O O O O O S-SIMPLE_CHEMICAL O O S-ORGANISM O O O O O O O
Uncontrolled hy-per-parathyroidism causes bone marrow fibrosis, leading to erythropoietin (EPO) resistance. 	erythropoietin	EPO	none	{'e1': {'word': 'erythropoietin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d166.s1.e0'}, 'e2': {'word': 'EPO', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d166.s1.e1'}, 'sentence_id': 'DDI-MedLine.d166.s1'}	O ( EPO O . O O O S-TISSUE S-MULTI-TISSUE_STRUCTURE O O O O S-GENE_OR_GENE_PRODUCT O O O O O
Medical treatment with cinacalcet is effective in reducing plasma parathyroid hormone (PTH) levels, but its effect on darbepoetin dosing is unknown. 	cinacalcet	darbepoetin	none	{'e1': {'word': 'cinacalcet', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d166.s2.e0'}, 'e2': {'word': 'darbepoetin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d166.s2.e1'}, 'sentence_id': 'DDI-MedLine.d166.s2'}	O reducing plasma O effect on O . S-SIMPLE_CHEMICAL O O O O S-ORGANISM_SUBSTANCE S-ORGAN O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O
The primary objective of the study was to ascertain the difference in darbepoetin responsiveness before and after 12 months of cinacalcet therapy. 	darbepoetin	cinacalcet	none	{'e1': {'word': 'darbepoetin', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d166.s6.e0'}, 'e2': {'word': 'cinacalcet', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d166.s6.e1'}, 'sentence_id': 'DDI-MedLine.d166.s6'}	O of the O darbepoetin responsiveness O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O S-SIMPLE_CHEMICAL O O
Reduction of PTH by cinacalcet is associated with a decrease in darbepoetin requirement. 	cinacalcet	darbepoetin	effect	{'e1': {'word': 'cinacalcet', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d166.s17.e0'}, 'e2': {'word': 'darbepoetin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d166.s17.e1'}, 'sentence_id': 'DDI-MedLine.d166.s17'}	O decrease in O . O O S-SIMPLE_CHEMICAL O O O O O O S-SIMPLE_CHEMICAL O O
Synergistic interaction between sunitinib and docetaxel is sequence dependent in human non-small lung cancer with EGFR TKIs-resistant mutation.	sunitinib	docetaxel	int	{'e1': {'word': 'sunitinib', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d179.s0.e0'}, 'e2': {'word': 'docetaxel', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d179.s0.e1'}, 'sentence_id': 'DDI-MedLine.d179.s0'}	O non-small lung O O O O O O O O O S-ORGANISM O S-ORGAN E-CANCER O O O O O O O
This study was aimed to investigate the efficacy of single use of sunitinib and that of concurrent or sequential administration of sunitinib and docetaxel in NSCLC cell lines that are resistant to EGFR TKIs.	sunitinib	sunitinib	none	{'e1': {'word': 'sunitinib', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d179.s2.e0'}, 'e2': {'word': 'sunitinib', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d179.s2.e1'}, 'sentence_id': 'DDI-MedLine.d179.s2'}	O to investigate O of sunitinib O concurrent or O docetaxel in O lines that O O O O O O O O O O O O O O O O O O O O O E-CELL O O O O O O O O
This study was aimed to investigate the efficacy of single use of sunitinib and that of concurrent or sequential administration of sunitinib and docetaxel in NSCLC cell lines that are resistant to EGFR TKIs.	sunitinib	docetaxel	none	{'e1': {'word': 'sunitinib', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d179.s2.e0'}, 'e2': {'word': 'docetaxel', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d179.s2.e2'}, 'sentence_id': 'DDI-MedLine.d179.s2'}	O to investigate O of sunitinib O concurrent or O docetaxel in O lines that O O O O O O O O O O O O O O O O O O O O O E-CELL O O O O O O O O
This study was aimed to investigate the efficacy of single use of sunitinib and that of concurrent or sequential administration of sunitinib and docetaxel in NSCLC cell lines that are resistant to EGFR TKIs.	sunitinib	docetaxel	none	{'e1': {'word': 'sunitinib', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d179.s2.e1'}, 'e2': {'word': 'docetaxel', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d179.s2.e2'}, 'sentence_id': 'DDI-MedLine.d179.s2'}	O to investigate O of sunitinib O concurrent or O docetaxel in O lines that O O O O O O O O O O O O O O O O O O O O O E-CELL O O O O O O O O
NSCLC cell lines with EGFR T790M mutation and K-ras mutation were exposed to either sunitinib or docetaxel or both based on various sequential administrations. 	sunitinib	docetaxel	none	{'e1': {'word': 'sunitinib', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d179.s3.e0'}, 'e2': {'word': 'docetaxel', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d179.s3.e1'}, 'sentence_id': 'DDI-MedLine.d179.s3'}	O T790M mutation E-CELL mutation were O docetaxel or O sequential administrations O O O O O O S-GENE_OR_GENE_PRODUCT O O O O O O O O O O O O O O O O
Sunitinib exhibited dose-dependent growth inhibition in NSCLC cell lines and arrested cell cycle at G1 phase, whereas docetaxel arrested at S phase. 	Sunitinib	docetaxel	none	{'e1': {'word': 'Sunitinib', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d179.s5.e0'}, 'e2': {'word': 'docetaxel', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d179.s5.e1'}, 'sentence_id': 'DDI-MedLine.d179.s5'}	S-SIMPLE_CHEMICAL cell lines O docetaxel arrested O O O O O O O E-CELL O O O E-CELL O O O O O O O O O O O O
Although single or concurrent use of sunitinib and docetaxel has some anti-proliferative effects, the sequential administrations of both drugs remarkably enhanced anti-tumor activity. 	sunitinib	docetaxel	effect	{'e1': {'word': 'sunitinib', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d179.s6.e0'}, 'e2': {'word': 'docetaxel', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d179.s6.e1'}, 'sentence_id': 'DDI-MedLine.d179.s6'}	O docetaxel has O administrations of O remarkably enhanced O O O O O O O O O O O O O O O O O O O O O O
When cells were exposed to docetaxel followed by sunitinib, synergism was observed. 	docetaxel	sunitinib	effect	{'e1': {'word': 'docetaxel', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d179.s7.e0'}, 'e2': {'word': 'sunitinib', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d179.s7.e1'}, 'sentence_id': 'DDI-MedLine.d179.s7'}	O to docetaxel S-CELL was observed O O O O O O O O O O O O
The molecular basis of this synergism is that the signaling pathways that were initially activated by docetaxel exposure were efficiently suppressed by the subsequent exposure to sunitinib. 	docetaxel	sunitinib	effect	{'e1': {'word': 'docetaxel', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d179.s8.e0'}, 'e2': {'word': 'sunitinib', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d179.s8.e1'}, 'sentence_id': 'DDI-MedLine.d179.s8'}	O of this O activated by O by the O to sunitinib O O O O O O O O O O O O O O O O O O O O O O O O
Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to sunitinib followed by docetaxel and concurrent administration.	Sunitinib	docetaxel	none	{'e1': {'word': 'Sunitinib', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d179.s10.e0'}, 'e2': {'word': 'docetaxel', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d179.s10.e1'}, 'sentence_id': 'DDI-MedLine.d179.s10'}	S-SIMPLE_CHEMICAL vitro in O lines with O T790M and O sequential administration O is superior O . O O O O O O E-CELL O O O O O O O S-GENE_OR_GENE_PRODUCT O O O O O O O O O O O O O O O O O O O O O
Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to sunitinib followed by docetaxel and concurrent administration.	Sunitinib	sunitinib	none	{'e1': {'word': 'Sunitinib', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d179.s10.e0'}, 'e2': {'word': 'sunitinib', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d179.s10.e2'}, 'sentence_id': 'DDI-MedLine.d179.s10'}	S-SIMPLE_CHEMICAL vitro in O lines with O T790M and O sequential administration O is superior O . O O O O O O E-CELL O O O O O O O S-GENE_OR_GENE_PRODUCT O O O O O O O O O O O O O O O O O O O O O
Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to sunitinib followed by docetaxel and concurrent administration.	Sunitinib	sunitinib	none	{'e1': {'word': 'Sunitinib', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d179.s10.e0'}, 'e2': {'word': 'sunitinib', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d179.s10.e3'}, 'sentence_id': 'DDI-MedLine.d179.s10'}	S-SIMPLE_CHEMICAL vitro in O lines with O T790M and O sequential administration O is superior O . O O O O O O E-CELL O O O O O O O S-GENE_OR_GENE_PRODUCT O O O O O O O O O O O O O O O O O O O O O
Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to sunitinib followed by docetaxel and concurrent administration.	Sunitinib	docetaxel	none	{'e1': {'word': 'Sunitinib', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d179.s10.e0'}, 'e2': {'word': 'docetaxel', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d179.s10.e4'}, 'sentence_id': 'DDI-MedLine.d179.s10'}	S-SIMPLE_CHEMICAL vitro in O lines with O T790M and O sequential administration O is superior O . O O O O O O E-CELL O O O O O O O S-GENE_OR_GENE_PRODUCT O O O O O O O O O O O O O O O O O O O O O
Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to sunitinib followed by docetaxel and concurrent administration.	docetaxel	sunitinib	effect	{'e1': {'word': 'docetaxel', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d179.s10.e1'}, 'e2': {'word': 'sunitinib', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d179.s10.e2'}, 'sentence_id': 'DDI-MedLine.d179.s10'}	S-SIMPLE_CHEMICAL vitro in O lines with O T790M and O sequential administration O is superior O . O O O O O O E-CELL O O O O O O O S-GENE_OR_GENE_PRODUCT O O O O O O O O O O O O O O O O O O O O O
Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to sunitinib followed by docetaxel and concurrent administration.	docetaxel	sunitinib	none	{'e1': {'word': 'docetaxel', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d179.s10.e1'}, 'e2': {'word': 'sunitinib', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d179.s10.e3'}, 'sentence_id': 'DDI-MedLine.d179.s10'}	S-SIMPLE_CHEMICAL vitro in O lines with O T790M and O sequential administration O is superior O . O O O O O O E-CELL O O O O O O O S-GENE_OR_GENE_PRODUCT O O O O O O O O O O O O O O O O O O O O O
Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to sunitinib followed by docetaxel and concurrent administration.	docetaxel	docetaxel	none	{'e1': {'word': 'docetaxel', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d179.s10.e1'}, 'e2': {'word': 'docetaxel', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d179.s10.e4'}, 'sentence_id': 'DDI-MedLine.d179.s10'}	S-SIMPLE_CHEMICAL vitro in O lines with O T790M and O sequential administration O is superior O . O O O O O O E-CELL O O O O O O O S-GENE_OR_GENE_PRODUCT O O O O O O O O O O O O O O O O O O O O O
Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to sunitinib followed by docetaxel and concurrent administration.	sunitinib	sunitinib	none	{'e1': {'word': 'sunitinib', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d179.s10.e2'}, 'e2': {'word': 'sunitinib', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d179.s10.e3'}, 'sentence_id': 'DDI-MedLine.d179.s10'}	S-SIMPLE_CHEMICAL vitro in O lines with O T790M and O sequential administration O is superior O . O O O O O O E-CELL O O O O O O O S-GENE_OR_GENE_PRODUCT O O O O O O O O O O O O O O O O O O O O O
Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to sunitinib followed by docetaxel and concurrent administration.	sunitinib	docetaxel	none	{'e1': {'word': 'sunitinib', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d179.s10.e2'}, 'e2': {'word': 'docetaxel', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d179.s10.e4'}, 'sentence_id': 'DDI-MedLine.d179.s10'}	S-SIMPLE_CHEMICAL vitro in O lines with O T790M and O sequential administration O is superior O . O O O O O O E-CELL O O O O O O O S-GENE_OR_GENE_PRODUCT O O O O O O O O O O O O O O O O O O O O O
Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to sunitinib followed by docetaxel and concurrent administration.	sunitinib	docetaxel	none	{'e1': {'word': 'sunitinib', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d179.s10.e3'}, 'e2': {'word': 'docetaxel', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d179.s10.e4'}, 'sentence_id': 'DDI-MedLine.d179.s10'}	S-SIMPLE_CHEMICAL vitro in O lines with O T790M and O sequential administration O is superior O . O O O O O O E-CELL O O O O O O O S-GENE_OR_GENE_PRODUCT O O O O O O O O O O O O O O O O O O O O O
"[Interaction between clopidogrel and proton pump inhibitors].
"	clopidogrel	proton pump inhibitors	none	{'e1': {'word': 'clopidogrel', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d143.s0.e0'}, 'e2': {'word': 'proton pump inhibitors', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d143.s0.e1'}, 'sentence_id': 'DDI-MedLine.d143.s0'}	O Interaction between O O O O O O O O O
The drug interaction between proton pump inhibitors and clopidogrel has been the subject of much study in recent years. 	proton pump inhibitors	clopidogrel	none	{'e1': {'word': 'proton pump inhibitors', 'word_index': [(2, 3)], 'id': 'DDI-MedLine.d143.s1.e0'}, 'e2': {'word': 'clopidogrel', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d143.s1.e1'}, 'sentence_id': 'DDI-MedLine.d143.s1'}	O between proton O has been O O O O O O O O O O O O O O O O O O
Contradictory results regarding the effect of proton pump inhibitors on platelet reactivity and on clinical outcome in clopidogrel-treated patients have been reported in literature. 	proton pump inhibitors	clopidogrel	none	{'e1': {'word': 'proton pump inhibitors', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d143.s2.e0'}, 'e2': {'word': 'clopidogrel', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d143.s2.e1'}, 'sentence_id': 'DDI-MedLine.d143.s2'}	O on clinical O been reported O O O O O O O O S-CELL O O O O O O O O O S-ORGANISM O O O O O O
Concomitant use of omeprazole and clopidogrel was found to decrease the exposure (AUC) to clopidogrel's active metabolite by 50% and to sharply increase platelet reactivity, as a result of inhibition by omeprazole of CYP2C19, a cytochrome P450 (CYP) enzyme. 	omeprazole	clopidogrel	mechanism	{'e1': {'word': 'omeprazole', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d143.s3.e0'}, 'e2': {'word': 'clopidogrel', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d143.s3.e1'}, 'sentence_id': 'DDI-MedLine.d143.s3'}	O exposure ( O clopidogrel 's O by 50 S-SIMPLE_CHEMICAL result of O of CYP2C19 O O O O O O O O O O O O O O O O O O O O O O S-CELL O O O O O O O O S-SIMPLE_CHEMICAL O O O O S-GENE_OR_GENE_PRODUCT S-GENE_OR_GENE_PRODUCT O O O O O
Concomitant use of omeprazole and clopidogrel was found to decrease the exposure (AUC) to clopidogrel's active metabolite by 50% and to sharply increase platelet reactivity, as a result of inhibition by omeprazole of CYP2C19, a cytochrome P450 (CYP) enzyme. 	omeprazole	omeprazole	none	{'e1': {'word': 'omeprazole', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d143.s3.e0'}, 'e2': {'word': 'omeprazole', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d143.s3.e2'}, 'sentence_id': 'DDI-MedLine.d143.s3'}	O exposure ( O clopidogrel 's O by 50 S-SIMPLE_CHEMICAL result of O of CYP2C19 O O O O O O O O O O O O O O O O O O O O O O S-CELL O O O O O O O O S-SIMPLE_CHEMICAL O O O O S-GENE_OR_GENE_PRODUCT S-GENE_OR_GENE_PRODUCT O O O O O
Concomitant use of omeprazole and clopidogrel was found to decrease the exposure (AUC) to clopidogrel's active metabolite by 50% and to sharply increase platelet reactivity, as a result of inhibition by omeprazole of CYP2C19, a cytochrome P450 (CYP) enzyme. 	clopidogrel	omeprazole	none	{'e1': {'word': 'clopidogrel', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d143.s3.e1'}, 'e2': {'word': 'omeprazole', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d143.s3.e2'}, 'sentence_id': 'DDI-MedLine.d143.s3'}	O exposure ( O clopidogrel 's O by 50 S-SIMPLE_CHEMICAL result of O of CYP2C19 O O O O O O O O O O O O O O O O O O O O O O S-CELL O O O O O O O O S-SIMPLE_CHEMICAL O O O O S-GENE_OR_GENE_PRODUCT S-GENE_OR_GENE_PRODUCT O O O O O
Pantoprazole has a much weaker effect on clopidogrel's pharmacokinetics and on platelet reactivity during concomitant use. 	Pantoprazole	clopidogrel	mechanism	{'e1': {'word': 'Pantoprazole', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d143.s4.e0'}, 'e2': {'word': 'clopidogrel', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d143.s4.e1'}, 'sentence_id': 'DDI-MedLine.d143.s4'}	O platelet reactivity O . O O O O O O O O O O S-CELL O O O O O
The influence of the other proton pump inhibitors when used simultaneously with clopidogrel has not yet been investigated in adequately randomized studies. 	proton pump inhibitors	clopidogrel	none	{'e1': {'word': 'proton pump inhibitors', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d143.s5.e0'}, 'e2': {'word': 'clopidogrel', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d143.s5.e1'}, 'sentence_id': 'DDI-MedLine.d143.s5'}	O the other O not yet O in adequately O O O O O O O O O O O O O O O O O O O O
Regulatory agencies state that the combination of clopidogrel and the CYP2C19 inhibitors omeprazole and esomeprazole should be avoided. 	clopidogrel	omeprazole	advise	{'e1': {'word': 'clopidogrel', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d143.s6.e0'}, 'e2': {'word': 'omeprazole', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d143.s6.e1'}, 'sentence_id': 'DDI-MedLine.d143.s6'}	O CYP2C19 inhibitors O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O
Regulatory agencies state that the combination of clopidogrel and the CYP2C19 inhibitors omeprazole and esomeprazole should be avoided. 	clopidogrel	esomeprazole	advise	{'e1': {'word': 'clopidogrel', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d143.s6.e0'}, 'e2': {'word': 'esomeprazole', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d143.s6.e2'}, 'sentence_id': 'DDI-MedLine.d143.s6'}	O CYP2C19 inhibitors O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O
Regulatory agencies state that the combination of clopidogrel and the CYP2C19 inhibitors omeprazole and esomeprazole should be avoided. 	omeprazole	esomeprazole	none	{'e1': {'word': 'omeprazole', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d143.s6.e1'}, 'e2': {'word': 'esomeprazole', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d143.s6.e2'}, 'sentence_id': 'DDI-MedLine.d143.s6'}	O CYP2C19 inhibitors O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O
To date, there is no conclusive evidence of a clinically-relevant interaction between any of the proton pump inhibitors and clopidogrel.	proton pump inhibitors	clopidogrel	none	{'e1': {'word': 'proton pump inhibitors', 'word_index': [(10, 12)], 'id': 'DDI-MedLine.d143.s7.e0'}, 'e2': {'word': 'clopidogrel', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d143.s7.e1'}, 'sentence_id': 'DDI-MedLine.d143.s7'}	O , there O of a O - relevant O proton pump O clopidogrel . O O O O O O O O O O O O O O O O O O O
"Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein.
"	lenalidomide	CCI-779	none	{'e1': {'word': 'lenalidomide', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d211.s0.e0'}, 'e2': {'word': 'CCI-779', 'word_index': [(2, 4)], 'id': 'DDI-MedLine.d211.s0.e1'}, 'sentence_id': 'DDI-MedLine.d211.s0'}	O and CCI O 779 in O : evidence O - CCI S-SIMPLE_CHEMICAL O O O O O S-ORGANISM O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O
"Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein.
"	lenalidomide	lenalidomide	none	{'e1': {'word': 'lenalidomide', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d211.s0.e0'}, 'e2': {'word': 'lenalidomide', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d211.s0.e2'}, 'sentence_id': 'DDI-MedLine.d211.s0'}	O and CCI O 779 in O : evidence O - CCI S-SIMPLE_CHEMICAL O O O O O S-ORGANISM O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O
"Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein.
"	lenalidomide	CCI-779	none	{'e1': {'word': 'lenalidomide', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d211.s0.e0'}, 'e2': {'word': 'CCI-779', 'word_index': [(11, 12)], 'id': 'DDI-MedLine.d211.s0.e3'}, 'sentence_id': 'DDI-MedLine.d211.s0'}	O and CCI O 779 in O : evidence O - CCI S-SIMPLE_CHEMICAL O O O O O S-ORGANISM O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O
"Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein.
"	CCI-779	lenalidomide	none	{'e1': {'word': 'CCI-779', 'word_index': [(2, 4)], 'id': 'DDI-MedLine.d211.s0.e1'}, 'e2': {'word': 'lenalidomide', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d211.s0.e2'}, 'sentence_id': 'DDI-MedLine.d211.s0'}	O and CCI O 779 in O : evidence O - CCI S-SIMPLE_CHEMICAL O O O O O S-ORGANISM O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O
"Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein.
"	CCI-779	CCI-779	none	{'e1': {'word': 'CCI-779', 'word_index': [(2, 4)], 'id': 'DDI-MedLine.d211.s0.e1'}, 'e2': {'word': 'CCI-779', 'word_index': [(11, 12)], 'id': 'DDI-MedLine.d211.s0.e3'}, 'sentence_id': 'DDI-MedLine.d211.s0'}	O and CCI O 779 in O : evidence O - CCI S-SIMPLE_CHEMICAL O O O O O S-ORGANISM O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O
"Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein.
"	lenalidomide	CCI-779	none	{'e1': {'word': 'lenalidomide', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d211.s0.e2'}, 'e2': {'word': 'CCI-779', 'word_index': [(11, 12)], 'id': 'DDI-MedLine.d211.s0.e3'}, 'sentence_id': 'DDI-MedLine.d211.s0'}	O and CCI O 779 in O : evidence O - CCI S-SIMPLE_CHEMICAL O O O O O S-ORGANISM O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O
The preclinical combination of lenalidomide with the mTOR inhibitor CCI-779 has displayed synergy in vitro and represents a novel combination in MM.	lenalidomide	CCI-779	effect	{'e1': {'word': 'lenalidomide', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d211.s2.e0'}, 'e2': {'word': 'CCI-779', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d211.s2.e1'}, 'sentence_id': 'DDI-MedLine.d211.s2'}	O of lenalidomide O vitro and O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O
"The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells.
"	dasatinib	paclitaxel	effect	{'e1': {'word': 'dasatinib', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d194.s0.e0'}, 'e2': {'word': 'paclitaxel', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d194.s0.e1'}, 'sentence_id': 'DDI-MedLine.d194.s0'}	O p27 ( O - enhanced O in human S-GENE_OR_GENE_PRODUCT . O O O O O O O S-SIMPLE_CHEMICAL O O S-ORGANISM S-ORGAN E-CANCER S-CELL O
The effect of dasatinib, an inhibitor of Src and Abl kinases, on paclitaxel sensitivity was measured in ovarian cancer cells and HEY xenografts. 	dasatinib	paclitaxel	none	{'e1': {'word': 'dasatinib', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d194.s4.e0'}, 'e2': {'word': 'paclitaxel', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d194.s4.e1'}, 'sentence_id': 'DDI-MedLine.d194.s4'}	O dasatinib , O kinases , O sensitivity was O O O O O S-GENE_OR_GENE_PRODUCT O O O O O S-SIMPLE_CHEMICAL O O O O S-ORGAN E-CANCER S-CELL O O S-CANCER O
The roles of p27(Kip1), Bcl-2, and Cdk1 in apoptosis induced by dasatinib and paclitaxel were assessed using a terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay, siRNA knockdown of gene expression, transfection with Bcl-2 and Cdk1 expression vectors, and flow cytometry. 	dasatinib	paclitaxel	none	{'e1': {'word': 'dasatinib', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d194.s5.e0'}, 'e2': {'word': 'paclitaxel', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d194.s5.e1'}, 'sentence_id': 'DDI-MedLine.d194.s5'}	O p27 ( O 2 , O in apoptosis S-GENE_OR_GENE_PRODUCT and paclitaxel O assessed using O - mediated O nick - O labeling ( O , siRNA O of gene O , transfection O Bcl - O expression vectors S-GENE_OR_GENE_PRODUCT . O O O O O O S-SIMPLE_CHEMICAL O O O O O O S-GENE_OR_GENE_PRODUCT O O O O O O O O O O O O O O O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O O O O O O O
HEY cells treated with dasatinib plus paclitaxel formed fewer colonies than did cells treated with either agent alone. 	dasatinib	paclitaxel	effect	{'e1': {'word': 'dasatinib', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d194.s9.e0'}, 'e2': {'word': 'paclitaxel', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d194.s9.e1'}, 'sentence_id': 'DDI-MedLine.d194.s9'}	O with dasatinib S-CELL than did O O O O S-SIMPLE_CHEMICAL O O O O O S-CELL O O O O O O
Treatment of HEY xenograft-bearing mice with dasatinib plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + paclitaxel vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); 	dasatinib	paclitaxel	effect	{'e1': {'word': 'dasatinib', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d194.s10.e0'}, 'e2': {'word': 'paclitaxel', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d194.s10.e1'}, 'sentence_id': 'DDI-MedLine.d194.s10'}	O plus paclitaxel O growth more O either agent S-CANCER + paclitaxel O paclitaxel : O = 0.53 S-ORGANISM confidence interval O 0.44 to O O S-SIMPLE_CHEMICAL O S-CANCER O O O O O O O O O O S-CANCER O O S-ORGANISM O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
Treatment of HEY xenograft-bearing mice with dasatinib plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + paclitaxel vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); 	dasatinib	dasatinib	none	{'e1': {'word': 'dasatinib', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d194.s10.e0'}, 'e2': {'word': 'dasatinib', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d194.s10.e2'}, 'sentence_id': 'DDI-MedLine.d194.s10'}	O plus paclitaxel O growth more O either agent S-CANCER + paclitaxel O paclitaxel : O = 0.53 S-ORGANISM confidence interval O 0.44 to O O S-SIMPLE_CHEMICAL O S-CANCER O O O O O O O O O O S-CANCER O O S-ORGANISM O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
Treatment of HEY xenograft-bearing mice with dasatinib plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + paclitaxel vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); 	dasatinib	paclitaxel	none	{'e1': {'word': 'dasatinib', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d194.s10.e0'}, 'e2': {'word': 'paclitaxel', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d194.s10.e3'}, 'sentence_id': 'DDI-MedLine.d194.s10'}	O plus paclitaxel O growth more O either agent S-CANCER + paclitaxel O paclitaxel : O = 0.53 S-ORGANISM confidence interval O 0.44 to O O S-SIMPLE_CHEMICAL O S-CANCER O O O O O O O O O O S-CANCER O O S-ORGANISM O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
Treatment of HEY xenograft-bearing mice with dasatinib plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + paclitaxel vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); 	dasatinib	paclitaxel	none	{'e1': {'word': 'dasatinib', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d194.s10.e0'}, 'e2': {'word': 'paclitaxel', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d194.s10.e4'}, 'sentence_id': 'DDI-MedLine.d194.s10'}	O plus paclitaxel O growth more O either agent S-CANCER + paclitaxel O paclitaxel : O = 0.53 S-ORGANISM confidence interval O 0.44 to O O S-SIMPLE_CHEMICAL O S-CANCER O O O O O O O O O O S-CANCER O O S-ORGANISM O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
Treatment of HEY xenograft-bearing mice with dasatinib plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + paclitaxel vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); 	paclitaxel	dasatinib	none	{'e1': {'word': 'paclitaxel', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d194.s10.e1'}, 'e2': {'word': 'dasatinib', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d194.s10.e2'}, 'sentence_id': 'DDI-MedLine.d194.s10'}	O plus paclitaxel O growth more O either agent S-CANCER + paclitaxel O paclitaxel : O = 0.53 S-ORGANISM confidence interval O 0.44 to O O S-SIMPLE_CHEMICAL O S-CANCER O O O O O O O O O O S-CANCER O O S-ORGANISM O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
Treatment of HEY xenograft-bearing mice with dasatinib plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + paclitaxel vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); 	paclitaxel	paclitaxel	none	{'e1': {'word': 'paclitaxel', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d194.s10.e1'}, 'e2': {'word': 'paclitaxel', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d194.s10.e3'}, 'sentence_id': 'DDI-MedLine.d194.s10'}	O plus paclitaxel O growth more O either agent S-CANCER + paclitaxel O paclitaxel : O = 0.53 S-ORGANISM confidence interval O 0.44 to O O S-SIMPLE_CHEMICAL O S-CANCER O O O O O O O O O O S-CANCER O O S-ORGANISM O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
Treatment of HEY xenograft-bearing mice with dasatinib plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + paclitaxel vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); 	paclitaxel	paclitaxel	none	{'e1': {'word': 'paclitaxel', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d194.s10.e1'}, 'e2': {'word': 'paclitaxel', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d194.s10.e4'}, 'sentence_id': 'DDI-MedLine.d194.s10'}	O plus paclitaxel O growth more O either agent S-CANCER + paclitaxel O paclitaxel : O = 0.53 S-ORGANISM confidence interval O 0.44 to O O S-SIMPLE_CHEMICAL O S-CANCER O O O O O O O O O O S-CANCER O O S-ORGANISM O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
Treatment of HEY xenograft-bearing mice with dasatinib plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + paclitaxel vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); 	dasatinib	paclitaxel	none	{'e1': {'word': 'dasatinib', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d194.s10.e2'}, 'e2': {'word': 'paclitaxel', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d194.s10.e3'}, 'sentence_id': 'DDI-MedLine.d194.s10'}	O plus paclitaxel O growth more O either agent S-CANCER + paclitaxel O paclitaxel : O = 0.53 S-ORGANISM confidence interval O 0.44 to O O S-SIMPLE_CHEMICAL O S-CANCER O O O O O O O O O O S-CANCER O O S-ORGANISM O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
Treatment of HEY xenograft-bearing mice with dasatinib plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + paclitaxel vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); 	dasatinib	paclitaxel	none	{'e1': {'word': 'dasatinib', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d194.s10.e2'}, 'e2': {'word': 'paclitaxel', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d194.s10.e4'}, 'sentence_id': 'DDI-MedLine.d194.s10'}	O plus paclitaxel O growth more O either agent S-CANCER + paclitaxel O paclitaxel : O = 0.53 S-ORGANISM confidence interval O 0.44 to O O S-SIMPLE_CHEMICAL O S-CANCER O O O O O O O O O O S-CANCER O O S-ORGANISM O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
Treatment of HEY xenograft-bearing mice with dasatinib plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + paclitaxel vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); 	paclitaxel	paclitaxel	none	{'e1': {'word': 'paclitaxel', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d194.s10.e3'}, 'e2': {'word': 'paclitaxel', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d194.s10.e4'}, 'sentence_id': 'DDI-MedLine.d194.s10'}	O plus paclitaxel O growth more O either agent S-CANCER + paclitaxel O paclitaxel : O = 0.53 S-ORGANISM confidence interval O 0.44 to O O S-SIMPLE_CHEMICAL O S-CANCER O O O O O O O O O O S-CANCER O O S-ORGANISM O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
dasatinib + paclitaxel vs. 	dasatinib	paclitaxel	none	{'e1': {'word': 'dasatinib', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d194.s11.e0'}, 'e2': {'word': 'paclitaxel', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d194.s11.e1'}, 'sentence_id': 'DDI-MedLine.d194.s11'}	O O S-SIMPLE_CHEMICAL O O
The siRNA knockdown of p27(Kip1) decreased dasatinib- and paclitaxel-induced apoptosis compared with a negative control siRNA (sub-G1 fraction, control siRNA vs. p27(Kip1) siRNA: 42.5% vs. 20.1%, difference = 22.4%, 95% CI = 20.1% to 24.7%, P = .017). 	dasatinib	paclitaxel	none	{'e1': {'word': 'dasatinib', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d194.s15.e0'}, 'e2': {'word': 'paclitaxel', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d194.s15.e1'}, 'sentence_id': 'DDI-MedLine.d194.s15'}	O of p27 O - and O siRNA ( O , control S-GENE_OR_GENE_PRODUCT ( Kip1 O siRNA : O % , O = 22.4 O 24.7 % O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
Studies with forced expression and siRNA knockdown of Bcl-2 and Cdk1 suggest that dasatinib-mediated induction of p27(Kip1) enhanced paclitaxel-induced apoptosis by negatively regulating Bcl-2 and Cdk1 expression. 	dasatinib	paclitaxel	effect	{'e1': {'word': 'dasatinib', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d194.s16.e0'}, 'e2': {'word': 'paclitaxel', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d194.s16.e1'}, 'sentence_id': 'DDI-MedLine.d194.s16'}	O of Bcl O suggest that O ( Kip1 O - 2 O . O O O O O O O S-GENE_OR_GENE_PRODUCT O O O O O O O S-GENE_OR_GENE_PRODUCT O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O O
Inhibition of Src family and Abl kinases with either siRNAs or dasatinib enhances paclitaxel sensitivity of ovarian cancer cells through p27(Kip1)-mediated suppression of Bcl-2 and Cdk1 expression.	dasatinib	paclitaxel	effect	{'e1': {'word': 'dasatinib', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d194.s17.e0'}, 'e2': {'word': 'paclitaxel', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d194.s17.e1'}, 'sentence_id': 'DDI-MedLine.d194.s17'}	O or dasatinib O sensitivity of S-GENE_OR_GENE_PRODUCT through p27 O of Bcl O Cdk1 expression O O O O O O O O S-SIMPLE_CHEMICAL O O S-ORGAN E-CANCER S-CELL O S-GENE_OR_GENE_PRODUCT O O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O O
[Efficacy of fixed combination amlodipine/valsartan in hospitalized patients with hypertensive disease]	amlodipine	valsartan	none	{'e1': {'word': 'amlodipine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d200.s0.e0'}, 'e2': {'word': 'valsartan', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d200.s0.e1'}, 'sentence_id': 'DDI-MedLine.d200.s0'}	O Efficacy of O with hypertensive O O O S-SIMPLE_CHEMICAL O O O O S-ORGANISM O O O O
Efficacy and tolerability of fixed amlodipine/valsartan combination was studied in 86 patients with hypertensive disease hospitalized in departments of general internal medicine or cardiology. 	amlodipine	valsartan	none	{'e1': {'word': 'amlodipine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d200.s1.e0'}, 'e2': {'word': 'valsartan', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d200.s1.e1'}, 'sentence_id': 'DDI-MedLine.d200.s1'}	O combination was O patients with O O O S-SIMPLE_CHEMICAL O O O O O O O S-ORGANISM O O O O O O O O O O O O O
All patients had indications for antihypertensive therapy and were randomized either to fixed combination amlodipine/valsartan (n=43) or to therapy which corresponded to the hospital formulary (n=43). 	amlodipine	valsartan	none	{'e1': {'word': 'amlodipine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d200.s2.e0'}, 'e2': {'word': 'valsartan', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d200.s2.e1'}, 'sentence_id': 'DDI-MedLine.d200.s2'}	O indications for S-ORGANISM combination amlodipine O n = O ( n O . O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O
Rate of achievement of target BP with fixed combination amlodipine/valsartan (93%) was comparable with that on traditional therapy (90%). 	amlodipine	valsartan	none	{'e1': {'word': 'amlodipine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d200.s7.e0'}, 'e2': {'word': 'valsartan', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d200.s7.e1'}, 'sentence_id': 'DDI-MedLine.d200.s7'}	O target BP O combination amlodipine O traditional therapy O % ) O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O
But the use of fixed combination amlodipine/valsartan compared with traditional therapy was associated with lower clinical and self measured BP, quicker achievement of target BP (5.8+/-2.3 and 9.2+/-1.8 days, respectively, 0.05), lesser number of antihypertensive drugs (2.5+/-0.6 and 3.0+/-0.9 days, respectively), lower rate of concealed inefficacy of treatment (12 and 31%, respectively, 0.05). 	amlodipine	valsartan	effect	{'e1': {'word': 'amlodipine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d200.s8.e0'}, 'e2': {'word': 'valsartan', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d200.s8.e1'}, 'sentence_id': 'DDI-MedLine.d200.s8'}	O of fixed O valsartan compared O was associated O clinical and O achievement of O / - S-SIMPLE_CHEMICAL of antihypertensive O ( 2.5 O 0.9 days O inefficacy of O 31 % O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
But the use of fixed combination amlodipine/valsartan compared with traditional therapy was associated with lower clinical and self measured BP, quicker achievement of target BP (5.8+/-2.3 and 9.2+/-1.8 days, respectively, 0.05), lesser number of antihypertensive drugs (2.5+/-0.6 and 3.0+/-0.9 days, respectively), lower rate of concealed inefficacy of treatment (12 and 31%, respectively, 0.05). 	amlodipine	antihypertensive drugs	none	{'e1': {'word': 'amlodipine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d200.s8.e0'}, 'e2': {'word': 'antihypertensive drugs', 'word_index': [(20, 21)], 'id': 'DDI-MedLine.d200.s8.e2'}, 'sentence_id': 'DDI-MedLine.d200.s8'}	O of fixed O valsartan compared O was associated O clinical and O achievement of O / - S-SIMPLE_CHEMICAL of antihypertensive O ( 2.5 O 0.9 days O inefficacy of O 31 % O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
But the use of fixed combination amlodipine/valsartan compared with traditional therapy was associated with lower clinical and self measured BP, quicker achievement of target BP (5.8+/-2.3 and 9.2+/-1.8 days, respectively, 0.05), lesser number of antihypertensive drugs (2.5+/-0.6 and 3.0+/-0.9 days, respectively), lower rate of concealed inefficacy of treatment (12 and 31%, respectively, 0.05). 	valsartan	antihypertensive drugs	none	{'e1': {'word': 'valsartan', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d200.s8.e1'}, 'e2': {'word': 'antihypertensive drugs', 'word_index': [(20, 21)], 'id': 'DDI-MedLine.d200.s8.e2'}, 'sentence_id': 'DDI-MedLine.d200.s8'}	O of fixed O valsartan compared O was associated O clinical and O achievement of O / - S-SIMPLE_CHEMICAL of antihypertensive O ( 2.5 O 0.9 days O inefficacy of O 31 % O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
We have demonstrated appropriateness of inhospital administration of fixed amlodipine/valsartan combination as an approach allowing to achieve target BP in shorter time, with the use of fewer antihypertensive drugs, and diminishing concealed inefficacy of treatment.	amlodipine	valsartan	effect	{'e1': {'word': 'amlodipine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d200.s10.e0'}, 'e2': {'word': 'valsartan', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d200.s10.e1'}, 'sentence_id': 'DDI-MedLine.d200.s10'}	O demonstrated appropriateness O fixed amlodipine O shorter time O . O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
We have demonstrated appropriateness of inhospital administration of fixed amlodipine/valsartan combination as an approach allowing to achieve target BP in shorter time, with the use of fewer antihypertensive drugs, and diminishing concealed inefficacy of treatment.	amlodipine	antihypertensive drugs	none	{'e1': {'word': 'amlodipine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d200.s10.e0'}, 'e2': {'word': 'antihypertensive drugs', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d200.s10.e2'}, 'sentence_id': 'DDI-MedLine.d200.s10'}	O demonstrated appropriateness O fixed amlodipine O shorter time O . O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
We have demonstrated appropriateness of inhospital administration of fixed amlodipine/valsartan combination as an approach allowing to achieve target BP in shorter time, with the use of fewer antihypertensive drugs, and diminishing concealed inefficacy of treatment.	valsartan	antihypertensive drugs	none	{'e1': {'word': 'valsartan', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d200.s10.e1'}, 'e2': {'word': 'antihypertensive drugs', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d200.s10.e2'}, 'sentence_id': 'DDI-MedLine.d200.s10'}	O demonstrated appropriateness O fixed amlodipine O shorter time O . O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
The incubations were performed in the absence and presence of the non-specific CYP inhibitor, 1-aminobenzotriazole (ABT) and isoform-specific inhibitors. 	1-aminobenzotriazole	ABT	none	{'e1': {'word': '1-aminobenzotriazole', 'word_index': [(3, 5)], 'id': 'DDI-MedLine.d189.s3.e0'}, 'e2': {'word': 'ABT', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d189.s3.e1'}, 'sentence_id': 'DDI-MedLine.d189.s3'}	O performed in O - aminobenzotriazole O isoform - O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O
ABT decreased the toxicity of precocene I, increased exposure to parent compound, and decreased metabolite levels in a dose-dependent manner. 	ABT	precocene I	effect	{'e1': {'word': 'ABT', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d189.s7.e0'}, 'e2': {'word': 'precocene I', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d189.s7.e1'}, 'sentence_id': 'DDI-MedLine.d189.s7'}	O toxicity of O and decreased O a dose O O O O O O O O O O O O O O O O O O O O O O
Of the isoform-specific CYP inhibitors tested for an effect on the precocene I metabolite profile, only tranylcypromine was noticeably effective, indicating a role of CYPs 2A6, 2C9, 2Cl9, and 2E1. 	precocene I	tranylcypromine	none	{'e1': {'word': 'precocene I', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d189.s8.e0'}, 'e2': {'word': 'tranylcypromine', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d189.s8.e1'}, 'sentence_id': 'DDI-MedLine.d189.s8'}	O isoform - O tested for O profile , O tranylcypromine was O 2A6 , O , and O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O O O O S-GENE_OR_GENE_PRODUCT O
With respect to toxicity, the order of CYP inhibitor effectiveness was ABT>diethyldithiocarbamate~tranylcypromine>ketoconazole. 	ABT	diethyldithiocarbamate	none	{'e1': {'word': 'ABT', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d189.s9.e0'}, 'e2': {'word': 'diethyldithiocarbamate', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d189.s9.e1'}, 'sentence_id': 'DDI-MedLine.d189.s9'}	O , the O > diethyldithiocarbamate O > ketoconazole O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O
With respect to toxicity, the order of CYP inhibitor effectiveness was ABT>diethyldithiocarbamate~tranylcypromine>ketoconazole. 	ABT	tranylcypromine	none	{'e1': {'word': 'ABT', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d189.s9.e0'}, 'e2': {'word': 'tranylcypromine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d189.s9.e2'}, 'sentence_id': 'DDI-MedLine.d189.s9'}	O , the O > diethyldithiocarbamate O > ketoconazole O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O
With respect to toxicity, the order of CYP inhibitor effectiveness was ABT>diethyldithiocarbamate~tranylcypromine>ketoconazole. 	ABT	ketoconazole	none	{'e1': {'word': 'ABT', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d189.s9.e0'}, 'e2': {'word': 'ketoconazole', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d189.s9.e3'}, 'sentence_id': 'DDI-MedLine.d189.s9'}	O , the O > diethyldithiocarbamate O > ketoconazole O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O
With respect to toxicity, the order of CYP inhibitor effectiveness was ABT>diethyldithiocarbamate~tranylcypromine>ketoconazole. 	diethyldithiocarbamate	tranylcypromine	none	{'e1': {'word': 'diethyldithiocarbamate', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d189.s9.e1'}, 'e2': {'word': 'tranylcypromine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d189.s9.e2'}, 'sentence_id': 'DDI-MedLine.d189.s9'}	O , the O > diethyldithiocarbamate O > ketoconazole O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O
With respect to toxicity, the order of CYP inhibitor effectiveness was ABT>diethyldithiocarbamate~tranylcypromine>ketoconazole. 	diethyldithiocarbamate	ketoconazole	none	{'e1': {'word': 'diethyldithiocarbamate', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d189.s9.e1'}, 'e2': {'word': 'ketoconazole', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d189.s9.e3'}, 'sentence_id': 'DDI-MedLine.d189.s9'}	O , the O > diethyldithiocarbamate O > ketoconazole O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O
With respect to toxicity, the order of CYP inhibitor effectiveness was ABT>diethyldithiocarbamate~tranylcypromine>ketoconazole. 	tranylcypromine	ketoconazole	none	{'e1': {'word': 'tranylcypromine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d189.s9.e2'}, 'e2': {'word': 'ketoconazole', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d189.s9.e3'}, 'sentence_id': 'DDI-MedLine.d189.s9'}	O , the O > diethyldithiocarbamate O > ketoconazole O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O
Furafylline and sulfaphenazole had no effect, while quinidine appeared to augment precocene I toxicity. 	Furafylline	sulfaphenazole	none	{'e1': {'word': 'Furafylline', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d189.s10.e0'}, 'e2': {'word': 'sulfaphenazole', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d189.s10.e1'}, 'sentence_id': 'DDI-MedLine.d189.s10'}	O augment precocene O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O
Furafylline and sulfaphenazole had no effect, while quinidine appeared to augment precocene I toxicity. 	Furafylline	quinidine	none	{'e1': {'word': 'Furafylline', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d189.s10.e0'}, 'e2': {'word': 'quinidine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d189.s10.e2'}, 'sentence_id': 'DDI-MedLine.d189.s10'}	O augment precocene O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O
Furafylline and sulfaphenazole had no effect, while quinidine appeared to augment precocene I toxicity. 	Furafylline	precocene I	none	{'e1': {'word': 'Furafylline', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d189.s10.e0'}, 'e2': {'word': 'precocene I', 'word_index': [(2, 3)], 'id': 'DDI-MedLine.d189.s10.e3'}, 'sentence_id': 'DDI-MedLine.d189.s10'}	O augment precocene O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O
Furafylline and sulfaphenazole had no effect, while quinidine appeared to augment precocene I toxicity. 	sulfaphenazole	quinidine	none	{'e1': {'word': 'sulfaphenazole', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d189.s10.e1'}, 'e2': {'word': 'quinidine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d189.s10.e2'}, 'sentence_id': 'DDI-MedLine.d189.s10'}	O augment precocene O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O
Furafylline and sulfaphenazole had no effect, while quinidine appeared to augment precocene I toxicity. 	sulfaphenazole	precocene I	none	{'e1': {'word': 'sulfaphenazole', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d189.s10.e1'}, 'e2': {'word': 'precocene I', 'word_index': [(2, 3)], 'id': 'DDI-MedLine.d189.s10.e3'}, 'sentence_id': 'DDI-MedLine.d189.s10'}	O augment precocene O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O
Furafylline and sulfaphenazole had no effect, while quinidine appeared to augment precocene I toxicity. 	quinidine	precocene I	effect	{'e1': {'word': 'quinidine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d189.s10.e2'}, 'e2': {'word': 'precocene I', 'word_index': [(2, 3)], 'id': 'DDI-MedLine.d189.s10.e3'}, 'sentence_id': 'DDI-MedLine.d189.s10'}	O augment precocene O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O
These results suggest that rat liver slices do not reproduce the reported in vivo biotransformation of precocene I and therefore may not be an appropriate model for precocene I metabolism. 	precocene I	precocene I	none	{'e1': {'word': 'precocene I', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d189.s11.e0'}, 'e2': {'word': 'precocene I', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d189.s11.e1'}, 'sentence_id': 'DDI-MedLine.d189.s11'}	O liver slices O biotransformation of O an appropriate O metabolism . S-ORGANISM S-ORGAN O O O O O O O O O O O O O O O O O O O O O O O O O
Calcium does not inhibit the absorption of 5 milligrams of nonheme or heme iron at doses less than 800 milligrams in nonpregnant women.	Calcium	nonheme iron	none	{'e1': {'word': 'Calcium', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d169.s0.e0'}, 'e2': {'word': 'nonheme iron', 'word_index': [(3, 3), (5, 5)], 'id': 'DDI-MedLine.d169.s0.e1'}, 'sentence_id': 'DDI-MedLine.d169.s0'}	O 5 milligrams O iron iron O than 800 O O O O O O O O O O O O O O O O O O O O S-ORGANISM O
Calcium does not inhibit the absorption of 5 milligrams of nonheme or heme iron at doses less than 800 milligrams in nonpregnant women.	Calcium	heme iron	none	{'e1': {'word': 'Calcium', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d169.s0.e0'}, 'e2': {'word': 'heme iron', 'word_index': [(3, 4)], 'id': 'DDI-MedLine.d169.s0.e2'}, 'sentence_id': 'DDI-MedLine.d169.s0'}	O 5 milligrams O iron iron O than 800 O O O O O O O O O O O O O O O O O O O O S-ORGANISM O
Calcium does not inhibit the absorption of 5 milligrams of nonheme or heme iron at doses less than 800 milligrams in nonpregnant women.	nonheme iron	heme iron	none	{'e1': {'word': 'nonheme iron', 'word_index': [(3, 3), (5, 5)], 'id': 'DDI-MedLine.d169.s0.e1'}, 'e2': {'word': 'heme iron', 'word_index': [(3, 4)], 'id': 'DDI-MedLine.d169.s0.e2'}, 'sentence_id': 'DDI-MedLine.d169.s0'}	O 5 milligrams O iron iron O than 800 O O O O O O O O O O O O O O O O O O O O S-ORGANISM O
Calcium is the only known component in the diet that may affect absorption of both nonheme and heme iron. 	Calcium	nonheme iron	mechanism	{'e1': {'word': 'Calcium', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d169.s1.e0'}, 'e2': {'word': 'nonheme iron', 'word_index': [(6, 6), (9, 9)], 'id': 'DDI-MedLine.d169.s1.e1'}, 'sentence_id': 'DDI-MedLine.d169.s1'}	O the diet O affect absorption O and heme O O O O O O O O O O O O O O O O O O
Calcium is the only known component in the diet that may affect absorption of both nonheme and heme iron. 	Calcium	heme iron	mechanism	{'e1': {'word': 'Calcium', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d169.s1.e0'}, 'e2': {'word': 'heme iron', 'word_index': [(8, 9)], 'id': 'DDI-MedLine.d169.s1.e2'}, 'sentence_id': 'DDI-MedLine.d169.s1'}	O the diet O affect absorption O and heme O O O O O O O O O O O O O O O O O O
Calcium is the only known component in the diet that may affect absorption of both nonheme and heme iron. 	nonheme iron	heme iron	none	{'e1': {'word': 'nonheme iron', 'word_index': [(6, 6), (9, 9)], 'id': 'DDI-MedLine.d169.s1.e1'}, 'e2': {'word': 'heme iron', 'word_index': [(8, 9)], 'id': 'DDI-MedLine.d169.s1.e2'}, 'sentence_id': 'DDI-MedLine.d169.s1'}	O the diet O affect absorption O and heme O O O O O O O O O O O O O O O O O O
However, the evidence for a calcium effect on iron absorption mainly comes from studies that did not isolate the effect of calcium from that of other dietary components, because it was detected in single-meal studies. 	calcium	iron	mechanism	{'e1': {'word': 'calcium', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d169.s2.e0'}, 'e2': {'word': 'iron', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d169.s2.e1'}, 'sentence_id': 'DDI-MedLine.d169.s2'}	O effect on O absorption mainly O that did O of other O because it O detected in O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
However, the evidence for a calcium effect on iron absorption mainly comes from studies that did not isolate the effect of calcium from that of other dietary components, because it was detected in single-meal studies. 	calcium	calcium	none	{'e1': {'word': 'calcium', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d169.s2.e0'}, 'e2': {'word': 'calcium', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d169.s2.e2'}, 'sentence_id': 'DDI-MedLine.d169.s2'}	O effect on O absorption mainly O that did O of other O because it O detected in O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
However, the evidence for a calcium effect on iron absorption mainly comes from studies that did not isolate the effect of calcium from that of other dietary components, because it was detected in single-meal studies. 	iron	calcium	none	{'e1': {'word': 'iron', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d169.s2.e1'}, 'e2': {'word': 'calcium', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d169.s2.e2'}, 'sentence_id': 'DDI-MedLine.d169.s2'}	O effect on O absorption mainly O that did O of other O because it O detected in O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
Our objective was to establish potential effects of calcium on absorption of nonheme and heme iron and the dose response for this effect in the absence of a meal. 	calcium	nonheme iron	none	{'e1': {'word': 'calcium', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d169.s3.e0'}, 'e2': {'word': 'nonheme iron', 'word_index': [(3, 3), (6, 6)], 'id': 'DDI-MedLine.d169.s3.e1'}, 'sentence_id': 'DDI-MedLine.d169.s3'}	O to establish O heme iron O dose response O effect in O O O O O O O O O O O O O O O O O O O O O O O O O O O
Our objective was to establish potential effects of calcium on absorption of nonheme and heme iron and the dose response for this effect in the absence of a meal. 	calcium	heme iron	none	{'e1': {'word': 'calcium', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d169.s3.e0'}, 'e2': {'word': 'heme iron', 'word_index': [(4, 5)], 'id': 'DDI-MedLine.d169.s3.e2'}, 'sentence_id': 'DDI-MedLine.d169.s3'}	O to establish O heme iron O dose response O effect in O O O O O O O O O O O O O O O O O O O O O O O O O O O
Our objective was to establish potential effects of calcium on absorption of nonheme and heme iron and the dose response for this effect in the absence of a meal. 	nonheme iron	heme iron	none	{'e1': {'word': 'nonheme iron', 'word_index': [(3, 3), (6, 6)], 'id': 'DDI-MedLine.d169.s3.e1'}, 'e2': {'word': 'heme iron', 'word_index': [(4, 5)], 'id': 'DDI-MedLine.d169.s3.e2'}, 'sentence_id': 'DDI-MedLine.d169.s3'}	O to establish O heme iron O dose response O effect in O O O O O O O O O O O O O O O O O O O O O O O O O O O
We evaluated the effects of calcium doses between 200 and 1500 mg on absorption of 5 mg nonheme iron (as ferrous sulfate). 	calcium	nonheme iron	none	{'e1': {'word': 'calcium', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d169.s5.e0'}, 'e2': {'word': 'nonheme iron', 'word_index': [(6, 7)], 'id': 'DDI-MedLine.d169.s5.e1'}, 'sentence_id': 'DDI-MedLine.d169.s5'}	O the effects O absorption of O iron ( O O O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O
We evaluated the effects of calcium doses between 200 and 1500 mg on absorption of 5 mg nonheme iron (as ferrous sulfate). 	calcium	ferrous sulfate	none	{'e1': {'word': 'calcium', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d169.s5.e0'}, 'e2': {'word': 'ferrous sulfate', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d169.s5.e2'}, 'sentence_id': 'DDI-MedLine.d169.s5'}	O the effects O absorption of O iron ( O O O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O
We evaluated the effects of calcium doses between 200 and 1500 mg on absorption of 5 mg nonheme iron (as ferrous sulfate). 	nonheme iron	ferrous sulfate	none	{'e1': {'word': 'nonheme iron', 'word_index': [(6, 7)], 'id': 'DDI-MedLine.d169.s5.e1'}, 'e2': {'word': 'ferrous sulfate', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d169.s5.e2'}, 'sentence_id': 'DDI-MedLine.d169.s5'}	O the effects O absorption of O iron ( O O O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O
We also evaluated the effects of calcium doses between 200 and 800 mg on absorption of 5 mg heme iron [as concentrated RBC (CRBC)]. 	calcium	heme iron	none	{'e1': {'word': 'calcium', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d169.s6.e0'}, 'e2': {'word': 'heme iron', 'word_index': [(6, 7)], 'id': 'DDI-MedLine.d169.s6.e1'}, 'sentence_id': 'DDI-MedLine.d169.s6'}	O evaluated the O between 200 O iron [ O ( CRBC O O O O O O O O O O O O O O O O O O O S-CELL O O O O O
Calcium was administered as calcium chloride in all studies and minerals were ingested on an empty stomach. 	Calcium	calcium chloride	none	{'e1': {'word': 'Calcium', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d169.s7.e0'}, 'e2': {'word': 'calcium chloride', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d169.s7.e1'}, 'sentence_id': 'DDI-MedLine.d169.s7'}	O all studies O ingested on O O O I-SIMPLE_CHEMICAL O O O O O O O O O O S-ORGANISM_SUBDIVISION O
Calcium was administered as calcium chloride in all studies and minerals were ingested on an empty stomach. 	Calcium	minerals	none	{'e1': {'word': 'Calcium', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d169.s7.e0'}, 'e2': {'word': 'minerals', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d169.s7.e2'}, 'sentence_id': 'DDI-MedLine.d169.s7'}	O all studies O ingested on O O O I-SIMPLE_CHEMICAL O O O O O O O O O O S-ORGANISM_SUBDIVISION O
Calcium was administered as calcium chloride in all studies and minerals were ingested on an empty stomach. 	calcium chloride	minerals	none	{'e1': {'word': 'calcium chloride', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d169.s7.e1'}, 'e2': {'word': 'minerals', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d169.s7.e2'}, 'sentence_id': 'DDI-MedLine.d169.s7'}	O all studies O ingested on O O O I-SIMPLE_CHEMICAL O O O O O O O O O O S-ORGANISM_SUBDIVISION O
Calcium doses   1000 mg diminished nonheme iron absorption by an average of 49.6%.	Calcium	nonheme iron	mechanism	{'e1': {'word': 'Calcium', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d169.s8.e0'}, 'e2': {'word': 'nonheme iron', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d169.s8.e1'}, 'sentence_id': 'DDI-MedLine.d169.s8'}	O absorption by O . O O O O O O O O O O O O O
A calcium dose of 800 mg diminished absorption of 5 mg heme iron by 37.7%. 	calcium	heme iron	mechanism	{'e1': {'word': 'calcium', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d169.s9.e0'}, 'e2': {'word': 'heme iron', 'word_index': [(5, 6)], 'id': 'DDI-MedLine.d169.s9.e1'}, 'sentence_id': 'DDI-MedLine.d169.s9'}	O calcium dose O mg heme O . O O O O O O O O O O O O O O
In conclusion, we demonstrated an isolated effect of calcium (as chloride) on absorption of 5 mg of iron provided as nonheme (as sulfate) and heme (as CRBC) iron. 	calcium	nonheme iron	mechanism	{'e1': {'word': 'calcium', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d169.s10.e0'}, 'e2': {'word': 'nonheme iron', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d169.s10.e1'}, 'sentence_id': 'DDI-MedLine.d169.s10'}	O , we O on absorption O 5 mg O provided as O . O O O O O O O I-SIMPLE_CHEMICAL O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O O O O
In conclusion, we demonstrated an isolated effect of calcium (as chloride) on absorption of 5 mg of iron provided as nonheme (as sulfate) and heme (as CRBC) iron. 	calcium	heme iron	mechanism	{'e1': {'word': 'calcium', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d169.s10.e0'}, 'e2': {'word': 'heme iron', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d169.s10.e2'}, 'sentence_id': 'DDI-MedLine.d169.s10'}	O , we O on absorption O 5 mg O provided as O . O O O O O O O I-SIMPLE_CHEMICAL O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O O O O
In conclusion, we demonstrated an isolated effect of calcium (as chloride) on absorption of 5 mg of iron provided as nonheme (as sulfate) and heme (as CRBC) iron. 	nonheme iron	heme iron	none	{'e1': {'word': 'nonheme iron', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d169.s10.e1'}, 'e2': {'word': 'heme iron', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d169.s10.e2'}, 'sentence_id': 'DDI-MedLine.d169.s10'}	O , we O on absorption O 5 mg O provided as O . O O O O O O O I-SIMPLE_CHEMICAL O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O O O O
"Ephedrine enhances the antinociceptive effect of dexmedetomidine in mice.
"	Ephedrine	dexmedetomidine	effect	{'e1': {'word': 'Ephedrine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d227.s0.e0'}, 'e2': {'word': 'dexmedetomidine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d227.s0.e1'}, 'sentence_id': 'DDI-MedLine.d227.s0'}	O . O O O O O O O S-ORGANISM O
The purpose of this study was to evaluate whether the psychostimulant drug ephedrine has any effect on dexmedetomidine-induced antinociception and locomotor inhibitor activity in mice in acute application.	ephedrine	dexmedetomidine	none	{'e1': {'word': 'ephedrine', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d227.s2.e0'}, 'e2': {'word': 'dexmedetomidine', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d227.s2.e1'}, 'sentence_id': 'DDI-MedLine.d227.s2'}	O this study O ephedrine has O on dexmedetomidine O locomotor inhibitor O application . O O O O O O O O O O O O O O O O O O O O O S-ORGANISM O O O O
saline + saline, ephedrine (10   mg/kg) + saline, saline + dexmedetomidine (15     g/kg) and ephedrine (10   mg/kg) + dexmedetomidine (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests. 	ephedrine	dexmedetomidine	none	{'e1': {'word': 'ephedrine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d227.s6.e0'}, 'e2': {'word': 'dexmedetomidine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d227.s6.e1'}, 'sentence_id': 'DDI-MedLine.d227.s6'}	O 10 mg O kg ) O ( 15 O / kg O + dexmedetomidine O 15 g O ) , O 30 min O hot plate O open field O . O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
saline + saline, ephedrine (10   mg/kg) + saline, saline + dexmedetomidine (15     g/kg) and ephedrine (10   mg/kg) + dexmedetomidine (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests. 	ephedrine	ephedrine	none	{'e1': {'word': 'ephedrine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d227.s6.e0'}, 'e2': {'word': 'ephedrine', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d227.s6.e2'}, 'sentence_id': 'DDI-MedLine.d227.s6'}	O 10 mg O kg ) O ( 15 O / kg O + dexmedetomidine O 15 g O ) , O 30 min O hot plate O open field O . O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
saline + saline, ephedrine (10   mg/kg) + saline, saline + dexmedetomidine (15     g/kg) and ephedrine (10   mg/kg) + dexmedetomidine (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests. 	ephedrine	dexmedetomidine	none	{'e1': {'word': 'ephedrine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d227.s6.e0'}, 'e2': {'word': 'dexmedetomidine', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d227.s6.e3'}, 'sentence_id': 'DDI-MedLine.d227.s6'}	O 10 mg O kg ) O ( 15 O / kg O + dexmedetomidine O 15 g O ) , O 30 min O hot plate O open field O . O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
saline + saline, ephedrine (10   mg/kg) + saline, saline + dexmedetomidine (15     g/kg) and ephedrine (10   mg/kg) + dexmedetomidine (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests. 	dexmedetomidine	ephedrine	none	{'e1': {'word': 'dexmedetomidine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d227.s6.e1'}, 'e2': {'word': 'ephedrine', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d227.s6.e2'}, 'sentence_id': 'DDI-MedLine.d227.s6'}	O 10 mg O kg ) O ( 15 O / kg O + dexmedetomidine O 15 g O ) , O 30 min O hot plate O open field O . O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
saline + saline, ephedrine (10   mg/kg) + saline, saline + dexmedetomidine (15     g/kg) and ephedrine (10   mg/kg) + dexmedetomidine (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests. 	dexmedetomidine	dexmedetomidine	none	{'e1': {'word': 'dexmedetomidine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d227.s6.e1'}, 'e2': {'word': 'dexmedetomidine', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d227.s6.e3'}, 'sentence_id': 'DDI-MedLine.d227.s6'}	O 10 mg O kg ) O ( 15 O / kg O + dexmedetomidine O 15 g O ) , O 30 min O hot plate O open field O . O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
saline + saline, ephedrine (10   mg/kg) + saline, saline + dexmedetomidine (15     g/kg) and ephedrine (10   mg/kg) + dexmedetomidine (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests. 	ephedrine	dexmedetomidine	none	{'e1': {'word': 'ephedrine', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d227.s6.e2'}, 'e2': {'word': 'dexmedetomidine', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d227.s6.e3'}, 'sentence_id': 'DDI-MedLine.d227.s6'}	O 10 mg O kg ) O ( 15 O / kg O + dexmedetomidine O 15 g O ) , O 30 min O hot plate O open field O . O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
In the hot plate test in mice, co-administration of 15     g/kg dexmedetomidine with 10   mg/kg ephedrine intraperitoneally not only enhanced, but also prolonged the duration of antinociception induced by dexmedetomidine. 	dexmedetomidine	ephedrine	effect	{'e1': {'word': 'dexmedetomidine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d227.s7.e0'}, 'e2': {'word': 'ephedrine', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d227.s7.e1'}, 'sentence_id': 'DDI-MedLine.d227.s7'}	O hot plate O , co-administration O / kg O kg ephedrine O , but O the duration S-ORGANISM dexmedetomidine . O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
In the hot plate test in mice, co-administration of 15     g/kg dexmedetomidine with 10   mg/kg ephedrine intraperitoneally not only enhanced, but also prolonged the duration of antinociception induced by dexmedetomidine. 	dexmedetomidine	dexmedetomidine	none	{'e1': {'word': 'dexmedetomidine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d227.s7.e0'}, 'e2': {'word': 'dexmedetomidine', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d227.s7.e2'}, 'sentence_id': 'DDI-MedLine.d227.s7'}	O hot plate O , co-administration O / kg O kg ephedrine O , but O the duration S-ORGANISM dexmedetomidine . O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
In the hot plate test in mice, co-administration of 15     g/kg dexmedetomidine with 10   mg/kg ephedrine intraperitoneally not only enhanced, but also prolonged the duration of antinociception induced by dexmedetomidine. 	ephedrine	dexmedetomidine	none	{'e1': {'word': 'ephedrine', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d227.s7.e1'}, 'e2': {'word': 'dexmedetomidine', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d227.s7.e2'}, 'sentence_id': 'DDI-MedLine.d227.s7'}	O hot plate O , co-administration O / kg O kg ephedrine O , but O the duration S-ORGANISM dexmedetomidine . O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
At the same time, the locomotor inhibitory effect of dexmedetomidine was counteracted by ephedrine. 	dexmedetomidine	ephedrine	effect	{'e1': {'word': 'dexmedetomidine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d227.s8.e0'}, 'e2': {'word': 'ephedrine', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d227.s8.e1'}, 'sentence_id': 'DDI-MedLine.d227.s8'}	O same time O inhibitory effect O by ephedrine O O O O O O O O O O O O O
We concluded that the combined administration of dexmedetomidine with ephedrine may have beneficial effects in the treatment of pain without causing sedation, which limits the use of dexmedetomidine as an analgesic in humans.	dexmedetomidine	ephedrine	effect	{'e1': {'word': 'dexmedetomidine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d227.s9.e0'}, 'e2': {'word': 'ephedrine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d227.s9.e1'}, 'sentence_id': 'DDI-MedLine.d227.s9'}	O that the O effects in O without causing O limits the O . O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM O
We concluded that the combined administration of dexmedetomidine with ephedrine may have beneficial effects in the treatment of pain without causing sedation, which limits the use of dexmedetomidine as an analgesic in humans.	dexmedetomidine	dexmedetomidine	none	{'e1': {'word': 'dexmedetomidine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d227.s9.e0'}, 'e2': {'word': 'dexmedetomidine', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d227.s9.e2'}, 'sentence_id': 'DDI-MedLine.d227.s9'}	O that the O effects in O without causing O limits the O . O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM O
We concluded that the combined administration of dexmedetomidine with ephedrine may have beneficial effects in the treatment of pain without causing sedation, which limits the use of dexmedetomidine as an analgesic in humans.	dexmedetomidine	analgesic	none	{'e1': {'word': 'dexmedetomidine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d227.s9.e0'}, 'e2': {'word': 'analgesic', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d227.s9.e3'}, 'sentence_id': 'DDI-MedLine.d227.s9'}	O that the O effects in O without causing O limits the O . O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM O
We concluded that the combined administration of dexmedetomidine with ephedrine may have beneficial effects in the treatment of pain without causing sedation, which limits the use of dexmedetomidine as an analgesic in humans.	ephedrine	dexmedetomidine	none	{'e1': {'word': 'ephedrine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d227.s9.e1'}, 'e2': {'word': 'dexmedetomidine', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d227.s9.e2'}, 'sentence_id': 'DDI-MedLine.d227.s9'}	O that the O effects in O without causing O limits the O . O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM O
We concluded that the combined administration of dexmedetomidine with ephedrine may have beneficial effects in the treatment of pain without causing sedation, which limits the use of dexmedetomidine as an analgesic in humans.	ephedrine	analgesic	none	{'e1': {'word': 'ephedrine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d227.s9.e1'}, 'e2': {'word': 'analgesic', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d227.s9.e3'}, 'sentence_id': 'DDI-MedLine.d227.s9'}	O that the O effects in O without causing O limits the O . O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM O
We concluded that the combined administration of dexmedetomidine with ephedrine may have beneficial effects in the treatment of pain without causing sedation, which limits the use of dexmedetomidine as an analgesic in humans.	dexmedetomidine	analgesic	none	{'e1': {'word': 'dexmedetomidine', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d227.s9.e2'}, 'e2': {'word': 'analgesic', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d227.s9.e3'}, 'sentence_id': 'DDI-MedLine.d227.s9'}	O that the O effects in O without causing O limits the O . O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-ORGANISM O
"Lapatinib enhances herceptin-mediated antibody-dependent cellular cytotoxicity by up-regulation of cell surface HER2 expression.
"	Lapatinib	herceptin	effect	{'e1': {'word': 'Lapatinib', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d164.s0.e0'}, 'e2': {'word': 'herceptin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d164.s0.e1'}, 'sentence_id': 'DDI-MedLine.d164.s0'}	S-SIMPLE_CHEMICAL cytotoxicity by O . O O O O O O S-CELL O O O O O O E-CELL O S-GENE_OR_GENE_PRODUCT O O
Although it was previously reported that lapatinib combined with Herceptin improved the progression-free survival rate compared with lapatinib alone for patients with Herceptin-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.	lapatinib	Herceptin	effect	{'e1': {'word': 'lapatinib', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d164.s1.e0'}, 'e2': {'word': 'Herceptin', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d164.s1.e1'}, 'sentence_id': 'DDI-MedLine.d164.s1'}	O with Herceptin O progression - O compared with O positive metastatic O be an O the synergism S-SIMPLE_CHEMICAL O O S-SIMPLE_CHEMICAL O O O O O O O O O S-SIMPLE_CHEMICAL O O S-ORGANISM O S-SIMPLE_CHEMICAL O O S-GENE_OR_GENE_PRODUCT O O O O E-CANCER O O O O O O O O O O O O O O O O O O O
Although it was previously reported that lapatinib combined with Herceptin improved the progression-free survival rate compared with lapatinib alone for patients with Herceptin-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.	lapatinib	lapatinib	none	{'e1': {'word': 'lapatinib', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d164.s1.e0'}, 'e2': {'word': 'lapatinib', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d164.s1.e2'}, 'sentence_id': 'DDI-MedLine.d164.s1'}	O with Herceptin O progression - O compared with O positive metastatic O be an O the synergism S-SIMPLE_CHEMICAL O O S-SIMPLE_CHEMICAL O O O O O O O O O S-SIMPLE_CHEMICAL O O S-ORGANISM O S-SIMPLE_CHEMICAL O O S-GENE_OR_GENE_PRODUCT O O O O E-CANCER O O O O O O O O O O O O O O O O O O O
Although it was previously reported that lapatinib combined with Herceptin improved the progression-free survival rate compared with lapatinib alone for patients with Herceptin-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.	lapatinib	Herceptin	none	{'e1': {'word': 'lapatinib', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d164.s1.e0'}, 'e2': {'word': 'Herceptin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d164.s1.e3'}, 'sentence_id': 'DDI-MedLine.d164.s1'}	O with Herceptin O progression - O compared with O positive metastatic O be an O the synergism S-SIMPLE_CHEMICAL O O S-SIMPLE_CHEMICAL O O O O O O O O O S-SIMPLE_CHEMICAL O O S-ORGANISM O S-SIMPLE_CHEMICAL O O S-GENE_OR_GENE_PRODUCT O O O O E-CANCER O O O O O O O O O O O O O O O O O O O
Although it was previously reported that lapatinib combined with Herceptin improved the progression-free survival rate compared with lapatinib alone for patients with Herceptin-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.	Herceptin	lapatinib	none	{'e1': {'word': 'Herceptin', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d164.s1.e1'}, 'e2': {'word': 'lapatinib', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d164.s1.e2'}, 'sentence_id': 'DDI-MedLine.d164.s1'}	O with Herceptin O progression - O compared with O positive metastatic O be an O the synergism S-SIMPLE_CHEMICAL O O S-SIMPLE_CHEMICAL O O O O O O O O O S-SIMPLE_CHEMICAL O O S-ORGANISM O S-SIMPLE_CHEMICAL O O S-GENE_OR_GENE_PRODUCT O O O O E-CANCER O O O O O O O O O O O O O O O O O O O
Although it was previously reported that lapatinib combined with Herceptin improved the progression-free survival rate compared with lapatinib alone for patients with Herceptin-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.	Herceptin	Herceptin	none	{'e1': {'word': 'Herceptin', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d164.s1.e1'}, 'e2': {'word': 'Herceptin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d164.s1.e3'}, 'sentence_id': 'DDI-MedLine.d164.s1'}	O with Herceptin O progression - O compared with O positive metastatic O be an O the synergism S-SIMPLE_CHEMICAL O O S-SIMPLE_CHEMICAL O O O O O O O O O S-SIMPLE_CHEMICAL O O S-ORGANISM O S-SIMPLE_CHEMICAL O O S-GENE_OR_GENE_PRODUCT O O O O E-CANCER O O O O O O O O O O O O O O O O O O O
Although it was previously reported that lapatinib combined with Herceptin improved the progression-free survival rate compared with lapatinib alone for patients with Herceptin-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.	lapatinib	Herceptin	none	{'e1': {'word': 'lapatinib', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d164.s1.e2'}, 'e2': {'word': 'Herceptin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d164.s1.e3'}, 'sentence_id': 'DDI-MedLine.d164.s1'}	O with Herceptin O progression - O compared with O positive metastatic O be an O the synergism S-SIMPLE_CHEMICAL O O S-SIMPLE_CHEMICAL O O O O O O O O O S-SIMPLE_CHEMICAL O O S-ORGANISM O S-SIMPLE_CHEMICAL O O S-GENE_OR_GENE_PRODUCT O O O O E-CANCER O O O O O O O O O O O O O O O O O O O
We evaluated how lapatinib interacts with Herceptin in HER2-positive breast cancer, with a particular focus on Herceptin-mediated antibody-dependent cellular cytotoxicity (ADCC). 	lapatinib	Herceptin	none	{'e1': {'word': 'lapatinib', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d164.s2.e0'}, 'e2': {'word': 'Herceptin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d164.s2.e1'}, 'sentence_id': 'DDI-MedLine.d164.s2'}	O how lapatinib O , with O on Herceptin S-SIMPLE_CHEMICAL ) . O O S-SIMPLE_CHEMICAL O S-GENE_OR_GENE_PRODUCT O O O E-CANCER O O O O O O S-SIMPLE_CHEMICAL O O O O O S-CELL O O O O O
We evaluated how lapatinib interacts with Herceptin in HER2-positive breast cancer, with a particular focus on Herceptin-mediated antibody-dependent cellular cytotoxicity (ADCC). 	lapatinib	Herceptin	none	{'e1': {'word': 'lapatinib', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d164.s2.e0'}, 'e2': {'word': 'Herceptin', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d164.s2.e2'}, 'sentence_id': 'DDI-MedLine.d164.s2'}	O how lapatinib O , with O on Herceptin S-SIMPLE_CHEMICAL ) . O O S-SIMPLE_CHEMICAL O S-GENE_OR_GENE_PRODUCT O O O E-CANCER O O O O O O S-SIMPLE_CHEMICAL O O O O O S-CELL O O O O O
We evaluated how lapatinib interacts with Herceptin in HER2-positive breast cancer, with a particular focus on Herceptin-mediated antibody-dependent cellular cytotoxicity (ADCC). 	Herceptin	Herceptin	none	{'e1': {'word': 'Herceptin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d164.s2.e1'}, 'e2': {'word': 'Herceptin', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d164.s2.e2'}, 'sentence_id': 'DDI-MedLine.d164.s2'}	O how lapatinib O , with O on Herceptin S-SIMPLE_CHEMICAL ) . O O S-SIMPLE_CHEMICAL O S-GENE_OR_GENE_PRODUCT O O O E-CANCER O O O O O O S-SIMPLE_CHEMICAL O O O O O S-CELL O O O O O
In an in vitro assay, lapatinib induced HER2 expression at the cell surface of HER2-positive breast cancer cell lines, leading to the enhancement of Herceptin-mediated ADCC. 	lapatinib	Herceptin	effect	{'e1': {'word': 'lapatinib', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d164.s3.e0'}, 'e2': {'word': 'Herceptin', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d164.s3.e1'}, 'sentence_id': 'DDI-MedLine.d164.s3'}	O in vitro O lapatinib induced O at the O positive breast O to the O of Herceptin S-SIMPLE_CHEMICAL O S-GENE_OR_GENE_PRODUCT O O O E-CELL O O S-GENE_OR_GENE_PRODUCT O O O E-CANCER E-CELL O O O O O O O S-SIMPLE_CHEMICAL O O O O
Furthermore, we present a case report in which a second Herceptin treatment following lapatinib resulted in the marked shrinkage of multiple metastatic tumors in HER2-positive breast cancer. 	Herceptin	lapatinib	effect	{'e1': {'word': 'Herceptin', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d164.s4.e0'}, 'e2': {'word': 'lapatinib', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d164.s4.e1'}, 'sentence_id': 'DDI-MedLine.d164.s4'}	O Herceptin treatment O lapatinib resulted O marked shrinkage O positive breast O . O O O O O O S-SIMPLE_CHEMICAL O O S-SIMPLE_CHEMICAL O O O O O O O O S-CANCER O S-GENE_OR_GENE_PRODUCT O O O E-CANCER O
Lapatinib may have the potential to convert Herceptin-refractory to Herceptin-sensitive tumors in HER2-positive breast cancer by up-regulation of the cell surface expression of HER2.	Lapatinib	Herceptin	none	{'e1': {'word': 'Lapatinib', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d164.s5.e0'}, 'e2': {'word': 'Herceptin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d164.s5.e1'}, 'sentence_id': 'DDI-MedLine.d164.s5'}	S-SIMPLE_CHEMICAL refractory to O tumors in O cancer by O of the O O O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O S-CANCER O S-GENE_OR_GENE_PRODUCT O O O E-CANCER O O O O O O E-CELL O O O S-GENE_OR_GENE_PRODUCT O
Lapatinib may have the potential to convert Herceptin-refractory to Herceptin-sensitive tumors in HER2-positive breast cancer by up-regulation of the cell surface expression of HER2.	Lapatinib	Herceptin	none	{'e1': {'word': 'Lapatinib', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d164.s5.e0'}, 'e2': {'word': 'Herceptin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d164.s5.e2'}, 'sentence_id': 'DDI-MedLine.d164.s5'}	S-SIMPLE_CHEMICAL refractory to O tumors in O cancer by O of the O O O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O S-CANCER O S-GENE_OR_GENE_PRODUCT O O O E-CANCER O O O O O O E-CELL O O O S-GENE_OR_GENE_PRODUCT O
Lapatinib may have the potential to convert Herceptin-refractory to Herceptin-sensitive tumors in HER2-positive breast cancer by up-regulation of the cell surface expression of HER2.	Herceptin	Herceptin	none	{'e1': {'word': 'Herceptin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d164.s5.e1'}, 'e2': {'word': 'Herceptin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d164.s5.e2'}, 'sentence_id': 'DDI-MedLine.d164.s5'}	S-SIMPLE_CHEMICAL refractory to O tumors in O cancer by O of the O O O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O S-CANCER O S-GENE_OR_GENE_PRODUCT O O O E-CANCER O O O O O O E-CELL O O O S-GENE_OR_GENE_PRODUCT O
"In vivo CYP3A activity is significantly lower in cyclosporine-treated as compared with tacrolimus-treated renal allograft recipients.
"	cyclosporine	tacrolimus	none	{'e1': {'word': 'cyclosporine', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d213.s0.e0'}, 'e2': {'word': 'tacrolimus', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d213.s0.e1'}, 'sentence_id': 'DDI-MedLine.d213.s0'}	O CYP3A activity O cyclosporine - S-GENE_OR_GENE_PRODUCT - treated O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O
In vitro studies have identified cyclosporine and tacrolimus as CYP3A inhibitors. 	cyclosporine	tacrolimus	none	{'e1': {'word': 'cyclosporine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d213.s1.e0'}, 'e2': {'word': 'tacrolimus', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d213.s1.e1'}, 'sentence_id': 'DDI-MedLine.d213.s1'}	O studies have O CYP3A inhibitors O O O S-SIMPLE_CHEMICAL O O O S-GENE_OR_GENE_PRODUCT O O
Systemic and apparent oral midazolam clearance were 24% (269    73 vs. 354    102  ml/min, P = 0.022) and 31% (479    190 vs. 688    265  ml/min, P = 0.013), respectively, lower in cyclosporine-treated patients (n = 20) than in matched tacrolimus-treated patients (n = 20). 	midazolam	cyclosporine	mechanism	{'e1': {'word': 'midazolam', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d213.s3.e0'}, 'e2': {'word': 'cyclosporine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d213.s3.e1'}, 'sentence_id': 'DDI-MedLine.d213.s3'}	O % ( O 354 102 O and 31 S-ORGANISM_SUBDIVISION vs. 688 S-SIMPLE_CHEMICAL , respectively O = 20 O tacrolimus - O ( n O 20 ) O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O S-ORGANISM O O O O O O O O O O O S-ORGANISM O O O O O O
Systemic and apparent oral midazolam clearance were 24% (269    73 vs. 354    102  ml/min, P = 0.022) and 31% (479    190 vs. 688    265  ml/min, P = 0.013), respectively, lower in cyclosporine-treated patients (n = 20) than in matched tacrolimus-treated patients (n = 20). 	midazolam	tacrolimus	none	{'e1': {'word': 'midazolam', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d213.s3.e0'}, 'e2': {'word': 'tacrolimus', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d213.s3.e2'}, 'sentence_id': 'DDI-MedLine.d213.s3'}	O % ( O 354 102 O and 31 S-ORGANISM_SUBDIVISION vs. 688 S-SIMPLE_CHEMICAL , respectively O = 20 O tacrolimus - O ( n O 20 ) O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O S-ORGANISM O O O O O O O O O O O S-ORGANISM O O O O O O
Systemic and apparent oral midazolam clearance were 24% (269    73 vs. 354    102  ml/min, P = 0.022) and 31% (479    190 vs. 688    265  ml/min, P = 0.013), respectively, lower in cyclosporine-treated patients (n = 20) than in matched tacrolimus-treated patients (n = 20). 	cyclosporine	tacrolimus	none	{'e1': {'word': 'cyclosporine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d213.s3.e1'}, 'e2': {'word': 'tacrolimus', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d213.s3.e2'}, 'sentence_id': 'DDI-MedLine.d213.s3'}	O % ( O 354 102 O and 31 S-ORGANISM_SUBDIVISION vs. 688 S-SIMPLE_CHEMICAL , respectively O = 20 O tacrolimus - O ( n O 20 ) O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O S-ORGANISM O O O O O O O O O O O S-ORGANISM O O O O O O
The latter displayed midazolam clearances similar to those in two larger cohorts of nonmatched tacrolimus-treated patients (n = 58 and n = 80) and to those receiving a calcineurin inhibitor-free regimen (n = 6). 	midazolam	tacrolimus	none	{'e1': {'word': 'midazolam', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d213.s4.e0'}, 'e2': {'word': 'tacrolimus', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d213.s4.e1'}, 'sentence_id': 'DDI-MedLine.d213.s4'}	O midazolam clearances O cohorts of O and n S-SIMPLE_CHEMICAL inhibitor - O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O O O O O O O O O O
The latter displayed midazolam clearances similar to those in two larger cohorts of nonmatched tacrolimus-treated patients (n = 58 and n = 80) and to those receiving a calcineurin inhibitor-free regimen (n = 6). 	midazolam	calcineurin inhibitor	none	{'e1': {'word': 'midazolam', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d213.s4.e0'}, 'e2': {'word': 'calcineurin inhibitor', 'word_index': [(9, 10)], 'id': 'DDI-MedLine.d213.s4.e2'}, 'sentence_id': 'DDI-MedLine.d213.s4'}	O midazolam clearances O cohorts of O and n S-SIMPLE_CHEMICAL inhibitor - O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O O O O O O O O O O
The latter displayed midazolam clearances similar to those in two larger cohorts of nonmatched tacrolimus-treated patients (n = 58 and n = 80) and to those receiving a calcineurin inhibitor-free regimen (n = 6). 	tacrolimus	calcineurin inhibitor	none	{'e1': {'word': 'tacrolimus', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d213.s4.e1'}, 'e2': {'word': 'calcineurin inhibitor', 'word_index': [(9, 10)], 'id': 'DDI-MedLine.d213.s4.e2'}, 'sentence_id': 'DDI-MedLine.d213.s4'}	O midazolam clearances O cohorts of O and n S-SIMPLE_CHEMICAL inhibitor - O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O O O O O O O O O O
This implies that in vivo hepatic and first-pass CYP3A activities are significantly lower in patients receiving cyclosporine than in those receiving tacrolimus, indicating that, at the doses generally used in clinical practice, cyclosporine is the stronger of the two with respect to CYP3A inhibition. 	cyclosporine	tacrolimus	none	{'e1': {'word': 'cyclosporine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d213.s5.e0'}, 'e2': {'word': 'tacrolimus', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d213.s5.e1'}, 'sentence_id': 'DDI-MedLine.d213.s5'}	O vivo hepatic O significantly lower O than in O tacrolimus , O the doses O is the O two with O O O S-GENE_OR_GENE_PRODUCT O O O O O S-ORGANISM O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O S-GENE_OR_GENE_PRODUCT O O
This implies that in vivo hepatic and first-pass CYP3A activities are significantly lower in patients receiving cyclosporine than in those receiving tacrolimus, indicating that, at the doses generally used in clinical practice, cyclosporine is the stronger of the two with respect to CYP3A inhibition. 	cyclosporine	cyclosporine	none	{'e1': {'word': 'cyclosporine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d213.s5.e0'}, 'e2': {'word': 'cyclosporine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d213.s5.e2'}, 'sentence_id': 'DDI-MedLine.d213.s5'}	O vivo hepatic O significantly lower O than in O tacrolimus , O the doses O is the O two with O O O S-GENE_OR_GENE_PRODUCT O O O O O S-ORGANISM O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O S-GENE_OR_GENE_PRODUCT O O
This implies that in vivo hepatic and first-pass CYP3A activities are significantly lower in patients receiving cyclosporine than in those receiving tacrolimus, indicating that, at the doses generally used in clinical practice, cyclosporine is the stronger of the two with respect to CYP3A inhibition. 	tacrolimus	cyclosporine	none	{'e1': {'word': 'tacrolimus', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d213.s5.e1'}, 'e2': {'word': 'cyclosporine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d213.s5.e2'}, 'sentence_id': 'DDI-MedLine.d213.s5'}	O vivo hepatic O significantly lower O than in O tacrolimus , O the doses O is the O two with O O O S-GENE_OR_GENE_PRODUCT O O O O O S-ORGANISM O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O S-GENE_OR_GENE_PRODUCT O O
"Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor.
"	ketoconazole	panobinostat	none	{'e1': {'word': 'ketoconazole', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d185.s0.e0'}, 'e2': {'word': 'panobinostat', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d185.s0.e1'}, 'sentence_id': 'DDI-MedLine.d185.s0'}	O inhibition on O of panobinostat S-SIMPLE_CHEMICAL O O S-GENE_OR_GENE_PRODUCT O O O O O O O S-SIMPLE_CHEMICAL O O O O O S-GENE_OR_GENE_PRODUCT E-GENE_OR_GENE_PRODUCT O O
"Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor.
"	ketoconazole	LBH589	none	{'e1': {'word': 'ketoconazole', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d185.s0.e0'}, 'e2': {'word': 'LBH589', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d185.s0.e2'}, 'sentence_id': 'DDI-MedLine.d185.s0'}	O inhibition on O of panobinostat S-SIMPLE_CHEMICAL O O S-GENE_OR_GENE_PRODUCT O O O O O O O S-SIMPLE_CHEMICAL O O O O O S-GENE_OR_GENE_PRODUCT E-GENE_OR_GENE_PRODUCT O O
"Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor.
"	ketoconazole	histone deacetylase inhibitor	none	{'e1': {'word': 'ketoconazole', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d185.s0.e0'}, 'e2': {'word': 'histone deacetylase inhibitor', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d185.s0.e3'}, 'sentence_id': 'DDI-MedLine.d185.s0'}	O inhibition on O of panobinostat S-SIMPLE_CHEMICAL O O S-GENE_OR_GENE_PRODUCT O O O O O O O S-SIMPLE_CHEMICAL O O O O O S-GENE_OR_GENE_PRODUCT E-GENE_OR_GENE_PRODUCT O O
"Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor.
"	panobinostat	LBH589	none	{'e1': {'word': 'panobinostat', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d185.s0.e1'}, 'e2': {'word': 'LBH589', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d185.s0.e2'}, 'sentence_id': 'DDI-MedLine.d185.s0'}	O inhibition on O of panobinostat S-SIMPLE_CHEMICAL O O S-GENE_OR_GENE_PRODUCT O O O O O O O S-SIMPLE_CHEMICAL O O O O O S-GENE_OR_GENE_PRODUCT E-GENE_OR_GENE_PRODUCT O O
"Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor.
"	panobinostat	histone deacetylase inhibitor	none	{'e1': {'word': 'panobinostat', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d185.s0.e1'}, 'e2': {'word': 'histone deacetylase inhibitor', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d185.s0.e3'}, 'sentence_id': 'DDI-MedLine.d185.s0'}	O inhibition on O of panobinostat S-SIMPLE_CHEMICAL O O S-GENE_OR_GENE_PRODUCT O O O O O O O S-SIMPLE_CHEMICAL O O O O O S-GENE_OR_GENE_PRODUCT E-GENE_OR_GENE_PRODUCT O O
"Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor.
"	LBH589	histone deacetylase inhibitor	none	{'e1': {'word': 'LBH589', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d185.s0.e2'}, 'e2': {'word': 'histone deacetylase inhibitor', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d185.s0.e3'}, 'sentence_id': 'DDI-MedLine.d185.s0'}	O inhibition on O of panobinostat S-SIMPLE_CHEMICAL O O S-GENE_OR_GENE_PRODUCT O O O O O O O S-SIMPLE_CHEMICAL O O O O O S-GENE_OR_GENE_PRODUCT E-GENE_OR_GENE_PRODUCT O O
This study evaluated the effect of a potent CYP3A inhibitor, ketoconazole, on the pharmacokinetics and safety of panobinostat.	ketoconazole	panobinostat	none	{'e1': {'word': 'ketoconazole', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d185.s2.e0'}, 'e2': {'word': 'panobinostat', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d185.s2.e1'}, 'sentence_id': 'DDI-MedLine.d185.s2'}	O effect of O ketoconazole , O O O O O O S-GENE_OR_GENE_PRODUCT O O S-SIMPLE_CHEMICAL O O O O O O O O O
On day 8, a single panobinostat dose was co-administered with ketoconazole. 	panobinostat	ketoconazole	none	{'e1': {'word': 'panobinostat', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d185.s5.e0'}, 'e2': {'word': 'ketoconazole', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d185.s5.e1'}, 'sentence_id': 'DDI-MedLine.d185.s5'}	O 8 , O dose was O with ketoconazole O O O O O O O O S-SIMPLE_CHEMICAL O
In the presence of ketoconazole, there was 1.6- and 1.8-fold increase in C (max) and AUC of panobinostat, respectively. 	ketoconazole	panobinostat	mechanism	{'e1': {'word': 'ketoconazole', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d185.s7.e0'}, 'e2': {'word': 'panobinostat', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d185.s7.e1'}, 'sentence_id': 'DDI-MedLine.d185.s7'}	O presence of O was 1.6 O ) and O panobinostat , S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O
Co-administration of panobinostat with CYP3A inhibitors is feasible as the observed increase in panobinostat PK parameters was not considered clinically relevant. 	panobinostat	panobinostat	none	{'e1': {'word': 'panobinostat', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d185.s12.e0'}, 'e2': {'word': 'panobinostat', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d185.s12.e1'}, 'sentence_id': 'DDI-MedLine.d185.s12'}	O not considered O . O O S-GENE_OR_GENE_PRODUCT O O O O O O O O O S-GENE_OR_GENE_PRODUCT O O O O O O O
Considering the variability in exposure following enzyme inhibition and the fact that chronic dosing of panobinostat was not studied with CYP3A inhibitors, close monitoring of panobinostat-related adverse events is necessary.	panobinostat	panobinostat	none	{'e1': {'word': 'panobinostat', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d185.s13.e0'}, 'e2': {'word': 'panobinostat', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d185.s13.e1'}, 'sentence_id': 'DDI-MedLine.d185.s13'}	O that chronic O was not O adverse events O . O O O O O O O O O O O O O O O O S-GENE_OR_GENE_PRODUCT O O O O O O O O O O O O O
"Prevention of emergence agitation in seven children receiving low-dose ketamine and propofol total intravenous anesthesia.
"	ketamine	propofol	none	{'e1': {'word': 'ketamine', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d199.s0.e0'}, 'e2': {'word': 'propofol', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d199.s0.e1'}, 'sentence_id': 'DDI-MedLine.d199.s0'}	O dose ketamine O total intravenous O O O O O O O O O O O O O S-IMMATERIAL_ANATOMICAL_ENTITY O O
We retrospectively reviewed the records of 7 pediatric oncology patients who received low-dose ketamine in conjunction with propofol for total intravenous anesthesia (TIVA) repeatedly for radiation therapy. 	ketamine	propofol	none	{'e1': {'word': 'ketamine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d199.s2.e0'}, 'e2': {'word': 'propofol', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d199.s2.e1'}, 'sentence_id': 'DDI-MedLine.d199.s2'}	O reviewed the O propofol for O radiation therapy O O O O O O S-ORGANISM O O O O O O O O O O O O S-IMMATERIAL_ANATOMICAL_ENTITY O O O O O O O O O
EA signs were observed in all 7 patients in association with propofol TIVA but did not recur in any of 123 subsequent anesthetics sessions during which low-dose ketamine was added to propofol. 	propofol	ketamine	none	{'e1': {'word': 'propofol', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d199.s3.e0'}, 'e2': {'word': 'ketamine', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d199.s3.e1'}, 'sentence_id': 'DDI-MedLine.d199.s3'}	O were observed O association with O not recur O which low O ketamine was O . O S-ORGANISM O O O O O O O O O O O O O O O O O O O O O O O O O O O
EA signs were observed in all 7 patients in association with propofol TIVA but did not recur in any of 123 subsequent anesthetics sessions during which low-dose ketamine was added to propofol. 	propofol	propofol	none	{'e1': {'word': 'propofol', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d199.s3.e0'}, 'e2': {'word': 'propofol', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d199.s3.e2'}, 'sentence_id': 'DDI-MedLine.d199.s3'}	O were observed O association with O not recur O which low O ketamine was O . O S-ORGANISM O O O O O O O O O O O O O O O O O O O O O O O O O O O
EA signs were observed in all 7 patients in association with propofol TIVA but did not recur in any of 123 subsequent anesthetics sessions during which low-dose ketamine was added to propofol. 	ketamine	propofol	none	{'e1': {'word': 'ketamine', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d199.s3.e1'}, 'e2': {'word': 'propofol', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d199.s3.e2'}, 'sentence_id': 'DDI-MedLine.d199.s3'}	O were observed O association with O not recur O which low O ketamine was O . O S-ORGANISM O O O O O O O O O O O O O O O O O O O O O O O O O O O
Based on this experience, we suggest that low-dose ketamine added to propofol may be associated with prevention of EA in children with a history of EA with propofol TIVA.	ketamine	propofol	effect	{'e1': {'word': 'ketamine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d199.s4.e0'}, 'e2': {'word': 'propofol', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d199.s4.e1'}, 'sentence_id': 'DDI-MedLine.d199.s4'}	O we suggest O - dose O may be O of EA O propofol TIVA O O O O O O O O O O O O O O O O O O O O O O O O O O O O
Based on this experience, we suggest that low-dose ketamine added to propofol may be associated with prevention of EA in children with a history of EA with propofol TIVA.	ketamine	propofol	none	{'e1': {'word': 'ketamine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d199.s4.e0'}, 'e2': {'word': 'propofol', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d199.s4.e2'}, 'sentence_id': 'DDI-MedLine.d199.s4'}	O we suggest O - dose O may be O of EA O propofol TIVA O O O O O O O O O O O O O O O O O O O O O O O O O O O O
Based on this experience, we suggest that low-dose ketamine added to propofol may be associated with prevention of EA in children with a history of EA with propofol TIVA.	propofol	propofol	none	{'e1': {'word': 'propofol', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d199.s4.e1'}, 'e2': {'word': 'propofol', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d199.s4.e2'}, 'sentence_id': 'DDI-MedLine.d199.s4'}	O we suggest O - dose O may be O of EA O propofol TIVA O O O O O O O O O O O O O O O O O O O O O O O O O O O O
Protective effect of acetyl-l-carnitine and  alpha lipoic acid against the acute toxicity of diepoxybutane to human lymphocytes.	acetyl-l-carnitine	alpha lipoic acid	none	{'e1': {'word': 'acetyl-l-carnitine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d159.s0.e0'}, 'e2': {'word': 'alpha lipoic acid', 'word_index': [(0, 2)], 'id': 'DDI-MedLine.d159.s0.e1'}, 'sentence_id': 'DDI-MedLine.d159.s0'}	O lipoic acid O to human O S-SIMPLE_CHEMICAL O O O S-SIMPLE_CHEMICAL O O S-SIMPLE_CHEMICAL O O O O O O O O S-ORGANISM S-CELL O
(ii) acetyl-l-carnitine elicits a significant protective effect on DEB induced toxicity, which was potentiated by  alpha-lipoic acid.	acetyl-l-carnitine	alpha-lipoic acid	effect	{'e1': {'word': 'acetyl-l-carnitine', 'word_index': [(3, 6)], 'id': 'DDI-MedLine.d159.s6.e0'}, 'e2': {'word': 'alpha-lipoic acid', 'word_index': [(16, 19)], 'id': 'DDI-MedLine.d159.s6.e1'}, 'sentence_id': 'DDI-MedLine.d159.s6'}	O ii ) O l - O elicits a S-SIMPLE_CHEMICAL toxicity , O was potentiated O alpha - O acid . S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O
"Enhancement of humoral immune responses to inactivated Newcastle disease and avian influenza vaccines by oral administration of ginseng stem-and-leaf saponins in chickens.
"	avian influenza vaccines	ginseng stem-and-leaf saponins	none	{'e1': {'word': 'avian influenza vaccines', 'word_index': [(0, 2)], 'id': 'DDI-MedLine.d154.s0.e0'}, 'e2': {'word': 'ginseng stem-and-leaf saponins', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d154.s0.e1'}, 'sentence_id': 'DDI-MedLine.d154.s0'}	O influenza vaccines O administration of O in chickens O O O O O O O O O O O S-ORGANISM_SUBDIVISION O O O O O O O S-ORGANISM_SUBDIVISION O O S-ORGANISM O
The objective of this study was to evaluate the effect of oral administration of ginseng stem-and-leaf saponins (GSLS) on the humoral immune responses of chickens to inactivated ND and AI vaccines. 	ginseng stem-and-leaf saponins	GSLS	none	{'e1': {'word': 'ginseng stem-and-leaf saponins', 'word_index': [(4, 9)], 'id': 'DDI-MedLine.d154.s2.e0'}, 'e2': {'word': 'GSLS', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d154.s2.e1'}, 'sentence_id': 'DDI-MedLine.d154.s2'}	O this study O ginseng stem O - leaf O on the O to inactivated O and AI O O O O O S-ORGANISM_SUBDIVISION O O O O O O O S-ORGANISM_SUBDIVISION O O O O O O O O O O S-ORGANISM O O O O O O O O O
The objective of this study was to evaluate the effect of oral administration of ginseng stem-and-leaf saponins (GSLS) on the humoral immune responses of chickens to inactivated ND and AI vaccines. 	ginseng stem-and-leaf saponins	inactivated ND vaccines	none	{'e1': {'word': 'ginseng stem-and-leaf saponins', 'word_index': [(4, 9)], 'id': 'DDI-MedLine.d154.s2.e0'}, 'e2': {'word': 'inactivated ND vaccines', 'word_index': [(14, 15), (18, 18)], 'id': 'DDI-MedLine.d154.s2.e2'}, 'sentence_id': 'DDI-MedLine.d154.s2'}	O this study O ginseng stem O - leaf O on the O to inactivated O and AI O O O O O S-ORGANISM_SUBDIVISION O O O O O O O S-ORGANISM_SUBDIVISION O O O O O O O O O O S-ORGANISM O O O O O O O O O
The objective of this study was to evaluate the effect of oral administration of ginseng stem-and-leaf saponins (GSLS) on the humoral immune responses of chickens to inactivated ND and AI vaccines. 	ginseng stem-and-leaf saponins	inactivated AI vaccines	none	{'e1': {'word': 'ginseng stem-and-leaf saponins', 'word_index': [(4, 9)], 'id': 'DDI-MedLine.d154.s2.e0'}, 'e2': {'word': 'inactivated AI vaccines', 'word_index': [(14, 14), (16, 16), (17, 17)], 'id': 'DDI-MedLine.d154.s2.e3'}, 'sentence_id': 'DDI-MedLine.d154.s2'}	O this study O ginseng stem O - leaf O on the O to inactivated O AI vaccines O O O O O S-ORGANISM_SUBDIVISION O O O O O O O S-ORGANISM_SUBDIVISION O O O O O O O O O O S-ORGANISM O O O O O O O O
The objective of this study was to evaluate the effect of oral administration of ginseng stem-and-leaf saponins (GSLS) on the humoral immune responses of chickens to inactivated ND and AI vaccines. 	GSLS	inactivated ND vaccines	none	{'e1': {'word': 'GSLS', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d154.s2.e1'}, 'e2': {'word': 'inactivated ND vaccines', 'word_index': [(14, 15), (18, 18)], 'id': 'DDI-MedLine.d154.s2.e2'}, 'sentence_id': 'DDI-MedLine.d154.s2'}	O this study O ginseng stem O - leaf O on the O to inactivated O and AI O O O O O S-ORGANISM_SUBDIVISION O O O O O O O S-ORGANISM_SUBDIVISION O O O O O O O O O O S-ORGANISM O O O O O O O O O
The objective of this study was to evaluate the effect of oral administration of ginseng stem-and-leaf saponins (GSLS) on the humoral immune responses of chickens to inactivated ND and AI vaccines. 	GSLS	inactivated AI vaccines	none	{'e1': {'word': 'GSLS', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d154.s2.e1'}, 'e2': {'word': 'inactivated AI vaccines', 'word_index': [(14, 14), (16, 16), (17, 17)], 'id': 'DDI-MedLine.d154.s2.e3'}, 'sentence_id': 'DDI-MedLine.d154.s2'}	O this study O ginseng stem O - leaf O on the O to inactivated O AI vaccines O O O O O S-ORGANISM_SUBDIVISION O O O O O O O S-ORGANISM_SUBDIVISION O O O O O O O O O O S-ORGANISM O O O O O O O O
The objective of this study was to evaluate the effect of oral administration of ginseng stem-and-leaf saponins (GSLS) on the humoral immune responses of chickens to inactivated ND and AI vaccines. 	inactivated ND vaccines	inactivated AI vaccines	none	{'e1': {'word': 'inactivated ND vaccines', 'word_index': [(14, 15), (18, 18)], 'id': 'DDI-MedLine.d154.s2.e2'}, 'e2': {'word': 'inactivated AI vaccines', 'word_index': [(15, 15), (17, 17), (18, 18)], 'id': 'DDI-MedLine.d154.s2.e3'}, 'sentence_id': 'DDI-MedLine.d154.s2'}	O this study O ginseng stem O - leaf O on the O to inactivated O and AI O O O O O S-ORGANISM_SUBDIVISION O O O O O O O S-ORGANISM_SUBDIVISION O O O O O O O O O O S-ORGANISM O O O O O O O O O
In experiment 1, oral administration of GSLS at a dose of 5 mg/kg of BW for 7 d on the immune response in chickens intramuscularly injected with inactivated ND vaccine was evaluated. 	GSLS	inactivated ND vaccine	none	{'e1': {'word': 'GSLS', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d154.s3.e0'}, 'e2': {'word': 'inactivated ND vaccine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d154.s3.e1'}, 'sentence_id': 'DDI-MedLine.d154.s3'}	O 1 , O / kg O BW for O d on S-ORGANISM_SUBDIVISION chickens intramuscularly O O O O O O O O O O O O O O O O O O O O O S-ORGANISM O O O O O O O O O
In experiment 2, the same regimen of GSLS was administered to chickens inoculated with inactivated AI vaccines, and an enhanced serum antibody response to AI vaccination was also observed. 	GSLS	inactivated AI vaccines	effect	{'e1': {'word': 'GSLS', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d154.s5.e0'}, 'e2': {'word': 'inactivated AI vaccines', 'word_index': [(5, 7)], 'id': 'DDI-MedLine.d154.s5.e1'}, 'sentence_id': 'DDI-MedLine.d154.s5'}	O 2 , O with inactivated O vaccines , O an enhanced O to AI O . O O O O O O S-ORGANISM O O O O O O O O O S-ORGANISM_SUBSTANCE O O O O O O O O O
Considering the safety of GSLS, because no adverse effect was found throughout the experiments, GSLS may be a promising oral adjuvant to improve immunization in poultry.	GSLS	GSLS	none	{'e1': {'word': 'GSLS', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d154.s6.e0'}, 'e2': {'word': 'GSLS', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d154.s6.e1'}, 'sentence_id': 'DDI-MedLine.d154.s6'}	O found throughout O GSLS may O improve immunization O . O O O O O O O O O O O O O O O O O S-ORGANISM_SUBDIVISION O O O O O O O
"Exposure to oral S-ketamine is unaffected by itraconazole but greatly increased by ticlopidine.
"	S-ketamine	itraconazole	none	{'e1': {'word': 'S-ketamine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d216.s0.e0'}, 'e2': {'word': 'itraconazole', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d216.s0.e1'}, 'sentence_id': 'DDI-MedLine.d216.s0'}	O by itraconazole O increased by S-ORGANISM_SUBDIVISION O O O O O O S-SIMPLE_CHEMICAL O O O O S-SIMPLE_CHEMICAL O
"Exposure to oral S-ketamine is unaffected by itraconazole but greatly increased by ticlopidine.
"	S-ketamine	ticlopidine	effect	{'e1': {'word': 'S-ketamine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d216.s0.e0'}, 'e2': {'word': 'ticlopidine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d216.s0.e2'}, 'sentence_id': 'DDI-MedLine.d216.s0'}	O by itraconazole O increased by S-ORGANISM_SUBDIVISION O O O O O O S-SIMPLE_CHEMICAL O O O O S-SIMPLE_CHEMICAL O
"Exposure to oral S-ketamine is unaffected by itraconazole but greatly increased by ticlopidine.
"	itraconazole	ticlopidine	none	{'e1': {'word': 'itraconazole', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d216.s0.e1'}, 'e2': {'word': 'ticlopidine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d216.s0.e2'}, 'sentence_id': 'DDI-MedLine.d216.s0'}	O by itraconazole O increased by S-ORGANISM_SUBDIVISION O O O O O O S-SIMPLE_CHEMICAL O O O O S-SIMPLE_CHEMICAL O
This study examined drug-drug interactions of oral S-ketamine with the cytochrome P450 (CYP) 2B6 inhibitor ticlopidine and the CYP3A inhibitor itraconazole. 	S-ketamine	ticlopidine	none	{'e1': {'word': 'S-ketamine', 'word_index': [(3, 4)], 'id': 'DDI-MedLine.d216.s1.e0'}, 'e2': {'word': 'ticlopidine', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d216.s1.e1'}, 'sentence_id': 'DDI-MedLine.d216.s1'}	O - drug O ketamine with O ticlopidine and O . O O O O S-ORGANISM_SUBDIVISION O O O O O S-GENE_OR_GENE_PRODUCT S-GENE_OR_GENE_PRODUCT O O O O O S-SIMPLE_CHEMICAL O O S-GENE_OR_GENE_PRODUCT O S-SIMPLE_CHEMICAL O
This study examined drug-drug interactions of oral S-ketamine with the cytochrome P450 (CYP) 2B6 inhibitor ticlopidine and the CYP3A inhibitor itraconazole. 	S-ketamine	itraconazole	none	{'e1': {'word': 'S-ketamine', 'word_index': [(3, 4)], 'id': 'DDI-MedLine.d216.s1.e0'}, 'e2': {'word': 'itraconazole', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d216.s1.e2'}, 'sentence_id': 'DDI-MedLine.d216.s1'}	O - drug O ketamine with O ticlopidine and O . O O O O S-ORGANISM_SUBDIVISION O O O O O S-GENE_OR_GENE_PRODUCT S-GENE_OR_GENE_PRODUCT O O O O O S-SIMPLE_CHEMICAL O O S-GENE_OR_GENE_PRODUCT O S-SIMPLE_CHEMICAL O
This study examined drug-drug interactions of oral S-ketamine with the cytochrome P450 (CYP) 2B6 inhibitor ticlopidine and the CYP3A inhibitor itraconazole. 	ticlopidine	itraconazole	none	{'e1': {'word': 'ticlopidine', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d216.s1.e1'}, 'e2': {'word': 'itraconazole', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d216.s1.e2'}, 'sentence_id': 'DDI-MedLine.d216.s1'}	O - drug O ketamine with O ticlopidine and O . O O O O S-ORGANISM_SUBDIVISION O O O O O S-GENE_OR_GENE_PRODUCT S-GENE_OR_GENE_PRODUCT O O O O O S-SIMPLE_CHEMICAL O O S-GENE_OR_GENE_PRODUCT O S-SIMPLE_CHEMICAL O
In this randomized, blinded, crossover study, 11 healthy volunteers ingested 0.2 mg/kg S-ketamine after pretreatments with oral ticlopidine (250 mg twice daily), itraconazole (200 mg once daily), or placebo in 6-day treatment periods at intervals of 4 weeks. 	S-ketamine	ticlopidine	none	{'e1': {'word': 'S-ketamine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d216.s2.e0'}, 'e2': {'word': 'ticlopidine', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d216.s2.e1'}, 'sentence_id': 'DDI-MedLine.d216.s2'}	O randomized , O , 11 O after pretreatments O oral ticlopidine O itraconazole ( O mg once O treatment periods O . O O O O O O O O O O O O O O O S-ORGANISM_SUBDIVISION S-SIMPLE_CHEMICAL O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O
In this randomized, blinded, crossover study, 11 healthy volunteers ingested 0.2 mg/kg S-ketamine after pretreatments with oral ticlopidine (250 mg twice daily), itraconazole (200 mg once daily), or placebo in 6-day treatment periods at intervals of 4 weeks. 	S-ketamine	itraconazole	none	{'e1': {'word': 'S-ketamine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d216.s2.e0'}, 'e2': {'word': 'itraconazole', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d216.s2.e2'}, 'sentence_id': 'DDI-MedLine.d216.s2'}	O randomized , O , 11 O after pretreatments O oral ticlopidine O itraconazole ( O mg once O treatment periods O . O O O O O O O O O O O O O O O S-ORGANISM_SUBDIVISION S-SIMPLE_CHEMICAL O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O
In this randomized, blinded, crossover study, 11 healthy volunteers ingested 0.2 mg/kg S-ketamine after pretreatments with oral ticlopidine (250 mg twice daily), itraconazole (200 mg once daily), or placebo in 6-day treatment periods at intervals of 4 weeks. 	ticlopidine	itraconazole	none	{'e1': {'word': 'ticlopidine', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d216.s2.e1'}, 'e2': {'word': 'itraconazole', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d216.s2.e2'}, 'sentence_id': 'DDI-MedLine.d216.s2'}	O randomized , O , 11 O after pretreatments O oral ticlopidine O itraconazole ( O mg once O treatment periods O . O O O O O O O O O O O O O O O S-ORGANISM_SUBDIVISION S-SIMPLE_CHEMICAL O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O
Ticlopidine treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral ketamine by 2.4-fold, whereas itraconazole treatment did not increase the exposure to S-ketamine. 	Ticlopidine	ketamine	mechanism	{'e1': {'word': 'Ticlopidine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d216.s3.e0'}, 'e2': {'word': 'ketamine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d216.s3.e1'}, 'sentence_id': 'DDI-MedLine.d216.s3'}	O time curve O ) of O not increase O S - O O O O S-ORGANISM_SUBSTANCE O O O O O O O O O O O O O O O S-ORGANISM_SUBDIVISION O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O
Ticlopidine treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral ketamine by 2.4-fold, whereas itraconazole treatment did not increase the exposure to S-ketamine. 	Ticlopidine	itraconazole	none	{'e1': {'word': 'Ticlopidine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d216.s3.e0'}, 'e2': {'word': 'itraconazole', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d216.s3.e2'}, 'sentence_id': 'DDI-MedLine.d216.s3'}	O time curve O ) of O not increase O S - O O O O S-ORGANISM_SUBSTANCE O O O O O O O O O O O O O O O S-ORGANISM_SUBDIVISION O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O
Ticlopidine treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral ketamine by 2.4-fold, whereas itraconazole treatment did not increase the exposure to S-ketamine. 	Ticlopidine	S-ketamine	none	{'e1': {'word': 'Ticlopidine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d216.s3.e0'}, 'e2': {'word': 'S-ketamine', 'word_index': [(10, 12)], 'id': 'DDI-MedLine.d216.s3.e3'}, 'sentence_id': 'DDI-MedLine.d216.s3'}	O time curve O ) of O not increase O S - O O O O S-ORGANISM_SUBSTANCE O O O O O O O O O O O O O O O S-ORGANISM_SUBDIVISION O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O
Ticlopidine treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral ketamine by 2.4-fold, whereas itraconazole treatment did not increase the exposure to S-ketamine. 	ketamine	itraconazole	none	{'e1': {'word': 'ketamine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d216.s3.e1'}, 'e2': {'word': 'itraconazole', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d216.s3.e2'}, 'sentence_id': 'DDI-MedLine.d216.s3'}	O time curve O ) of O not increase O S - O O O O S-ORGANISM_SUBSTANCE O O O O O O O O O O O O O O O S-ORGANISM_SUBDIVISION O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O
Ticlopidine treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral ketamine by 2.4-fold, whereas itraconazole treatment did not increase the exposure to S-ketamine. 	ketamine	S-ketamine	none	{'e1': {'word': 'ketamine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d216.s3.e1'}, 'e2': {'word': 'S-ketamine', 'word_index': [(10, 12)], 'id': 'DDI-MedLine.d216.s3.e3'}, 'sentence_id': 'DDI-MedLine.d216.s3'}	O time curve O ) of O not increase O S - O O O O S-ORGANISM_SUBSTANCE O O O O O O O O O O O O O O O S-ORGANISM_SUBDIVISION O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O
Ticlopidine treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral ketamine by 2.4-fold, whereas itraconazole treatment did not increase the exposure to S-ketamine. 	itraconazole	S-ketamine	none	{'e1': {'word': 'itraconazole', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d216.s3.e2'}, 'e2': {'word': 'S-ketamine', 'word_index': [(10, 12)], 'id': 'DDI-MedLine.d216.s3.e3'}, 'sentence_id': 'DDI-MedLine.d216.s3'}	O time curve O ) of O not increase O S - O O O O S-ORGANISM_SUBSTANCE O O O O O O O O O O O O O O O S-ORGANISM_SUBDIVISION O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O
The ratio of norketamine AUC(0-   ) to ketamine AUC(0-   ) was significantly decreased in the ticlopidine (P &lt; 0.001) and itraconazole phases (P = 0.006) as compared to placebo. 	norketamine	ketamine	none	{'e1': {'word': 'norketamine', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d216.s4.e0'}, 'e2': {'word': 'ketamine', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d216.s4.e1'}, 'sentence_id': 'DDI-MedLine.d216.s4'}	O norketamine AUC O ketamine AUC O - ) O ) and O P = O ) as O to placebo O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O
The ratio of norketamine AUC(0-   ) to ketamine AUC(0-   ) was significantly decreased in the ticlopidine (P &lt; 0.001) and itraconazole phases (P = 0.006) as compared to placebo. 	norketamine	ticlopidine	none	{'e1': {'word': 'norketamine', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d216.s4.e0'}, 'e2': {'word': 'ticlopidine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d216.s4.e2'}, 'sentence_id': 'DDI-MedLine.d216.s4'}	O norketamine AUC O ketamine AUC O - ) O ) and O P = O ) as O to placebo O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O
The ratio of norketamine AUC(0-   ) to ketamine AUC(0-   ) was significantly decreased in the ticlopidine (P &lt; 0.001) and itraconazole phases (P = 0.006) as compared to placebo. 	norketamine	itraconazole	none	{'e1': {'word': 'norketamine', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d216.s4.e0'}, 'e2': {'word': 'itraconazole', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d216.s4.e3'}, 'sentence_id': 'DDI-MedLine.d216.s4'}	O norketamine AUC O ketamine AUC O - ) O ) and O P = O ) as O to placebo O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O
The ratio of norketamine AUC(0-   ) to ketamine AUC(0-   ) was significantly decreased in the ticlopidine (P &lt; 0.001) and itraconazole phases (P = 0.006) as compared to placebo. 	ketamine	ticlopidine	none	{'e1': {'word': 'ketamine', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d216.s4.e1'}, 'e2': {'word': 'ticlopidine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d216.s4.e2'}, 'sentence_id': 'DDI-MedLine.d216.s4'}	O norketamine AUC O ketamine AUC O - ) O ) and O P = O ) as O to placebo O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O
The ratio of norketamine AUC(0-   ) to ketamine AUC(0-   ) was significantly decreased in the ticlopidine (P &lt; 0.001) and itraconazole phases (P = 0.006) as compared to placebo. 	ketamine	itraconazole	none	{'e1': {'word': 'ketamine', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d216.s4.e1'}, 'e2': {'word': 'itraconazole', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d216.s4.e3'}, 'sentence_id': 'DDI-MedLine.d216.s4'}	O norketamine AUC O ketamine AUC O - ) O ) and O P = O ) as O to placebo O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O
The ratio of norketamine AUC(0-   ) to ketamine AUC(0-   ) was significantly decreased in the ticlopidine (P &lt; 0.001) and itraconazole phases (P = 0.006) as compared to placebo. 	ticlopidine	itraconazole	none	{'e1': {'word': 'ticlopidine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d216.s4.e2'}, 'e2': {'word': 'itraconazole', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d216.s4.e3'}, 'sentence_id': 'DDI-MedLine.d216.s4'}	O norketamine AUC O ketamine AUC O - ) O ) and O P = O ) as O to placebo O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O
In the ticlopidine and itraconazole phases, the areas under the effect-time curves (self-reported drowsiness and performance) were significantly higher than those in the placebo phase (P < 0.05). 	ticlopidine	itraconazole	none	{'e1': {'word': 'ticlopidine', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d216.s5.e0'}, 'e2': {'word': 'itraconazole', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d216.s5.e1'}, 'sentence_id': 'DDI-MedLine.d216.s5'}	O ticlopidine and O the areas S-SIMPLE_CHEMICAL and performance O higher than S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
The findings suggest that the dosage of S-ketamine should be reduced in patients receiving ticlopidine.	S-ketamine	ticlopidine	advise	{'e1': {'word': 'S-ketamine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d216.s6.e0'}, 'e2': {'word': 'ticlopidine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d216.s6.e1'}, 'sentence_id': 'DDI-MedLine.d216.s6'}	O that the O in patients O O O O O O O O O O O O S-ORGANISM O S-SIMPLE_CHEMICAL O
"Distinct synergistic action of piperacillin and methylglyoxal against Pseudomonas aeruginosa.
"	piperacillin	methylglyoxal	none	{'e1': {'word': 'piperacillin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d204.s0.e0'}, 'e2': {'word': 'methylglyoxal', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d204.s0.e1'}, 'sentence_id': 'DDI-MedLine.d204.s0'}	O Pseudomonas aeruginosa O O O S-SIMPLE_CHEMICAL O O O O O O
Results revealed that the strains were resistant to many drugs at high levels, only piperacillin, carbenicillin, amikacin and ciprofloxacin showed resistances at comparatively lower levels. 	piperacillin	carbenicillin	none	{'e1': {'word': 'piperacillin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d204.s7.e0'}, 'e2': {'word': 'carbenicillin', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d204.s7.e1'}, 'sentence_id': 'DDI-MedLine.d204.s7'}	O to many O carbenicillin , O resistances at O . O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O
Results revealed that the strains were resistant to many drugs at high levels, only piperacillin, carbenicillin, amikacin and ciprofloxacin showed resistances at comparatively lower levels. 	piperacillin	amikacin	none	{'e1': {'word': 'piperacillin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d204.s7.e0'}, 'e2': {'word': 'amikacin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d204.s7.e2'}, 'sentence_id': 'DDI-MedLine.d204.s7'}	O to many O carbenicillin , O resistances at O . O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O
Results revealed that the strains were resistant to many drugs at high levels, only piperacillin, carbenicillin, amikacin and ciprofloxacin showed resistances at comparatively lower levels. 	piperacillin	ciprofloxacin	none	{'e1': {'word': 'piperacillin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d204.s7.e0'}, 'e2': {'word': 'ciprofloxacin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d204.s7.e3'}, 'sentence_id': 'DDI-MedLine.d204.s7'}	O to many O carbenicillin , O resistances at O . O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O
Results revealed that the strains were resistant to many drugs at high levels, only piperacillin, carbenicillin, amikacin and ciprofloxacin showed resistances at comparatively lower levels. 	carbenicillin	amikacin	none	{'e1': {'word': 'carbenicillin', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d204.s7.e1'}, 'e2': {'word': 'amikacin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d204.s7.e2'}, 'sentence_id': 'DDI-MedLine.d204.s7'}	O to many O carbenicillin , O resistances at O . O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O
Results revealed that the strains were resistant to many drugs at high levels, only piperacillin, carbenicillin, amikacin and ciprofloxacin showed resistances at comparatively lower levels. 	carbenicillin	ciprofloxacin	none	{'e1': {'word': 'carbenicillin', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d204.s7.e1'}, 'e2': {'word': 'ciprofloxacin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d204.s7.e3'}, 'sentence_id': 'DDI-MedLine.d204.s7'}	O to many O carbenicillin , O resistances at O . O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O
Results revealed that the strains were resistant to many drugs at high levels, only piperacillin, carbenicillin, amikacin and ciprofloxacin showed resistances at comparatively lower levels. 	amikacin	ciprofloxacin	none	{'e1': {'word': 'amikacin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d204.s7.e2'}, 'e2': {'word': 'ciprofloxacin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d204.s7.e3'}, 'sentence_id': 'DDI-MedLine.d204.s7'}	O to many O carbenicillin , O resistances at O . O O O O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O
Distinct and statistically significant synergism was observed between methylglyoxal and piperacillin by disc diffusion tests when compared with their individual effects. 	methylglyoxal	piperacillin	effect	{'e1': {'word': 'methylglyoxal', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d204.s9.e0'}, 'e2': {'word': 'piperacillin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d204.s9.e1'}, 'sentence_id': 'DDI-MedLine.d204.s9'}	O methylglyoxal and O diffusion tests O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O
Synergism was also noted when methylglyoxal was combined with carbenicillin and amikacin.	methylglyoxal	carbenicillin	effect	{'e1': {'word': 'methylglyoxal', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d204.s11.e0'}, 'e2': {'word': 'carbenicillin', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d204.s11.e1'}, 'sentence_id': 'DDI-MedLine.d204.s11'}	O carbenicillin and O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O
Synergism was also noted when methylglyoxal was combined with carbenicillin and amikacin.	methylglyoxal	amikacin	effect	{'e1': {'word': 'methylglyoxal', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d204.s11.e0'}, 'e2': {'word': 'amikacin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d204.s11.e2'}, 'sentence_id': 'DDI-MedLine.d204.s11'}	O carbenicillin and O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O
Synergism was also noted when methylglyoxal was combined with carbenicillin and amikacin.	carbenicillin	amikacin	none	{'e1': {'word': 'carbenicillin', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d204.s11.e1'}, 'e2': {'word': 'amikacin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d204.s11.e2'}, 'sentence_id': 'DDI-MedLine.d204.s11'}	O carbenicillin and O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O
The 3-Deazaneplanocin A (DZNep), one of S-adenosylhomocysteine (AdoHcy) hydrolase inhibitors, has shown antitumor activities in a broad range of solid tumors and acute myeloid leukemia. 	3-Deazaneplanocin A	DZNep	none	{'e1': {'word': '3-Deazaneplanocin A', 'word_index': [(0, 2)], 'id': 'DDI-MedLine.d180.s1.e0'}, 'e2': {'word': 'DZNep', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d180.s1.e1'}, 'sentence_id': 'DDI-MedLine.d180.s1'}	O Deazaneplanocin A O DZNep ) O one of O broad range O solid tumors O acute myeloid O O O O O O O I-SIMPLE_CHEMICAL O O O O O O O O S-CANCER O O O O O O O S-CANCER O O S-CELL E-CANCER O
We also found that Bcl-2 was overexpressed in DZNep insensitive cells, and cotreatment with DZNep and ABT-737, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DZNep insensitive MM cells. 	DZNep	DZNep	none	{'e1': {'word': 'DZNep', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d180.s10.e0'}, 'e2': {'word': 'DZNep', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d180.s10.e1'}, 'sentence_id': 'DDI-MedLine.d180.s10'}	O found that O overexpressed in O cotreatment with O 737 , O 2 family O , synergistically O growth and O DZNep insensitive O O O O S-CELL O O O O O O O O O O O O O O O O O O O O O O O O O O O S-CELL O
We also found that Bcl-2 was overexpressed in DZNep insensitive cells, and cotreatment with DZNep and ABT-737, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DZNep insensitive MM cells. 	DZNep	ABT-737	none	{'e1': {'word': 'DZNep', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d180.s10.e0'}, 'e2': {'word': 'ABT-737', 'word_index': [(9, 10)], 'id': 'DDI-MedLine.d180.s10.e2'}, 'sentence_id': 'DDI-MedLine.d180.s10'}	O found that O overexpressed in O cotreatment with O 737 , O 2 family O , synergistically O growth and O DZNep insensitive O O O O S-CELL O O O O O O O O O O O O O O O O O O O O O O O O O O O S-CELL O
We also found that Bcl-2 was overexpressed in DZNep insensitive cells, and cotreatment with DZNep and ABT-737, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DZNep insensitive MM cells. 	DZNep	DZNep	none	{'e1': {'word': 'DZNep', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d180.s10.e0'}, 'e2': {'word': 'DZNep', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d180.s10.e3'}, 'sentence_id': 'DDI-MedLine.d180.s10'}	O found that O overexpressed in O cotreatment with O 737 , O 2 family O , synergistically O growth and O DZNep insensitive O O O O S-CELL O O O O O O O O O O O O O O O O O O O O O O O O O O O S-CELL O
We also found that Bcl-2 was overexpressed in DZNep insensitive cells, and cotreatment with DZNep and ABT-737, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DZNep insensitive MM cells. 	DZNep	ABT-737	effect	{'e1': {'word': 'DZNep', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d180.s10.e1'}, 'e2': {'word': 'ABT-737', 'word_index': [(9, 10)], 'id': 'DDI-MedLine.d180.s10.e2'}, 'sentence_id': 'DDI-MedLine.d180.s10'}	O found that O overexpressed in O cotreatment with O 737 , O 2 family O , synergistically O growth and O DZNep insensitive O O O O S-CELL O O O O O O O O O O O O O O O O O O O O O O O O O O O S-CELL O
We also found that Bcl-2 was overexpressed in DZNep insensitive cells, and cotreatment with DZNep and ABT-737, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DZNep insensitive MM cells. 	DZNep	DZNep	none	{'e1': {'word': 'DZNep', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d180.s10.e1'}, 'e2': {'word': 'DZNep', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d180.s10.e3'}, 'sentence_id': 'DDI-MedLine.d180.s10'}	O found that O overexpressed in O cotreatment with O 737 , O 2 family O , synergistically O growth and O DZNep insensitive O O O O S-CELL O O O O O O O O O O O O O O O O O O O O O O O O O O O S-CELL O
We also found that Bcl-2 was overexpressed in DZNep insensitive cells, and cotreatment with DZNep and ABT-737, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DZNep insensitive MM cells. 	ABT-737	DZNep	none	{'e1': {'word': 'ABT-737', 'word_index': [(9, 10)], 'id': 'DDI-MedLine.d180.s10.e2'}, 'e2': {'word': 'DZNep', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d180.s10.e3'}, 'sentence_id': 'DDI-MedLine.d180.s10'}	O found that O overexpressed in O cotreatment with O 737 , O 2 family O , synergistically O growth and O DZNep insensitive O O O O S-CELL O O O O O O O O O O O O O O O O O O O O O O O O O O O S-CELL O
In addition, DZNep insensitivity might be associated with overexpression of Bcl-2, and the combination of ABT-737 and DZNep could synergistically induced apoptosis. 	DZNep	ABT-737	none	{'e1': {'word': 'DZNep', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d180.s12.e0'}, 'e2': {'word': 'ABT-737', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d180.s12.e1'}, 'sentence_id': 'DDI-MedLine.d180.s12'}	O , DZNep O - 2 O and the O and DZNep O O O O O O O O O O O O O O O O O O O O O O O O O
In addition, DZNep insensitivity might be associated with overexpression of Bcl-2, and the combination of ABT-737 and DZNep could synergistically induced apoptosis. 	DZNep	DZNep	none	{'e1': {'word': 'DZNep', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d180.s12.e0'}, 'e2': {'word': 'DZNep', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d180.s12.e2'}, 'sentence_id': 'DDI-MedLine.d180.s12'}	O , DZNep O - 2 O and the O and DZNep O O O O O O O O O O O O O O O O O O O O O O O O O
In addition, DZNep insensitivity might be associated with overexpression of Bcl-2, and the combination of ABT-737 and DZNep could synergistically induced apoptosis. 	ABT-737	DZNep	effect	{'e1': {'word': 'ABT-737', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d180.s12.e1'}, 'e2': {'word': 'DZNep', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d180.s12.e2'}, 'sentence_id': 'DDI-MedLine.d180.s12'}	O , DZNep O - 2 O and the O and DZNep O O O O O O O O O O O O O O O O O O O O O O O O O
"In vitro activity of minocycline combined with fosfomycin against clinical isolates of methicillin-resistant Staphylococcus aureus.
"	minocycline	fosfomycin	none	{'e1': {'word': 'minocycline', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d163.s0.e0'}, 'e2': {'word': 'fosfomycin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d163.s0.e1'}, 'sentence_id': 'DDI-MedLine.d163.s0'}	O activity of O clinical isolates O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O
"In vitro activity of minocycline combined with fosfomycin against clinical isolates of methicillin-resistant Staphylococcus aureus.
"	minocycline	methicillin	none	{'e1': {'word': 'minocycline', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d163.s0.e0'}, 'e2': {'word': 'methicillin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d163.s0.e2'}, 'sentence_id': 'DDI-MedLine.d163.s0'}	O activity of O clinical isolates O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O
"In vitro activity of minocycline combined with fosfomycin against clinical isolates of methicillin-resistant Staphylococcus aureus.
"	fosfomycin	methicillin	none	{'e1': {'word': 'fosfomycin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d163.s0.e1'}, 'e2': {'word': 'methicillin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d163.s0.e2'}, 'sentence_id': 'DDI-MedLine.d163.s0'}	O activity of O clinical isolates O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O
This study aimed to evaluate the in vitro activity of minocycline combined with fosfomycin against isolates of methicillin-resistant Staphylococcus aureus (MRSA). 	minocycline	fosfomycin	none	{'e1': {'word': 'minocycline', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d163.s1.e0'}, 'e2': {'word': 'fosfomycin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d163.s1.e1'}, 'sentence_id': 'DDI-MedLine.d163.s1'}	O evaluate the O combined with O - resistant O ( MRSA O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O
This study aimed to evaluate the in vitro activity of minocycline combined with fosfomycin against isolates of methicillin-resistant Staphylococcus aureus (MRSA). 	minocycline	methicillin	none	{'e1': {'word': 'minocycline', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d163.s1.e0'}, 'e2': {'word': 'methicillin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d163.s1.e2'}, 'sentence_id': 'DDI-MedLine.d163.s1'}	O evaluate the O combined with O - resistant O ( MRSA O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O
This study aimed to evaluate the in vitro activity of minocycline combined with fosfomycin against isolates of methicillin-resistant Staphylococcus aureus (MRSA). 	fosfomycin	methicillin	none	{'e1': {'word': 'fosfomycin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d163.s1.e1'}, 'e2': {'word': 'methicillin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d163.s1.e2'}, 'sentence_id': 'DDI-MedLine.d163.s1'}	O evaluate the O combined with O - resistant O ( MRSA O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O
The susceptibility results for minocycline and fosfomycin were interpreted according to the most relevant criteria. 	minocycline	fosfomycin	none	{'e1': {'word': 'minocycline', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d163.s4.e0'}, 'e2': {'word': 'fosfomycin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d163.s4.e1'}, 'sentence_id': 'DDI-MedLine.d163.s4'}	O for minocycline O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O
The combination of minocycline and fosfomycin can be synergistic against MRSA. 	minocycline	fosfomycin	effect	{'e1': {'word': 'minocycline', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d163.s7.e0'}, 'e2': {'word': 'fosfomycin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d163.s7.e1'}, 'sentence_id': 'DDI-MedLine.d163.s7'}	O minocycline and O O O O S-SIMPLE_CHEMICAL O O O O O O
In the present study, we tested whether the highly specific metabotropic glutamate receptor 5 antagonist, 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine, reduces dopaminergic and noradrenergic neuronal loss in monkeys rendered parkinsonian by chronic treatment with low doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. 	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	none	{'e1': {'word': '3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine', 'word_index': [(8, 18)], 'id': 'DDI-MedLine.d161.s3.e0'}, 'e2': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(27, 33)], 'id': 'DDI-MedLine.d161.s3.e1'}, 'sentence_id': 'DDI-MedLine.d161.s3'}	O present study O whether the O , 3 O methyl - O , 3 O - 4 O , reduces O rendered parkinsonian O with low O 4 - O 6 - O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O O O S-ORGANISM O O O O O O O O O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O
Weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). 	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	none	{'e1': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(0, 3)], 'id': 'DDI-MedLine.d161.s4.e0'}, 'e2': {'word': '3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine', 'word_index': [(15, 30)], 'id': 'DDI-MedLine.d161.s4.e1'}, 'sentence_id': 'DDI-MedLine.d161.s4'}	O 4 - O 0.2 - O mg / O body weight O administration of O - [ O 2 - O - 1 O - yl O ethynyl ] O or vehicle O were performed O the development O parkinsonian motor O in either O the two O groups ( O - methyl I-SIMPLE_CHEMICAL ( 2 O - yl O ethynyl ] O - methyl O 4 - O , 2 O , 6 O tetrahydropyridine / O . O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O
Weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). 	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	none	{'e1': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(0, 3)], 'id': 'DDI-MedLine.d161.s4.e0'}, 'e2': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(51, 54)], 'id': 'DDI-MedLine.d161.s4.e2'}, 'sentence_id': 'DDI-MedLine.d161.s4'}	O 4 - O 0.2 - O mg / O body weight O administration of O - [ O 2 - O - 1 O - yl O ethynyl ] O or vehicle O were performed O the development O parkinsonian motor O in either O the two O groups ( O - methyl I-SIMPLE_CHEMICAL ( 2 O - yl O ethynyl ] O - methyl O 4 - O , 2 O , 6 O tetrahydropyridine / O . O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O
Weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). 	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	none	{'e1': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(0, 3)], 'id': 'DDI-MedLine.d161.s4.e0'}, 'e2': {'word': '3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine', 'word_index': [(54, 63)], 'id': 'DDI-MedLine.d161.s4.e3'}, 'sentence_id': 'DDI-MedLine.d161.s4'}	O 4 - O 0.2 - O mg / O body weight O administration of O - [ O 2 - O - 1 O - yl O ethynyl ] O or vehicle O were performed O the development O parkinsonian motor O in either O the two O groups ( O - methyl I-SIMPLE_CHEMICAL ( 2 O - yl O ethynyl ] O - methyl O 4 - O , 2 O , 6 O tetrahydropyridine / O . O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O
Weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). 	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	none	{'e1': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(0, 3)], 'id': 'DDI-MedLine.d161.s4.e0'}, 'e2': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(63, 76)], 'id': 'DDI-MedLine.d161.s4.e4'}, 'sentence_id': 'DDI-MedLine.d161.s4'}	O 4 - O 0.2 - O mg / O body weight O administration of O - [ O 2 - O - 1 O - yl O ethynyl ] O or vehicle O were performed O the development O parkinsonian motor O in either O the two O groups ( O - methyl I-SIMPLE_CHEMICAL ( 2 O - yl O ethynyl ] O - methyl O 4 - O , 2 O , 6 O tetrahydropyridine / O . O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O
Weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). 	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	none	{'e1': {'word': '3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine', 'word_index': [(15, 30)], 'id': 'DDI-MedLine.d161.s4.e1'}, 'e2': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(51, 54)], 'id': 'DDI-MedLine.d161.s4.e2'}, 'sentence_id': 'DDI-MedLine.d161.s4'}	O 4 - O 0.2 - O mg / O body weight O administration of O - [ O 2 - O - 1 O - yl O ethynyl ] O or vehicle O were performed O the development O parkinsonian motor O in either O the two O groups ( O - methyl I-SIMPLE_CHEMICAL ( 2 O - yl O ethynyl ] O - methyl O 4 - O , 2 O , 6 O tetrahydropyridine / O . O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O
Weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). 	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	none	{'e1': {'word': '3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine', 'word_index': [(15, 30)], 'id': 'DDI-MedLine.d161.s4.e1'}, 'e2': {'word': '3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine', 'word_index': [(54, 63)], 'id': 'DDI-MedLine.d161.s4.e3'}, 'sentence_id': 'DDI-MedLine.d161.s4'}	O 4 - O 0.2 - O mg / O body weight O administration of O - [ O 2 - O - 1 O - yl O ethynyl ] O or vehicle O were performed O the development O parkinsonian motor O in either O the two O groups ( O - methyl I-SIMPLE_CHEMICAL ( 2 O - yl O ethynyl ] O - methyl O 4 - O , 2 O , 6 O tetrahydropyridine / O . O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O
Weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). 	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	none	{'e1': {'word': '3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine', 'word_index': [(15, 30)], 'id': 'DDI-MedLine.d161.s4.e1'}, 'e2': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(63, 76)], 'id': 'DDI-MedLine.d161.s4.e4'}, 'sentence_id': 'DDI-MedLine.d161.s4'}	O 4 - O 0.2 - O mg / O body weight O administration of O - [ O 2 - O - 1 O - yl O ethynyl ] O or vehicle O were performed O the development O parkinsonian motor O in either O the two O groups ( O - methyl I-SIMPLE_CHEMICAL ( 2 O - yl O ethynyl ] O - methyl O 4 - O , 2 O , 6 O tetrahydropyridine / O . O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O
Weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). 	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	none	{'e1': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(51, 54)], 'id': 'DDI-MedLine.d161.s4.e2'}, 'e2': {'word': '3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine', 'word_index': [(54, 63)], 'id': 'DDI-MedLine.d161.s4.e3'}, 'sentence_id': 'DDI-MedLine.d161.s4'}	O 4 - O 0.2 - O mg / O body weight O administration of O - [ O 2 - O - 1 O - yl O ethynyl ] O or vehicle O were performed O the development O parkinsonian motor O in either O the two O groups ( O - methyl I-SIMPLE_CHEMICAL ( 2 O - yl O ethynyl ] O - methyl O 4 - O , 2 O , 6 O tetrahydropyridine / O . O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O
Weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). 	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	none	{'e1': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(51, 54)], 'id': 'DDI-MedLine.d161.s4.e2'}, 'e2': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(63, 76)], 'id': 'DDI-MedLine.d161.s4.e4'}, 'sentence_id': 'DDI-MedLine.d161.s4'}	O 4 - O 0.2 - O mg / O body weight O administration of O - [ O 2 - O - 1 O - yl O ethynyl ] O or vehicle O were performed O the development O parkinsonian motor O in either O the two O groups ( O - methyl I-SIMPLE_CHEMICAL ( 2 O - yl O ethynyl ] O - methyl O 4 - O , 2 O , 6 O tetrahydropyridine / O . O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O
Weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). 	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	none	{'e1': {'word': '3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine', 'word_index': [(54, 63)], 'id': 'DDI-MedLine.d161.s4.e3'}, 'e2': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(63, 76)], 'id': 'DDI-MedLine.d161.s4.e4'}, 'sentence_id': 'DDI-MedLine.d161.s4'}	O 4 - O 0.2 - O mg / O body weight O administration of O - [ O 2 - O - 1 O - yl O ethynyl ] O or vehicle O were performed O the development O parkinsonian motor O in either O the two O groups ( O - methyl I-SIMPLE_CHEMICAL ( 2 O - yl O ethynyl ] O - methyl O 4 - O , 2 O , 6 O tetrahydropyridine / O . O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O
After 21 weeks of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment, all 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated animals displayed parkinsonian symptoms, whereas none of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys were significantly affected. 	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	none	{'e1': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(0, 10)], 'id': 'DDI-MedLine.d161.s5.e0'}, 'e2': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(14, 25)], 'id': 'DDI-MedLine.d161.s5.e1'}, 'sentence_id': 'DDI-MedLine.d161.s5'}	O - methyl O - phenyl O 3 , O tetrahydropyridine treatment O all 1 O methyl - O 2 , O , 6 O tetrahydropyridine / O - treated O none of O 1 - O - 4 O phenyl - O , 2 O 3 , O - tetrahydropyridine O 3 - O ( 2 O methyl - I-SIMPLE_CHEMICAL affected . O O O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O S-ORGANISM O O O O
After 21 weeks of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment, all 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated animals displayed parkinsonian symptoms, whereas none of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys were significantly affected. 	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	none	{'e1': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(0, 10)], 'id': 'DDI-MedLine.d161.s5.e0'}, 'e2': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(34, 50)], 'id': 'DDI-MedLine.d161.s5.e2'}, 'sentence_id': 'DDI-MedLine.d161.s5'}	O - methyl O - phenyl O 3 , O tetrahydropyridine treatment O all 1 O methyl - O 2 , O , 6 O tetrahydropyridine / O - treated O none of O 1 - O - 4 O phenyl - O , 2 O 3 , O - tetrahydropyridine O 3 - O ( 2 O methyl - I-SIMPLE_CHEMICAL affected . O O O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O S-ORGANISM O O O O
After 21 weeks of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment, all 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated animals displayed parkinsonian symptoms, whereas none of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys were significantly affected. 	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	none	{'e1': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(0, 10)], 'id': 'DDI-MedLine.d161.s5.e0'}, 'e2': {'word': '3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine', 'word_index': [(52, 60)], 'id': 'DDI-MedLine.d161.s5.e3'}, 'sentence_id': 'DDI-MedLine.d161.s5'}	O - methyl O - phenyl O 3 , O tetrahydropyridine treatment O all 1 O methyl - O 2 , O , 6 O tetrahydropyridine / O - treated O none of O 1 - O - 4 O phenyl - O , 2 O 3 , O - tetrahydropyridine O 3 - O ( 2 O methyl - I-SIMPLE_CHEMICAL affected . O O O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O S-ORGANISM O O O O
After 21 weeks of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment, all 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated animals displayed parkinsonian symptoms, whereas none of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys were significantly affected. 	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	none	{'e1': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(14, 25)], 'id': 'DDI-MedLine.d161.s5.e1'}, 'e2': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(34, 50)], 'id': 'DDI-MedLine.d161.s5.e2'}, 'sentence_id': 'DDI-MedLine.d161.s5'}	O - methyl O - phenyl O 3 , O tetrahydropyridine treatment O all 1 O methyl - O 2 , O , 6 O tetrahydropyridine / O - treated O none of O 1 - O - 4 O phenyl - O , 2 O 3 , O - tetrahydropyridine O 3 - O ( 2 O methyl - I-SIMPLE_CHEMICAL affected . O O O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O S-ORGANISM O O O O
After 21 weeks of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment, all 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated animals displayed parkinsonian symptoms, whereas none of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys were significantly affected. 	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	none	{'e1': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(14, 25)], 'id': 'DDI-MedLine.d161.s5.e1'}, 'e2': {'word': '3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine', 'word_index': [(52, 60)], 'id': 'DDI-MedLine.d161.s5.e3'}, 'sentence_id': 'DDI-MedLine.d161.s5'}	O - methyl O - phenyl O 3 , O tetrahydropyridine treatment O all 1 O methyl - O 2 , O , 6 O tetrahydropyridine / O - treated O none of O 1 - O - 4 O phenyl - O , 2 O 3 , O - tetrahydropyridine O 3 - O ( 2 O methyl - I-SIMPLE_CHEMICAL affected . O O O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O S-ORGANISM O O O O
After 21 weeks of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment, all 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated animals displayed parkinsonian symptoms, whereas none of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys were significantly affected. 	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	effect	{'e1': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(34, 50)], 'id': 'DDI-MedLine.d161.s5.e2'}, 'e2': {'word': '3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine', 'word_index': [(52, 60)], 'id': 'DDI-MedLine.d161.s5.e3'}, 'sentence_id': 'DDI-MedLine.d161.s5'}	O - methyl O - phenyl O 3 , O tetrahydropyridine treatment O all 1 O methyl - O 2 , O , 6 O tetrahydropyridine / O - treated O none of O 1 - O - 4 O phenyl - O , 2 O 3 , O - tetrahydropyridine O 3 - O ( 2 O methyl - I-SIMPLE_CHEMICAL affected . O O O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O S-ORGANISM O O O O
These behavioural observations were consistent with in vivo positron emission tomography dopamine transporter imaging data, and with post-mortem stereological counts of midbrain dopaminergic neurons, as well as striatal intensity measurements of dopamine transporter and tyrosine hydroxylase immunoreactivity, which were all significantly higher in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated animals than in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated monkeys. 	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	effect	{'e1': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(12, 21)], 'id': 'DDI-MedLine.d161.s6.e0'}, 'e2': {'word': '3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine', 'word_index': [(21, 27)], 'id': 'DDI-MedLine.d161.s6.e1'}, 'sentence_id': 'DDI-MedLine.d161.s6'}	O with in O post-mortem stereological O of dopamine O immunoreactivity , O 4 - O 2 , O 6 - O [ ( O thiazol - O treated animals O 1 , S-SIMPLE_CHEMICAL vehicle - O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O I-SIMPLE_CHEMICAL E-GENE_OR_GENE_PRODUCT O O O O O O O O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O S-ORGANISM O
These behavioural observations were consistent with in vivo positron emission tomography dopamine transporter imaging data, and with post-mortem stereological counts of midbrain dopaminergic neurons, as well as striatal intensity measurements of dopamine transporter and tyrosine hydroxylase immunoreactivity, which were all significantly higher in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated animals than in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated monkeys. 	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	none	{'e1': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(12, 21)], 'id': 'DDI-MedLine.d161.s6.e0'}, 'e2': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(30, 33)], 'id': 'DDI-MedLine.d161.s6.e2'}, 'sentence_id': 'DDI-MedLine.d161.s6'}	O with in O post-mortem stereological O of dopamine O immunoreactivity , O 4 - O 2 , O 6 - O [ ( O thiazol - O treated animals O 1 , S-SIMPLE_CHEMICAL vehicle - O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O I-SIMPLE_CHEMICAL E-GENE_OR_GENE_PRODUCT O O O O O O O O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O S-ORGANISM O
These behavioural observations were consistent with in vivo positron emission tomography dopamine transporter imaging data, and with post-mortem stereological counts of midbrain dopaminergic neurons, as well as striatal intensity measurements of dopamine transporter and tyrosine hydroxylase immunoreactivity, which were all significantly higher in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated animals than in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated monkeys. 	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	none	{'e1': {'word': '3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine', 'word_index': [(21, 27)], 'id': 'DDI-MedLine.d161.s6.e1'}, 'e2': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(30, 33)], 'id': 'DDI-MedLine.d161.s6.e2'}, 'sentence_id': 'DDI-MedLine.d161.s6'}	O with in O post-mortem stereological O of dopamine O immunoreactivity , O 4 - O 2 , O 6 - O [ ( O thiazol - O treated animals O 1 , S-SIMPLE_CHEMICAL vehicle - O O O O O O O O O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O I-SIMPLE_CHEMICAL E-GENE_OR_GENE_PRODUCT O O O O O O O O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O S-ORGANISM O
The 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine treatment also had a significant effect on the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced loss of norepinephrine neurons in the locus coeruleus and adjoining A5 and A7 noradrenaline cell groups. 	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	effect	{'e1': {'word': '3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine', 'word_index': [(0, 19)], 'id': 'DDI-MedLine.d161.s7.e0'}, 'e2': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(23, 39)], 'id': 'DDI-MedLine.d161.s7.e1'}, 'sentence_id': 'DDI-MedLine.d161.s7'}	O [ ( O - methyl O 1 , O - thiazol O 4 - O ) ethynyl O pyridine treatment O the 1 O methyl - O - phenyl O 1 , O , 3 O 6 - O in the O coeruleus and O A5 and O noradrenaline cell O O O O I-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O S-SIMPLE_CHEMICAL O O O S-CELLULAR_COMPONENT O O O O O O S-SIMPLE_CHEMICAL E-CELL O O
In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated animals, almost 40% loss of tyrosine hydroxylase-positive norepinephrine neurons was found in locus coeruleus/A5/A7 noradrenaline cell groups, whereas the extent of neuronal loss was lower than 15% of control values in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys. 	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	none	{'e1': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(0, 11)], 'id': 'DDI-MedLine.d161.s8.e0'}, 'e2': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(51, 51)], 'id': 'DDI-MedLine.d161.s8.e1'}, 'sentence_id': 'DDI-MedLine.d161.s8'}	O - methyl O 4 - O - 1 O - tetrahydropyridine O vehicle - O animals , O 40 % O norepinephrine neurons O found in O coeruleus / O / A7 O cell groups O whereas the O of neuronal O was lower O 15 % O control values I-SIMPLE_CHEMICAL / 3 O [ ( O - thiazol O 4 - O monkeys . O O O O O O O I-SIMPLE_CHEMICAL E-GENE_OR_GENE_PRODUCT O O S-SIMPLE_CHEMICAL O O O O S-CELLULAR_COMPONENT O O O O O S-SIMPLE_CHEMICAL E-CELL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O S-ORGANISM O
In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated animals, almost 40% loss of tyrosine hydroxylase-positive norepinephrine neurons was found in locus coeruleus/A5/A7 noradrenaline cell groups, whereas the extent of neuronal loss was lower than 15% of control values in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys. 	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	none	{'e1': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(0, 11)], 'id': 'DDI-MedLine.d161.s8.e0'}, 'e2': {'word': '3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine', 'word_index': [(53, 63)], 'id': 'DDI-MedLine.d161.s8.e2'}, 'sentence_id': 'DDI-MedLine.d161.s8'}	O - methyl O 4 - O - 1 O - tetrahydropyridine O vehicle - O animals , O 40 % O norepinephrine neurons O found in O coeruleus / O / A7 O cell groups O whereas the O of neuronal O was lower O 15 % O control values I-SIMPLE_CHEMICAL / 3 O [ ( O - thiazol O 4 - O monkeys . O O O O O O O I-SIMPLE_CHEMICAL E-GENE_OR_GENE_PRODUCT O O S-SIMPLE_CHEMICAL O O O O S-CELLULAR_COMPONENT O O O O O S-SIMPLE_CHEMICAL E-CELL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O S-ORGANISM O
In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated animals, almost 40% loss of tyrosine hydroxylase-positive norepinephrine neurons was found in locus coeruleus/A5/A7 noradrenaline cell groups, whereas the extent of neuronal loss was lower than 15% of control values in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys. 	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	effect	{'e1': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(51, 51)], 'id': 'DDI-MedLine.d161.s8.e1'}, 'e2': {'word': '3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine', 'word_index': [(53, 63)], 'id': 'DDI-MedLine.d161.s8.e2'}, 'sentence_id': 'DDI-MedLine.d161.s8'}	O - methyl O 4 - O - 1 O - tetrahydropyridine O vehicle - O animals , O 40 % O norepinephrine neurons O found in O coeruleus / O / A7 O cell groups O whereas the O of neuronal O was lower O 15 % O control values I-SIMPLE_CHEMICAL / 3 O [ ( O - thiazol O 4 - O monkeys . O O O O O O O I-SIMPLE_CHEMICAL E-GENE_OR_GENE_PRODUCT O O S-SIMPLE_CHEMICAL O O O O S-CELLULAR_COMPONENT O O O O O S-SIMPLE_CHEMICAL E-CELL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O S-ORGANISM O
Our data demonstrate that chronic treatment with the metabotropic glutamate receptor 5 antagonist, 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine, significantly reduces 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity towards dopaminergic and noradrenergic cell groups in non-human primates. 	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	effect	{'e1': {'word': '3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine', 'word_index': [(6, 12)], 'id': 'DDI-MedLine.d161.s9.e0'}, 'e2': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(14, 19)], 'id': 'DDI-MedLine.d161.s9.e1'}, 'sentence_id': 'DDI-MedLine.d161.s9'}	O that chronic O glutamate receptor O 1 , O 4 - O reduces 1 O 2 , O tetrahydropyridine toxicity O noradrenergic cell O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O E-CELL O O O S-ORGANISM O
To determine whether the co-injection of extracellular matrix degrading enzymes improves retinal transduction following intravitreal delivery of adeno-associated virus-2 (AAV2).	adeno-associated virus-2	AAV2	none	{'e1': {'word': 'adeno-associated virus-2', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d190.s1.e0'}, 'e2': {'word': 'AAV2', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d190.s1.e1'}, 'sentence_id': 'DDI-MedLine.d190.s1'}	O whether the O following intravitreal O AAV2 ) O O O S-IMMATERIAL_ANATOMICAL_ENTITY S-CELLULAR_COMPONENT O O O S-MULTI-TISSUE_STRUCTURE O O O O O O O O O O S-ORGANISM O O
AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, heparinase III, or chondroitin ABC lyase. 	AAV2	collagenase	none	{'e1': {'word': 'AAV2', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d190.s2.e0'}, 'e2': {'word': 'collagenase', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d190.s2.e1'}, 'sentence_id': 'DDI-MedLine.d190.s2'}	S-ORGANISM enhanced green O a chicken O was delivered O with enzymes O , or O O O O O O O O O O O O S-ORGANISM O E-GENE_OR_GENE_PRODUCT O O O O O O O O O S-ORGANISM O O O O O S-GENE_OR_GENE_PRODUCT O S-GENE_OR_GENE_PRODUCT O O O O O O S-SIMPLE_CHEMICAL O O O
AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, heparinase III, or chondroitin ABC lyase. 	AAV2	hyaluronan lyase	none	{'e1': {'word': 'AAV2', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d190.s2.e0'}, 'e2': {'word': 'hyaluronan lyase', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d190.s2.e2'}, 'sentence_id': 'DDI-MedLine.d190.s2'}	S-ORGANISM enhanced green O a chicken O was delivered O with enzymes O , or O O O O O O O O O O O O S-ORGANISM O E-GENE_OR_GENE_PRODUCT O O O O O O O O O S-ORGANISM O O O O O S-GENE_OR_GENE_PRODUCT O S-GENE_OR_GENE_PRODUCT O O O O O O S-SIMPLE_CHEMICAL O O O
AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, heparinase III, or chondroitin ABC lyase. 	AAV2	heparinase III	none	{'e1': {'word': 'AAV2', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d190.s2.e0'}, 'e2': {'word': 'heparinase III', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d190.s2.e3'}, 'sentence_id': 'DDI-MedLine.d190.s2'}	S-ORGANISM enhanced green O a chicken O was delivered O with enzymes O , or O O O O O O O O O O O O S-ORGANISM O E-GENE_OR_GENE_PRODUCT O O O O O O O O O S-ORGANISM O O O O O S-GENE_OR_GENE_PRODUCT O S-GENE_OR_GENE_PRODUCT O O O O O O S-SIMPLE_CHEMICAL O O O
AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, heparinase III, or chondroitin ABC lyase. 	AAV2	chondroitin ABC lyase	none	{'e1': {'word': 'AAV2', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d190.s2.e0'}, 'e2': {'word': 'chondroitin ABC lyase', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d190.s2.e4'}, 'sentence_id': 'DDI-MedLine.d190.s2'}	S-ORGANISM enhanced green O a chicken O was delivered O with enzymes O , or O O O O O O O O O O O O S-ORGANISM O E-GENE_OR_GENE_PRODUCT O O O O O O O O O S-ORGANISM O O O O O S-GENE_OR_GENE_PRODUCT O S-GENE_OR_GENE_PRODUCT O O O O O O S-SIMPLE_CHEMICAL O O O
AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, heparinase III, or chondroitin ABC lyase. 	collagenase	hyaluronan lyase	none	{'e1': {'word': 'collagenase', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d190.s2.e1'}, 'e2': {'word': 'hyaluronan lyase', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d190.s2.e2'}, 'sentence_id': 'DDI-MedLine.d190.s2'}	S-ORGANISM enhanced green O a chicken O was delivered O with enzymes O , or O O O O O O O O O O O O S-ORGANISM O E-GENE_OR_GENE_PRODUCT O O O O O O O O O S-ORGANISM O O O O O S-GENE_OR_GENE_PRODUCT O S-GENE_OR_GENE_PRODUCT O O O O O O S-SIMPLE_CHEMICAL O O O
AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, heparinase III, or chondroitin ABC lyase. 	collagenase	heparinase III	none	{'e1': {'word': 'collagenase', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d190.s2.e1'}, 'e2': {'word': 'heparinase III', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d190.s2.e3'}, 'sentence_id': 'DDI-MedLine.d190.s2'}	S-ORGANISM enhanced green O a chicken O was delivered O with enzymes O , or O O O O O O O O O O O O S-ORGANISM O E-GENE_OR_GENE_PRODUCT O O O O O O O O O S-ORGANISM O O O O O S-GENE_OR_GENE_PRODUCT O S-GENE_OR_GENE_PRODUCT O O O O O O S-SIMPLE_CHEMICAL O O O
AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, heparinase III, or chondroitin ABC lyase. 	collagenase	chondroitin ABC lyase	none	{'e1': {'word': 'collagenase', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d190.s2.e1'}, 'e2': {'word': 'chondroitin ABC lyase', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d190.s2.e4'}, 'sentence_id': 'DDI-MedLine.d190.s2'}	S-ORGANISM enhanced green O a chicken O was delivered O with enzymes O , or O O O O O O O O O O O O S-ORGANISM O E-GENE_OR_GENE_PRODUCT O O O O O O O O O S-ORGANISM O O O O O S-GENE_OR_GENE_PRODUCT O S-GENE_OR_GENE_PRODUCT O O O O O O S-SIMPLE_CHEMICAL O O O
AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, heparinase III, or chondroitin ABC lyase. 	hyaluronan lyase	heparinase III	none	{'e1': {'word': 'hyaluronan lyase', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d190.s2.e2'}, 'e2': {'word': 'heparinase III', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d190.s2.e3'}, 'sentence_id': 'DDI-MedLine.d190.s2'}	S-ORGANISM enhanced green O a chicken O was delivered O with enzymes O , or O O O O O O O O O O O O S-ORGANISM O E-GENE_OR_GENE_PRODUCT O O O O O O O O O S-ORGANISM O O O O O S-GENE_OR_GENE_PRODUCT O S-GENE_OR_GENE_PRODUCT O O O O O O S-SIMPLE_CHEMICAL O O O
AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, heparinase III, or chondroitin ABC lyase. 	hyaluronan lyase	chondroitin ABC lyase	none	{'e1': {'word': 'hyaluronan lyase', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d190.s2.e2'}, 'e2': {'word': 'chondroitin ABC lyase', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d190.s2.e4'}, 'sentence_id': 'DDI-MedLine.d190.s2'}	S-ORGANISM enhanced green O a chicken O was delivered O with enzymes O , or O O O O O O O O O O O O S-ORGANISM O E-GENE_OR_GENE_PRODUCT O O O O O O O O O S-ORGANISM O O O O O S-GENE_OR_GENE_PRODUCT O S-GENE_OR_GENE_PRODUCT O O O O O O S-SIMPLE_CHEMICAL O O O
AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, heparinase III, or chondroitin ABC lyase. 	heparinase III	chondroitin ABC lyase	none	{'e1': {'word': 'heparinase III', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d190.s2.e3'}, 'e2': {'word': 'chondroitin ABC lyase', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d190.s2.e4'}, 'sentence_id': 'DDI-MedLine.d190.s2'}	S-ORGANISM enhanced green O a chicken O was delivered O with enzymes O , or O O O O O O O O O O O O S-ORGANISM O E-GENE_OR_GENE_PRODUCT O O O O O O O O O S-ORGANISM O O O O O S-GENE_OR_GENE_PRODUCT O S-GENE_OR_GENE_PRODUCT O O O O O O S-SIMPLE_CHEMICAL O O O
The addition of heparinase III or chondroitin ABC lyase greatly enhanced transduction of the retinal ganglion cell layer and increased the depth of transduction into the outer retina. 	heparinase III	chondroitin ABC lyase	none	{'e1': {'word': 'heparinase III', 'word_index': [(1, 2)], 'id': 'DDI-MedLine.d190.s5.e0'}, 'e2': {'word': 'chondroitin ABC lyase', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d190.s5.e1'}, 'sentence_id': 'DDI-MedLine.d190.s5'}	O heparinase III O the retinal O layer and O O O S-SIMPLE_CHEMICAL O O O O O O O S-MULTI-TISSUE_STRUCTURE O E-CELL O O O O O O O O O O O O
Hyaluronan lyase had a limited effect and collagenase was ineffective. 	Hyaluronan lyase	collagenase	none	{'e1': {'word': 'Hyaluronan lyase', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d190.s6.e0'}, 'e2': {'word': 'collagenase', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d190.s6.e1'}, 'sentence_id': 'DDI-MedLine.d190.s6'}	S-GENE_OR_GENE_PRODUCT . O O O O O O S-GENE_OR_GENE_PRODUCT O O O
Electroretinograms survived with higher concentrations of heparinase III and chondroitin ABC lyase than were required for optimal retinal transduction. 	heparinase III	chondroitin ABC lyase	none	{'e1': {'word': 'heparinase III', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d190.s7.e0'}, 'e2': {'word': 'chondroitin ABC lyase', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d190.s7.e1'}, 'sentence_id': 'DDI-MedLine.d190.s7'}	O transduction . O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O S-MULTI-TISSUE_STRUCTURE O O
AAV2-mediated retinal transduction is improved by co-injection of heparinase III or chondroitin ABC lyase. 	AAV2	heparinase III	effect	{'e1': {'word': 'AAV2', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d190.s8.e0'}, 'e2': {'word': 'heparinase III', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d190.s8.e1'}, 'sentence_id': 'DDI-MedLine.d190.s8'}	S-ORGANISM transduction is O by co-injection O S-MULTI-TISSUE_STRUCTURE O O O O O O O O O S-SIMPLE_CHEMICAL O O O
AAV2-mediated retinal transduction is improved by co-injection of heparinase III or chondroitin ABC lyase. 	AAV2	chondroitin ABC lyase	effect	{'e1': {'word': 'AAV2', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d190.s8.e0'}, 'e2': {'word': 'chondroitin ABC lyase', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d190.s8.e2'}, 'sentence_id': 'DDI-MedLine.d190.s8'}	S-ORGANISM transduction is O by co-injection O S-MULTI-TISSUE_STRUCTURE O O O O O O O O O S-SIMPLE_CHEMICAL O O O
AAV2-mediated retinal transduction is improved by co-injection of heparinase III or chondroitin ABC lyase. 	heparinase III	chondroitin ABC lyase	none	{'e1': {'word': 'heparinase III', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d190.s8.e1'}, 'e2': {'word': 'chondroitin ABC lyase', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d190.s8.e2'}, 'sentence_id': 'DDI-MedLine.d190.s8'}	S-ORGANISM transduction is O by co-injection O S-MULTI-TISSUE_STRUCTURE O O O O O O O O O S-SIMPLE_CHEMICAL O O O
Implanon   failure in an HIV-positive woman on antiretroviral therapy resulting in two ectopic pregnancies.	Implanon	antiretroviral	effect	{'e1': {'word': 'Implanon', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d208.s0.e0'}, 'e2': {'word': 'antiretroviral', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d208.s0.e1'}, 'sentence_id': 'DDI-MedLine.d208.s0'}	O on antiretroviral O O O O O O O O O O O O O O O O
We present an interesting case of an HIV-positive woman on antiretroviral therapy having tubal pregnancies on two separate occasions with Implanon in place.	antiretroviral	Implanon	effect	{'e1': {'word': 'antiretroviral', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d208.s3.e0'}, 'e2': {'word': 'Implanon', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d208.s3.e1'}, 'sentence_id': 'DDI-MedLine.d208.s3'}	O an interesting O on antiretroviral O tubal pregnancies O O O O O O O O O O O O O O O O O O O O O O O
"[Influence of hemantane and doxycycline on MPTP-evoked behavior violations in C57BL/6 mice].
"	hemantane	doxycycline	none	{'e1': {'word': 'hemantane', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d214.s0.e0'}, 'e2': {'word': 'doxycycline', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d214.s0.e1'}, 'sentence_id': 'DDI-MedLine.d214.s0'}	O Influence of O in C57BL O mice ] O O O O O O O O O O O O O S-ORGANISM O O
The effects of anti-parkinsonian drug hemantane [(2-adamantyl)hexamethylenimine] (10 mg/kg, p. o.) 	anti-parkinsonian drug	hemantane	none	{'e1': {'word': 'anti-parkinsonian drug', 'word_index': [(1, 2)], 'id': 'DDI-MedLine.d214.s1.e0'}, 'e2': {'word': 'hemantane', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d214.s1.e1'}, 'sentence_id': 'DDI-MedLine.d214.s1'}	O anti-parkinsonian drug O hexamethylenimine ] O mg / O O O O O O O O O O O O O O O O O O O O O O
The effects of anti-parkinsonian drug hemantane [(2-adamantyl)hexamethylenimine] (10 mg/kg, p. o.) 	anti-parkinsonian drug	(2-adamantyl)hexamethylenimine	none	{'e1': {'word': 'anti-parkinsonian drug', 'word_index': [(1, 2)], 'id': 'DDI-MedLine.d214.s1.e0'}, 'e2': {'word': '(2-adamantyl)hexamethylenimine', 'word_index': [(3, 4)], 'id': 'DDI-MedLine.d214.s1.e2'}, 'sentence_id': 'DDI-MedLine.d214.s1'}	O anti-parkinsonian drug O hexamethylenimine ] O mg / O O O O O O O O O O O O O O O O O O O O O O
The effects of anti-parkinsonian drug hemantane [(2-adamantyl)hexamethylenimine] (10 mg/kg, p. o.) 	hemantane	(2-adamantyl)hexamethylenimine	none	{'e1': {'word': 'hemantane', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d214.s1.e1'}, 'e2': {'word': '(2-adamantyl)hexamethylenimine', 'word_index': [(3, 4)], 'id': 'DDI-MedLine.d214.s1.e2'}, 'sentence_id': 'DDI-MedLine.d214.s1'}	O anti-parkinsonian drug O hexamethylenimine ] O mg / O O O O O O O O O O O O O O O O O O O O O O
and/or antibiotic drug doxycycline (100 mg/kg, p. o.), as well as that of neurotoxin 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine (MPTP) (4 x 20 mg/kg, i. p.) 	antibiotic drug	doxycycline	none	{'e1': {'word': 'antibiotic drug', 'word_index': [(1, 2)], 'id': 'DDI-MedLine.d214.s2.e0'}, 'e2': {'word': 'doxycycline', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d214.s2.e1'}, 'sentence_id': 'DDI-MedLine.d214.s2'}	O antibiotic drug O ( 100 O kg , O 1 - O phenyl - O ) ( O x 20 O , i. O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O
and/or antibiotic drug doxycycline (100 mg/kg, p. o.), as well as that of neurotoxin 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine (MPTP) (4 x 20 mg/kg, i. p.) 	antibiotic drug	1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine	none	{'e1': {'word': 'antibiotic drug', 'word_index': [(1, 2)], 'id': 'DDI-MedLine.d214.s2.e0'}, 'e2': {'word': '1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine', 'word_index': [(10, 15)], 'id': 'DDI-MedLine.d214.s2.e2'}, 'sentence_id': 'DDI-MedLine.d214.s2'}	O antibiotic drug O ( 100 O kg , O 1 - O phenyl - O ) ( O x 20 O , i. O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O
and/or antibiotic drug doxycycline (100 mg/kg, p. o.), as well as that of neurotoxin 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine (MPTP) (4 x 20 mg/kg, i. p.) 	antibiotic drug	MPTP	none	{'e1': {'word': 'antibiotic drug', 'word_index': [(1, 2)], 'id': 'DDI-MedLine.d214.s2.e0'}, 'e2': {'word': 'MPTP', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d214.s2.e3'}, 'sentence_id': 'DDI-MedLine.d214.s2'}	O antibiotic drug O ( 100 O kg , O 1 - O phenyl - O ) ( O x 20 O , i. O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O
and/or antibiotic drug doxycycline (100 mg/kg, p. o.), as well as that of neurotoxin 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine (MPTP) (4 x 20 mg/kg, i. p.) 	doxycycline	1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine	none	{'e1': {'word': 'doxycycline', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d214.s2.e1'}, 'e2': {'word': '1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine', 'word_index': [(10, 15)], 'id': 'DDI-MedLine.d214.s2.e2'}, 'sentence_id': 'DDI-MedLine.d214.s2'}	O antibiotic drug O ( 100 O kg , O 1 - O phenyl - O ) ( O x 20 O , i. O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O
and/or antibiotic drug doxycycline (100 mg/kg, p. o.), as well as that of neurotoxin 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine (MPTP) (4 x 20 mg/kg, i. p.) 	doxycycline	MPTP	none	{'e1': {'word': 'doxycycline', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d214.s2.e1'}, 'e2': {'word': 'MPTP', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d214.s2.e3'}, 'sentence_id': 'DDI-MedLine.d214.s2'}	O antibiotic drug O ( 100 O kg , O 1 - O phenyl - O ) ( O x 20 O , i. O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O
and/or antibiotic drug doxycycline (100 mg/kg, p. o.), as well as that of neurotoxin 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine (MPTP) (4 x 20 mg/kg, i. p.) 	1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine	MPTP	none	{'e1': {'word': '1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine', 'word_index': [(10, 15)], 'id': 'DDI-MedLine.d214.s2.e2'}, 'e2': {'word': 'MPTP', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d214.s2.e3'}, 'sentence_id': 'DDI-MedLine.d214.s2'}	O antibiotic drug O ( 100 O kg , O 1 - O phenyl - O ) ( O x 20 O , i. O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O I-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O
Acute administration of hemantane or doxycycline failed to influence locomotion in mice, while their combination normalized motor activity. 	hemantane	doxycycline	effect	{'e1': {'word': 'hemantane', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d214.s5.e0'}, 'e2': {'word': 'doxycycline', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d214.s5.e1'}, 'sentence_id': 'DDI-MedLine.d214.s5'}	O doxycycline failed O O O O O O O O O O S-ORGANISM O O O O O O O O
"Interaction of dacarbazine and imexon, in vitro and in vivo, in human A375 melanoma cells.
"	dacarbazine	imexon	none	{'e1': {'word': 'dacarbazine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d147.s0.e0'}, 'e2': {'word': 'imexon', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d147.s0.e1'}, 'sentence_id': 'DDI-MedLine.d147.s0'}	O , in O melanoma cells O O O O O O O O O O O S-ORGANISM S-CELL E-CANCER S-CELL O
We evaluated mechanisms of interaction between the alkyating agent dacarbazine (DTIC) and the pro-oxidant, imexon, in the human A375 melanoma cell line.	dacarbazine	DTIC	none	{'e1': {'word': 'dacarbazine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d147.s1.e0'}, 'e2': {'word': 'DTIC', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d147.s1.e1'}, 'sentence_id': 'DDI-MedLine.d147.s1'}	O mechanisms of O and the O line . O O O O O O O O O O O O O O O O O O S-ORGANISM S-CELL E-CANCER E-CELL O O
We evaluated mechanisms of interaction between the alkyating agent dacarbazine (DTIC) and the pro-oxidant, imexon, in the human A375 melanoma cell line.	dacarbazine	imexon	none	{'e1': {'word': 'dacarbazine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d147.s1.e0'}, 'e2': {'word': 'imexon', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d147.s1.e2'}, 'sentence_id': 'DDI-MedLine.d147.s1'}	O mechanisms of O and the O line . O O O O O O O O O O O O O O O O O O S-ORGANISM S-CELL E-CANCER E-CELL O O
We evaluated mechanisms of interaction between the alkyating agent dacarbazine (DTIC) and the pro-oxidant, imexon, in the human A375 melanoma cell line.	DTIC	imexon	none	{'e1': {'word': 'DTIC', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d147.s1.e1'}, 'e2': {'word': 'imexon', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d147.s1.e2'}, 'sentence_id': 'DDI-MedLine.d147.s1'}	O mechanisms of O and the O line . O O O O O O O O O O O O O O O O O O S-ORGANISM S-CELL E-CANCER E-CELL O O
The effect of DTIC and imexon, alone and in combination, was evaluated for growth inhibition (MTT), radiolabeled drug uptake, cellular thiol content (HPLC), and DNA strand breaks (Comet assay). 	DTIC	imexon	none	{'e1': {'word': 'DTIC', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d147.s2.e0'}, 'e2': {'word': 'imexon', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d147.s2.e1'}, 'sentence_id': 'DDI-MedLine.d147.s2'}	O DTIC and O , was O growth inhibition O radiolabeled drug O thiol content O strand breaks O Comet assay O O O O O O O O O O O O O O O O O O S-CELL O O O O O O O S-CELLULAR_COMPONENT O O O O O O O
There was a >75% reduction in cellular glutathione and cysteine with imexon but not DTIC. 	imexon	DTIC	none	{'e1': {'word': 'imexon', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d147.s6.e0'}, 'e2': {'word': 'DTIC', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d147.s6.e1'}, 'sentence_id': 'DDI-MedLine.d147.s6'}	O % reduction O and cysteine O imexon but O DTIC . O O O O S-CELL S-SIMPLE_CHEMICAL O S-AMINO_ACID O O O O O O
Imexon and dacarbazine show additive effects in vitro but not in vivo in human A375 melanoma cells.	Imexon	dacarbazine	effect	{'e1': {'word': 'Imexon', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d147.s8.e0'}, 'e2': {'word': 'dacarbazine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d147.s8.e1'}, 'sentence_id': 'DDI-MedLine.d147.s8'}	O in vitro O vivo in O O O O O O O O O O O S-ORGANISM S-CELL E-CANCER S-CELL O
The authors report the case of an infant with confirmed congenital hypothyroidism on levothyroxine who experienced a possible drug interaction with simeticone. 	levothyroxine	simeticone	int	{'e1': {'word': 'levothyroxine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d181.s4.e0'}, 'e2': {'word': 'simeticone', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d181.s4.e1'}, 'sentence_id': 'DDI-MedLine.d181.s4'}	O the case O on levothyroxine O with simeticone O O O O O O O O O O O O O O O O O O O O
Questioning revealed the child was taking Infacol drops before feeds while on levothyroxine. 	Infacol	levothyroxine	none	{'e1': {'word': 'Infacol', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d181.s6.e0'}, 'e2': {'word': 'levothyroxine', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d181.s6.e1'}, 'sentence_id': 'DDI-MedLine.d181.s6'}	O on levothyroxine O O O O O O O O O O O O O
Drug interaction of thyroxine with simeticone has not been reported previously and is not listed in the British National Formulary for Children. 	thyroxine	simeticone	none	{'e1': {'word': 'thyroxine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d181.s8.e0'}, 'e2': {'word': 'simeticone', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d181.s8.e1'}, 'sentence_id': 'DDI-MedLine.d181.s8'}	O with simeticone O British National O Children . S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O
The aim of the present study was to investigate whether HB-EGF is a therapeutic target for T-ALL, and to further elucidate the antitumor effects of a specific inhibitor of HB-EGF, cross-reacting material 197 (CRM197). 	cross-reacting material 197	CRM197	none	{'e1': {'word': 'cross-reacting material 197', 'word_index': [(19, 21)], 'id': 'DDI-MedLine.d201.s4.e0'}, 'e2': {'word': 'CRM197', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d201.s4.e1'}, 'sentence_id': 'DDI-MedLine.d201.s4'}	O the present O investigate whether O EGF is O for T O the antitumor O of HB O cross-reacting material O CRM197 ) O O O O S-GENE_OR_GENE_PRODUCT O O O O O O O O O O O O O O S-CANCER O O O O O O O O S-GENE_OR_GENE_PRODUCT O O O O O O O O
We elucidated the expression of HB-EGF in T-ALL cell lines, and evaluated the effect of CRM197 on these cells alone or in combination with anticancer agent. 	CRM197	anticancer agent	none	{'e1': {'word': 'CRM197', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d201.s5.e0'}, 'e2': {'word': 'anticancer agent', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d201.s5.e1'}, 'sentence_id': 'DDI-MedLine.d201.s5'}	O the expression O , and O of CRM197 O . O O O S-GENE_OR_GENE_PRODUCT O O O O E-CELL O O O O O O O O O O S-CELL O O O O O S-CANCER O O
CRM197 induced apoptosis, and furthermore, the combination of CRM197 plus doxorubicin enhanced cytotoxicity in a T-ALL cell line. 	CRM197	CRM197	none	{'e1': {'word': 'CRM197', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d201.s9.e0'}, 'e2': {'word': 'CRM197', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d201.s9.e1'}, 'sentence_id': 'DDI-MedLine.d201.s9'}	O , the O in a O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O E-CELL O O
CRM197 induced apoptosis, and furthermore, the combination of CRM197 plus doxorubicin enhanced cytotoxicity in a T-ALL cell line. 	CRM197	doxorubicin	none	{'e1': {'word': 'CRM197', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d201.s9.e0'}, 'e2': {'word': 'doxorubicin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d201.s9.e2'}, 'sentence_id': 'DDI-MedLine.d201.s9'}	O , the O in a O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O E-CELL O O
CRM197 induced apoptosis, and furthermore, the combination of CRM197 plus doxorubicin enhanced cytotoxicity in a T-ALL cell line. 	CRM197	doxorubicin	effect	{'e1': {'word': 'CRM197', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d201.s9.e1'}, 'e2': {'word': 'doxorubicin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d201.s9.e2'}, 'sentence_id': 'DDI-MedLine.d201.s9'}	O , the O in a O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O E-CELL O O
"Amphetamine locomotor sensitization and conditioned place preference in adolescent male and female rats neonatally treated with quinpirole.
"	Amphetamine	quinpirole	none	{'e1': {'word': 'Amphetamine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d184.s0.e0'}, 'e2': {'word': 'quinpirole', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d184.s0.e1'}, 'sentence_id': 'DDI-MedLine.d184.s0'}	O female rats O O O O O O O O O O O S-ORGANISM O O O S-SIMPLE_CHEMICAL O
The objective was to analyze the effects of neonatal quinpirole treatment on effects of amphetamine in adolescent rats using locomotor sensitization and conditioned place preference procedures. 	quinpirole	amphetamine	none	{'e1': {'word': 'quinpirole', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d184.s2.e0'}, 'e2': {'word': 'amphetamine', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d184.s2.e1'}, 'sentence_id': 'DDI-MedLine.d184.s2'}	O to analyze O amphetamine in O locomotor sensitization O place preference O O O O O S-SIMPLE_CHEMICAL O O O O O O O S-ORGANISM O O O O O O O O O
In female rats, neonatal quinpirole treatment enhanced amphetamine locomotor sensitization compared with quinpirole-free controls sensitized to amphetamine. 	quinpirole	amphetamine	effect	{'e1': {'word': 'quinpirole', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d184.s5.e0'}, 'e2': {'word': 'amphetamine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d184.s5.e1'}, 'sentence_id': 'DDI-MedLine.d184.s5'}	O rats , O sensitization compared S-ORGANISM controls sensitized O amphetamine . O S-SIMPLE_CHEMICAL O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O
In female rats, neonatal quinpirole treatment enhanced amphetamine locomotor sensitization compared with quinpirole-free controls sensitized to amphetamine. 	quinpirole	quinpirole	none	{'e1': {'word': 'quinpirole', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d184.s5.e0'}, 'e2': {'word': 'quinpirole', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d184.s5.e2'}, 'sentence_id': 'DDI-MedLine.d184.s5'}	O rats , O sensitization compared S-ORGANISM controls sensitized O amphetamine . O S-SIMPLE_CHEMICAL O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O
In female rats, neonatal quinpirole treatment enhanced amphetamine locomotor sensitization compared with quinpirole-free controls sensitized to amphetamine. 	quinpirole	amphetamine	none	{'e1': {'word': 'quinpirole', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d184.s5.e0'}, 'e2': {'word': 'amphetamine', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d184.s5.e3'}, 'sentence_id': 'DDI-MedLine.d184.s5'}	O rats , O sensitization compared S-ORGANISM controls sensitized O amphetamine . O S-SIMPLE_CHEMICAL O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O
In female rats, neonatal quinpirole treatment enhanced amphetamine locomotor sensitization compared with quinpirole-free controls sensitized to amphetamine. 	amphetamine	quinpirole	none	{'e1': {'word': 'amphetamine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d184.s5.e1'}, 'e2': {'word': 'quinpirole', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d184.s5.e2'}, 'sentence_id': 'DDI-MedLine.d184.s5'}	O rats , O sensitization compared S-ORGANISM controls sensitized O amphetamine . O S-SIMPLE_CHEMICAL O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O
In female rats, neonatal quinpirole treatment enhanced amphetamine locomotor sensitization compared with quinpirole-free controls sensitized to amphetamine. 	amphetamine	amphetamine	none	{'e1': {'word': 'amphetamine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d184.s5.e1'}, 'e2': {'word': 'amphetamine', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d184.s5.e3'}, 'sentence_id': 'DDI-MedLine.d184.s5'}	O rats , O sensitization compared S-ORGANISM controls sensitized O amphetamine . O S-SIMPLE_CHEMICAL O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O
In female rats, neonatal quinpirole treatment enhanced amphetamine locomotor sensitization compared with quinpirole-free controls sensitized to amphetamine. 	quinpirole	amphetamine	none	{'e1': {'word': 'quinpirole', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d184.s5.e2'}, 'e2': {'word': 'amphetamine', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d184.s5.e3'}, 'sentence_id': 'DDI-MedLine.d184.s5'}	O rats , O sensitization compared S-ORGANISM controls sensitized O amphetamine . O S-SIMPLE_CHEMICAL O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O
Male rats demonstrated sensitization to amphetamine, although this was muted compared with female rats, and were unaffected by neonatal quinpirole. 	amphetamine	quinpirole	none	{'e1': {'word': 'amphetamine', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d184.s6.e0'}, 'e2': {'word': 'quinpirole', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d184.s6.e1'}, 'sentence_id': 'DDI-MedLine.d184.s6'}	O to amphetamine S-ORGANISM muted compared O O O O O O O O O O O O S-ORGANISM O O O O O O S-SIMPLE_CHEMICAL O
Rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. 	quinpirole	amphetamine	none	{'e1': {'word': 'quinpirole', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d184.s8.e0'}, 'e2': {'word': 'amphetamine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d184.s8.e1'}, 'sentence_id': 'DDI-MedLine.d184.s8'}	O quinpirole enhanced O context compared O controls conditioned O with amphetamine S-SIMPLE_CHEMICAL with saline O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
Rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. 	quinpirole	quinpirole	none	{'e1': {'word': 'quinpirole', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d184.s8.e0'}, 'e2': {'word': 'quinpirole', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d184.s8.e2'}, 'sentence_id': 'DDI-MedLine.d184.s8'}	O quinpirole enhanced O context compared O controls conditioned O with amphetamine S-SIMPLE_CHEMICAL with saline O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
Rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. 	quinpirole	amphetamine	none	{'e1': {'word': 'quinpirole', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d184.s8.e0'}, 'e2': {'word': 'amphetamine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d184.s8.e3'}, 'sentence_id': 'DDI-MedLine.d184.s8'}	O quinpirole enhanced O context compared O controls conditioned O with amphetamine S-SIMPLE_CHEMICAL with saline O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
Rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. 	quinpirole	amphetamine	none	{'e1': {'word': 'quinpirole', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d184.s8.e0'}, 'e2': {'word': 'amphetamine', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d184.s8.e4'}, 'sentence_id': 'DDI-MedLine.d184.s8'}	O quinpirole enhanced O context compared O controls conditioned O with amphetamine S-SIMPLE_CHEMICAL with saline O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
Rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. 	amphetamine	quinpirole	none	{'e1': {'word': 'amphetamine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d184.s8.e1'}, 'e2': {'word': 'quinpirole', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d184.s8.e2'}, 'sentence_id': 'DDI-MedLine.d184.s8'}	O quinpirole enhanced O context compared O controls conditioned O with amphetamine S-SIMPLE_CHEMICAL with saline O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
Rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. 	amphetamine	amphetamine	none	{'e1': {'word': 'amphetamine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d184.s8.e1'}, 'e2': {'word': 'amphetamine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d184.s8.e3'}, 'sentence_id': 'DDI-MedLine.d184.s8'}	O quinpirole enhanced O context compared O controls conditioned O with amphetamine S-SIMPLE_CHEMICAL with saline O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
Rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. 	amphetamine	amphetamine	none	{'e1': {'word': 'amphetamine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d184.s8.e1'}, 'e2': {'word': 'amphetamine', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d184.s8.e4'}, 'sentence_id': 'DDI-MedLine.d184.s8'}	O quinpirole enhanced O context compared O controls conditioned O with amphetamine S-SIMPLE_CHEMICAL with saline O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
Rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. 	quinpirole	amphetamine	none	{'e1': {'word': 'quinpirole', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d184.s8.e2'}, 'e2': {'word': 'amphetamine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d184.s8.e3'}, 'sentence_id': 'DDI-MedLine.d184.s8'}	O quinpirole enhanced O context compared O controls conditioned O with amphetamine S-SIMPLE_CHEMICAL with saline O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
Rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. 	quinpirole	amphetamine	none	{'e1': {'word': 'quinpirole', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d184.s8.e2'}, 'e2': {'word': 'amphetamine', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d184.s8.e4'}, 'sentence_id': 'DDI-MedLine.d184.s8'}	O quinpirole enhanced O context compared O controls conditioned O with amphetamine S-SIMPLE_CHEMICAL with saline O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
Rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. 	amphetamine	amphetamine	none	{'e1': {'word': 'amphetamine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d184.s8.e3'}, 'e2': {'word': 'amphetamine', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d184.s8.e4'}, 'sentence_id': 'DDI-MedLine.d184.s8'}	O quinpirole enhanced O context compared O controls conditioned O with amphetamine S-SIMPLE_CHEMICAL with saline O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
"Interaction study of moxifloxacin and lomefloxacin with co-administered drugs.
"	moxifloxacin	lomefloxacin	none	{'e1': {'word': 'moxifloxacin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d231.s0.e0'}, 'e2': {'word': 'lomefloxacin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d231.s0.e1'}, 'sentence_id': 'DDI-MedLine.d231.s0'}	O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O
Moxifloxacin and lomefloxacin are fluoroquinolone antibiotics used in treating urinary and respiratory tract infections. 	Moxifloxacin	lomefloxacin	none	{'e1': {'word': 'Moxifloxacin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d231.s1.e0'}, 'e2': {'word': 'lomefloxacin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d231.s1.e1'}, 'sentence_id': 'DDI-MedLine.d231.s1'}	O tract infections O S-SIMPLE_CHEMICAL O O O O O O S-ORGANISM_SUBSTANCE O O E-ORGANISM_SUBDIVISION O O
Moxifloxacin and lomefloxacin are fluoroquinolone antibiotics used in treating urinary and respiratory tract infections. 	Moxifloxacin	fluoroquinolone antibiotics	none	{'e1': {'word': 'Moxifloxacin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d231.s1.e0'}, 'e2': {'word': 'fluoroquinolone antibiotics', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d231.s1.e2'}, 'sentence_id': 'DDI-MedLine.d231.s1'}	O tract infections O S-SIMPLE_CHEMICAL O O O O O O S-ORGANISM_SUBSTANCE O O E-ORGANISM_SUBDIVISION O O
Moxifloxacin and lomefloxacin are fluoroquinolone antibiotics used in treating urinary and respiratory tract infections. 	lomefloxacin	fluoroquinolone antibiotics	none	{'e1': {'word': 'lomefloxacin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d231.s1.e1'}, 'e2': {'word': 'fluoroquinolone antibiotics', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d231.s1.e2'}, 'sentence_id': 'DDI-MedLine.d231.s1'}	O tract infections O S-SIMPLE_CHEMICAL O O O O O O S-ORGANISM_SUBSTANCE O O E-ORGANISM_SUBDIVISION O O
Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. 	moxifloxacin	fluoroquinolones	none	{'e1': {'word': 'moxifloxacin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d231.s3.e0'}, 'e2': {'word': 'fluoroquinolones', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d231.s3.e1'}, 'sentence_id': 'DDI-MedLine.d231.s3'}	O the interaction S-SIMPLE_CHEMICAL multi minerals O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O
Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. 	moxifloxacin	sucralfate	none	{'e1': {'word': 'moxifloxacin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d231.s3.e0'}, 'e2': {'word': 'sucralfate', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d231.s3.e2'}, 'sentence_id': 'DDI-MedLine.d231.s3'}	O the interaction S-SIMPLE_CHEMICAL multi minerals O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O
Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. 	moxifloxacin	gelusil	none	{'e1': {'word': 'moxifloxacin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d231.s3.e0'}, 'e2': {'word': 'gelusil', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d231.s3.e3'}, 'sentence_id': 'DDI-MedLine.d231.s3'}	O the interaction S-SIMPLE_CHEMICAL multi minerals O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O
Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. 	moxifloxacin	erythromycin	none	{'e1': {'word': 'moxifloxacin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d231.s3.e0'}, 'e2': {'word': 'erythromycin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d231.s3.e4'}, 'sentence_id': 'DDI-MedLine.d231.s3'}	O the interaction S-SIMPLE_CHEMICAL multi minerals O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O
Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. 	moxifloxacin	multi minerals	none	{'e1': {'word': 'moxifloxacin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d231.s3.e0'}, 'e2': {'word': 'multi minerals', 'word_index': [(4, 5)], 'id': 'DDI-MedLine.d231.s3.e5'}, 'sentence_id': 'DDI-MedLine.d231.s3'}	O the interaction S-SIMPLE_CHEMICAL multi minerals O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O
Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. 	fluoroquinolones	sucralfate	none	{'e1': {'word': 'fluoroquinolones', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d231.s3.e1'}, 'e2': {'word': 'sucralfate', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d231.s3.e2'}, 'sentence_id': 'DDI-MedLine.d231.s3'}	O the interaction S-SIMPLE_CHEMICAL multi minerals O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O
Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. 	fluoroquinolones	gelusil	none	{'e1': {'word': 'fluoroquinolones', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d231.s3.e1'}, 'e2': {'word': 'gelusil', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d231.s3.e3'}, 'sentence_id': 'DDI-MedLine.d231.s3'}	O the interaction S-SIMPLE_CHEMICAL multi minerals O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O
Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. 	fluoroquinolones	erythromycin	none	{'e1': {'word': 'fluoroquinolones', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d231.s3.e1'}, 'e2': {'word': 'erythromycin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d231.s3.e4'}, 'sentence_id': 'DDI-MedLine.d231.s3'}	O the interaction S-SIMPLE_CHEMICAL multi minerals O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O
Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. 	fluoroquinolones	multi minerals	none	{'e1': {'word': 'fluoroquinolones', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d231.s3.e1'}, 'e2': {'word': 'multi minerals', 'word_index': [(4, 5)], 'id': 'DDI-MedLine.d231.s3.e5'}, 'sentence_id': 'DDI-MedLine.d231.s3'}	O the interaction S-SIMPLE_CHEMICAL multi minerals O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O
Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. 	sucralfate	gelusil	none	{'e1': {'word': 'sucralfate', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d231.s3.e2'}, 'e2': {'word': 'gelusil', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d231.s3.e3'}, 'sentence_id': 'DDI-MedLine.d231.s3'}	O the interaction S-SIMPLE_CHEMICAL multi minerals O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O
Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. 	sucralfate	erythromycin	none	{'e1': {'word': 'sucralfate', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d231.s3.e2'}, 'e2': {'word': 'erythromycin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d231.s3.e4'}, 'sentence_id': 'DDI-MedLine.d231.s3'}	O the interaction S-SIMPLE_CHEMICAL multi minerals O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O
Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. 	sucralfate	multi minerals	none	{'e1': {'word': 'sucralfate', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d231.s3.e2'}, 'e2': {'word': 'multi minerals', 'word_index': [(4, 5)], 'id': 'DDI-MedLine.d231.s3.e5'}, 'sentence_id': 'DDI-MedLine.d231.s3'}	O the interaction S-SIMPLE_CHEMICAL multi minerals O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O
Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. 	gelusil	erythromycin	none	{'e1': {'word': 'gelusil', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d231.s3.e3'}, 'e2': {'word': 'erythromycin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d231.s3.e4'}, 'sentence_id': 'DDI-MedLine.d231.s3'}	O the interaction S-SIMPLE_CHEMICAL multi minerals O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O
Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. 	gelusil	multi minerals	none	{'e1': {'word': 'gelusil', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d231.s3.e3'}, 'e2': {'word': 'multi minerals', 'word_index': [(4, 5)], 'id': 'DDI-MedLine.d231.s3.e5'}, 'sentence_id': 'DDI-MedLine.d231.s3'}	O the interaction S-SIMPLE_CHEMICAL multi minerals O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O
Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. 	erythromycin	multi minerals	none	{'e1': {'word': 'erythromycin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d231.s3.e4'}, 'e2': {'word': 'multi minerals', 'word_index': [(4, 5)], 'id': 'DDI-MedLine.d231.s3.e5'}, 'sentence_id': 'DDI-MedLine.d231.s3'}	O the interaction S-SIMPLE_CHEMICAL multi minerals O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O
The response of moxifloxacin and lomefloxacin after interaction with co-administered drugs at different conditions and temperature were noted using a Shimadzu HPLC system with PDA detector. 	moxifloxacin	lomefloxacin	none	{'e1': {'word': 'moxifloxacin', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d231.s6.e0'}, 'e2': {'word': 'lomefloxacin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d231.s6.e1'}, 'sentence_id': 'DDI-MedLine.d231.s6'}	O moxifloxacin and O conditions and O noted using S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O O O O O O O O O O O O O O O O O O O O
Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. 	Moxifloxacin	Lomefloxacin	none	{'e1': {'word': 'Moxifloxacin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d231.s8.e0'}, 'e2': {'word': 'Lomefloxacin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d231.s8.e1'}, 'sentence_id': 'DDI-MedLine.d231.s8'}	O whereas with O media and O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O
Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. 	Moxifloxacin	sucralfate	mechanism	{'e1': {'word': 'Moxifloxacin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d231.s8.e0'}, 'e2': {'word': 'sucralfate', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d231.s8.e2'}, 'sentence_id': 'DDI-MedLine.d231.s8'}	O whereas with O media and O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O
Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. 	Moxifloxacin	gelusil	mechanism	{'e1': {'word': 'Moxifloxacin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d231.s8.e0'}, 'e2': {'word': 'gelusil', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d231.s8.e3'}, 'sentence_id': 'DDI-MedLine.d231.s8'}	O whereas with O media and O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O
Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. 	Moxifloxacin	erythromycin	mechanism	{'e1': {'word': 'Moxifloxacin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d231.s8.e0'}, 'e2': {'word': 'erythromycin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d231.s8.e4'}, 'sentence_id': 'DDI-MedLine.d231.s8'}	O whereas with O media and O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O
Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. 	Moxifloxacin	multi-minerals	mechanism	{'e1': {'word': 'Moxifloxacin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d231.s8.e0'}, 'e2': {'word': 'multi-minerals', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d231.s8.e5'}, 'sentence_id': 'DDI-MedLine.d231.s8'}	O whereas with O media and O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O
Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. 	Lomefloxacin	sucralfate	mechanism	{'e1': {'word': 'Lomefloxacin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d231.s8.e1'}, 'e2': {'word': 'sucralfate', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d231.s8.e2'}, 'sentence_id': 'DDI-MedLine.d231.s8'}	O whereas with O media and O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O
Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. 	Lomefloxacin	gelusil	mechanism	{'e1': {'word': 'Lomefloxacin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d231.s8.e1'}, 'e2': {'word': 'gelusil', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d231.s8.e3'}, 'sentence_id': 'DDI-MedLine.d231.s8'}	O whereas with O media and O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O
Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. 	Lomefloxacin	erythromycin	mechanism	{'e1': {'word': 'Lomefloxacin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d231.s8.e1'}, 'e2': {'word': 'erythromycin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d231.s8.e4'}, 'sentence_id': 'DDI-MedLine.d231.s8'}	O whereas with O media and O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O
Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. 	Lomefloxacin	multi-minerals	mechanism	{'e1': {'word': 'Lomefloxacin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d231.s8.e1'}, 'e2': {'word': 'multi-minerals', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d231.s8.e5'}, 'sentence_id': 'DDI-MedLine.d231.s8'}	O whereas with O media and O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O
Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. 	sucralfate	gelusil	none	{'e1': {'word': 'sucralfate', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d231.s8.e2'}, 'e2': {'word': 'gelusil', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d231.s8.e3'}, 'sentence_id': 'DDI-MedLine.d231.s8'}	O whereas with O media and O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O
Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. 	sucralfate	erythromycin	none	{'e1': {'word': 'sucralfate', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d231.s8.e2'}, 'e2': {'word': 'erythromycin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d231.s8.e4'}, 'sentence_id': 'DDI-MedLine.d231.s8'}	O whereas with O media and O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O
Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. 	sucralfate	multi-minerals	none	{'e1': {'word': 'sucralfate', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d231.s8.e2'}, 'e2': {'word': 'multi-minerals', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d231.s8.e5'}, 'sentence_id': 'DDI-MedLine.d231.s8'}	O whereas with O media and O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O
Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. 	gelusil	erythromycin	none	{'e1': {'word': 'gelusil', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d231.s8.e3'}, 'e2': {'word': 'erythromycin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d231.s8.e4'}, 'sentence_id': 'DDI-MedLine.d231.s8'}	O whereas with O media and O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O
Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. 	gelusil	multi-minerals	none	{'e1': {'word': 'gelusil', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d231.s8.e3'}, 'e2': {'word': 'multi-minerals', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d231.s8.e5'}, 'sentence_id': 'DDI-MedLine.d231.s8'}	O whereas with O media and O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O
Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. 	erythromycin	multi-minerals	none	{'e1': {'word': 'erythromycin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d231.s8.e4'}, 'e2': {'word': 'multi-minerals', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d231.s8.e5'}, 'sentence_id': 'DDI-MedLine.d231.s8'}	O whereas with O media and O O O O O O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O O O
"Interaction of celecoxib with different anti-cancer drugs is antagonistic in breast but not in other cancer cells.
"	celecoxib	anti-cancer drugs	effect	{'e1': {'word': 'celecoxib', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d217.s0.e0'}, 'e2': {'word': 'anti-cancer drugs', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d217.s0.e1'}, 'sentence_id': 'DDI-MedLine.d217.s0'}	O but not O cancer cells S-SIMPLE_CHEMICAL O O O O O O O O O O O O E-CANCER S-CELL O
This study investigates the ability of cyclooxygenase-2 inhibitors to sensitize cells from different origins to several chemotherapeutic agents. 	cyclooxygenase-2 inhibitors	chemotherapeutic agents	none	{'e1': {'word': 'cyclooxygenase-2 inhibitors', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d217.s2.e0'}, 'e2': {'word': 'chemotherapeutic agents', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d217.s2.e1'}, 'sentence_id': 'DDI-MedLine.d217.s2'}	O ability of O sensitize cells O O O O S-GENE_OR_GENE_PRODUCT O O O O O S-CELL O O O O O O O O
The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.	5-FU	cisplatin	none	{'e1': {'word': '5-FU', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d217.s4.e0'}, 'e2': {'word': 'cisplatin', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d217.s4.e1'}, 'sentence_id': 'DDI-MedLine.d217.s4'}	O cell cycle O ( HeLa O HCT116 , E-CELL U251 ) O cisplatin , O and etoposide O O S-CELLULAR_COMPONENT O O O O E-CANCER E-CELL O O O O S-CELL O O O S-CELL O S-CELL O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL S-SIMPLE_CHEMICAL O O O O O O O
The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.	5-FU	doxorubicin	none	{'e1': {'word': '5-FU', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d217.s4.e0'}, 'e2': {'word': 'doxorubicin', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d217.s4.e2'}, 'sentence_id': 'DDI-MedLine.d217.s4'}	O cell cycle O ( HeLa O HCT116 , E-CELL U251 ) O cisplatin , O and etoposide O O S-CELLULAR_COMPONENT O O O O E-CANCER E-CELL O O O O S-CELL O O O S-CELL O S-CELL O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL S-SIMPLE_CHEMICAL O O O O O O O
The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.	5-FU	etoposide	none	{'e1': {'word': '5-FU', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d217.s4.e0'}, 'e2': {'word': 'etoposide', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d217.s4.e3'}, 'sentence_id': 'DDI-MedLine.d217.s4'}	O cell cycle O ( HeLa O HCT116 , E-CELL U251 ) O cisplatin , O and etoposide O O S-CELLULAR_COMPONENT O O O O E-CANCER E-CELL O O O O S-CELL O O O S-CELL O S-CELL O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL S-SIMPLE_CHEMICAL O O O O O O O
The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.	5-FU	celecoxib	none	{'e1': {'word': '5-FU', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d217.s4.e0'}, 'e2': {'word': 'celecoxib', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d217.s4.e4'}, 'sentence_id': 'DDI-MedLine.d217.s4'}	O cell cycle O ( HeLa O HCT116 , E-CELL U251 ) O cisplatin , O and etoposide O O S-CELLULAR_COMPONENT O O O O E-CANCER E-CELL O O O O S-CELL O O O S-CELL O S-CELL O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL S-SIMPLE_CHEMICAL O O O O O O O
The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.	cisplatin	doxorubicin	none	{'e1': {'word': 'cisplatin', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d217.s4.e1'}, 'e2': {'word': 'doxorubicin', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d217.s4.e2'}, 'sentence_id': 'DDI-MedLine.d217.s4'}	O cell cycle O ( HeLa O HCT116 , E-CELL U251 ) O cisplatin , O and etoposide O O S-CELLULAR_COMPONENT O O O O E-CANCER E-CELL O O O O S-CELL O O O S-CELL O S-CELL O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL S-SIMPLE_CHEMICAL O O O O O O O
The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.	cisplatin	etoposide	none	{'e1': {'word': 'cisplatin', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d217.s4.e1'}, 'e2': {'word': 'etoposide', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d217.s4.e3'}, 'sentence_id': 'DDI-MedLine.d217.s4'}	O cell cycle O ( HeLa O HCT116 , E-CELL U251 ) O cisplatin , O and etoposide O O S-CELLULAR_COMPONENT O O O O E-CANCER E-CELL O O O O S-CELL O O O S-CELL O S-CELL O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL S-SIMPLE_CHEMICAL O O O O O O O
The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.	cisplatin	celecoxib	none	{'e1': {'word': 'cisplatin', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d217.s4.e1'}, 'e2': {'word': 'celecoxib', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d217.s4.e4'}, 'sentence_id': 'DDI-MedLine.d217.s4'}	O cell cycle O ( HeLa O HCT116 , E-CELL U251 ) O cisplatin , O and etoposide O O S-CELLULAR_COMPONENT O O O O E-CANCER E-CELL O O O O S-CELL O O O S-CELL O S-CELL O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL S-SIMPLE_CHEMICAL O O O O O O O
The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.	doxorubicin	etoposide	none	{'e1': {'word': 'doxorubicin', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d217.s4.e2'}, 'e2': {'word': 'etoposide', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d217.s4.e3'}, 'sentence_id': 'DDI-MedLine.d217.s4'}	O cell cycle O ( HeLa O HCT116 , E-CELL U251 ) O cisplatin , O and etoposide O O S-CELLULAR_COMPONENT O O O O E-CANCER E-CELL O O O O S-CELL O O O S-CELL O S-CELL O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL S-SIMPLE_CHEMICAL O O O O O O O
The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.	doxorubicin	celecoxib	none	{'e1': {'word': 'doxorubicin', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d217.s4.e2'}, 'e2': {'word': 'celecoxib', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d217.s4.e4'}, 'sentence_id': 'DDI-MedLine.d217.s4'}	O cell cycle O ( HeLa O HCT116 , E-CELL U251 ) O cisplatin , O and etoposide O O S-CELLULAR_COMPONENT O O O O E-CANCER E-CELL O O O O S-CELL O O O S-CELL O S-CELL O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL S-SIMPLE_CHEMICAL O O O O O O O
The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.	etoposide	celecoxib	none	{'e1': {'word': 'etoposide', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d217.s4.e3'}, 'e2': {'word': 'celecoxib', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d217.s4.e4'}, 'sentence_id': 'DDI-MedLine.d217.s4'}	O cell cycle O ( HeLa O HCT116 , E-CELL U251 ) O cisplatin , O and etoposide O O S-CELLULAR_COMPONENT O O O O E-CANCER E-CELL O O O O S-CELL O O O S-CELL O S-CELL O O O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL S-SIMPLE_CHEMICAL O O O O O O O
We found antagonism between celecoxib and the four drugs in the breast cancer cells MCF7 following all incubation schedules and between celecoxib and doxorubicin in all cell lines except for two combinations in HCT116 cells. 	celecoxib	celecoxib	none	{'e1': {'word': 'celecoxib', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d217.s5.e0'}, 'e2': {'word': 'celecoxib', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d217.s5.e1'}, 'sentence_id': 'DDI-MedLine.d217.s5'}	O antagonism between O in the O celecoxib and O two combinations S-SIMPLE_CHEMICAL O O O O O O O E-CANCER S-CELL S-CELL O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O E-CELL O O O O O O S-CELL S-CELL O
We found antagonism between celecoxib and the four drugs in the breast cancer cells MCF7 following all incubation schedules and between celecoxib and doxorubicin in all cell lines except for two combinations in HCT116 cells. 	celecoxib	doxorubicin	none	{'e1': {'word': 'celecoxib', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d217.s5.e0'}, 'e2': {'word': 'doxorubicin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d217.s5.e2'}, 'sentence_id': 'DDI-MedLine.d217.s5'}	O antagonism between O in the O celecoxib and O two combinations S-SIMPLE_CHEMICAL O O O O O O O E-CANCER S-CELL S-CELL O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O E-CELL O O O O O O S-CELL S-CELL O
We found antagonism between celecoxib and the four drugs in the breast cancer cells MCF7 following all incubation schedules and between celecoxib and doxorubicin in all cell lines except for two combinations in HCT116 cells. 	celecoxib	doxorubicin	effect	{'e1': {'word': 'celecoxib', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d217.s5.e1'}, 'e2': {'word': 'doxorubicin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d217.s5.e2'}, 'sentence_id': 'DDI-MedLine.d217.s5'}	O antagonism between O in the O celecoxib and O two combinations S-SIMPLE_CHEMICAL O O O O O O O E-CANCER S-CELL S-CELL O O O O O O S-SIMPLE_CHEMICAL O S-SIMPLE_CHEMICAL O O E-CELL O O O O O O S-CELL S-CELL O
These results, if confirmed in-vivo, indicate that celecoxib is not a suitable chemosensitizer for breast cancer or with doxorubicin for other cancers. 	celecoxib	doxorubicin	none	{'e1': {'word': 'celecoxib', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d217.s11.e0'}, 'e2': {'word': 'doxorubicin', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d217.s11.e1'}, 'sentence_id': 'DDI-MedLine.d217.s11'}	O in - O a suitable O for breast O with doxorubicin O O O O O O O S-SIMPLE_CHEMICAL O O O O O O O E-CANCER O O S-SIMPLE_CHEMICAL O O E-CANCER O
